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ABSTRACT
Neovascularization is an essential process to repair ischemic tissues following
myocardial infarction, stroke, diabetic complications, or transplant procedures. Blood vessels
are generated by distinct vasculogenic and angiogenic processes. Although multiple pro-
angiogenic factors have been identified, limited success has been achieved translating these as
clinical therapeutics. Furthermore, recent studies have shown that vasculogenesis contributes to
adult neovascularization in multiple settings.
Harnessing the vasculogenic potential of embryonic stem cells is an emerging concept
to generate neovasculature. The differentiation of embryonic stem cells into endothelium has
been well documented, however most studies focus on genetic or chemokine regulation.
Limited information exists which implicates the role of the extracellular microenvironment in
stem cell differentiation. Heparan sulfate glycosaminoglycans (HSGAG) are a crucial part of the
dynamic extracellular matrix and have been shown to regulate multiple signaling cascades,
including vasculogenic specific growth factors VEGF and FGF. The goal of this thesis is to
elucidate the role of HSGAG in vasculogenesis.
An embryonic stem cell embryoid body model was used to establish the necessity of
sulfated HSGAG for endothelial differentiation. We identified that the chemical composition of
HSGAG sulfation patterns change with differentiation. Perturbation of HSGAG structure by
chemical, enzymatic, or genetic modification effectively inhibited vasculogenesis. Genetic
silencing of HSGAG modifying enzyme, N-deacetylase/N-sulfotransferase-1, translated to
inhibition of HSGAG sulfation and resulted in impaired blood vessel development in zebrafish
embryos. Interestingly, vessel formation in both embryonic stem cell and zebrafish models was
restored by the addition of exogenous HSGAG, opening the door for engineering glyco-based
microenvironments for controlling vascular development.
To explore novel mechanisms of vasculogenesis modulated by HSGAG perturbation, we
performed a global transcriptome analysis of N-deacetylase/N-sulfotransferase-1 mutant
zebrafish embryos. Several novel pathways were identified that regulate vascular
differentiation, including Foxo3A and Insulin-Like Growth Factor (IGF) pathways. We explored
the role of IGFs in vasculogenesis specifically and determined for the first time that IGF1 and
IGF2 promote mesoderm and endothelial differentiation, mediated through HIFla stabilization,
in embryonic stem cells. In summary, we've identified several mechanisms by which HSGAG
regulate neovascularization, laying the groundwork for incorporating HSGAG in strategies for
ischemic tissue regeneration.
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Glossary of Terms
Heparan Sulfate Glycosaminoglycans (HSGAG): Linear polysaccharides made of repeating
N-acetylglucosamine and glucuronic acid units attached to proteins on the cell surface and in
the extracellular matrix. Anionic sulfate groups on the linear chain interact with biological
molecules to regulate cell function.
HSGAG Sulfate Modifying Enzymes: A series of enzymes in the Golgi apparatus work
sequentially to add non-template driven sulfate groups to the polysaccharide chain. N-
deacetylase/N-sulfotransferase is the rate limiting enzyme because subsequent sulfate
modifications occur in relation to N-sulfation.
Embryoid Bodies: Spontaneous aggregation of embryonic stem cells into spherical bodies
which initiates differentiation. EB are used as a model of embryogenesis because diverse cell
lineages develop within them from embryonic stem cells in a three dimensional manner.
Vasculogenesis: The process of de novo generation of endothelial cells from stem cells and
their migration to form vascular tubes.
Angiogenesis: The process of blood vessel generation by sprouting and intussusception of
endothelial cells from existing vessels.
Capillary Electrophoresis: A technique of separating ionic species in an electric field by mass
and charge characteristics. Species are run in a capillary with a conductive salt buffer and
detected by UV absorbance, fluorescence, or other methods.
Morpholino: Designed to target and sterically block a gene sequence and evade cellular
nucleases, morpholinos are oligonucleotides containing morpholine rings instead of ribose rings
and phosphorodiamidate linkages.
shRNA: Short Hairpin RNA, a sequence of RNA engineered with a universal promoter which
generates a hairpin structure when transcribed. Cellular machinery processes the hairpin
structure into siRNA, which silences the target sequence.
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CHAPTER 1. Introduction
Embryonic stem cells were first isolated from mouse embryos in 1981, but cells that
could self-renew and generate diverse specialized cell lineages have been researched for over
half a century. (Friel, 2005) Embryonic stem cells (ES) are isolated from the inner cell mass of
a fertilized egg and by definition have unlimited self-renewal capacity. They hold tremendous
clinical potential because they are pluripotent and thus have the ability to differentiate into all
cell types of the human body, including neurons, muscle, bone, and endothelium. Stem cells
are also present in the adult, but in contrast to embryonic stem cells, they are multipotent and
can only differentiate into defined cell lineages. Despite decades of research, efficient directed
differentiation of stem cells is still an important aspiration of regenerative medicine.
The goal of regenerative medicine is to generate specific tissues that can be used to
replace or repair damaged tissues in the body. Attempts to engineer tissues of defined cell
types in vitro have been limited by the inability to adequately vascularize tissue constructs.
Lack of efficient oxygen and nutrient delivery within these constructs restricts their size and
viability, and therefore limits their therapeutic potential. (Lovett, 2009) Furthermore, the
integration of tissues in vivo is contingent upon the generation of new blood vessels that
incorporate into the host vasculature. Therefore, the ability to generate vasculature is a major
focus of tissue engineering and regenerative medicine.
Harnessing the potential of stem cells to differentiate into endothelium has emerged as a
significant method for generating neovasculature. Apart from the utility of novel methods of
neovascularization for tissue engineering applications, there is an urgent need to control blood
vessel development for the treatment of numerous diseases. Compromised circulation to
organs and tissues, or ischemia, is the basis for many devastating diseases like myocardial
infarction and stroke. Myocardial infarction is the largest cause of death in the United States and
rapidly escalating as the largest cause of morbidity in the developing world. Cerebrovascular
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accidents, or strokes, are the second leading cause of death and the largest factor of adult
disability. (AHA, 2010) Vessel damage caused by diabetic hyperglycemia causes peripheral
ischemia throughout the body and decreased capacity for wound healing. The uncontrolled
growth of vessels also leads to disease, like diabetic proliferative retinopathy and endometriosis.
It is well established that tumors grow and become malignant by generating blood vessel
networks and much effort has been spent identifying ways to inhibit tumor neovascularization.
Clearly, harnessing the potential of stem cells to identify novel mechanisms of blood vessel
development has significant clinical applications.
The differentiation of embryonic stem cells into endothelium has been well documented,
but much remains unknown about the process. While many of the paracrine factors, including
Vascular Endothelial Growth Factor (VEGF) and Fibroblast Growth Factor (FGF), and genes,
including GATA binding factor 2 (GATA2) and E-twenty six (Ets) transcription factor, have been
implicated in vasculogenesis, very little focus has been given to the role of the extracellular
microenvironment. (Risau, 1998) (Flamme, 1995) (Lugus, 2007) (Wang, 1997) It has been
established that most signaling molecules interact with the actively changing extracellular
matrix. (Hynes, 2009) Controlling the extracellular matrix may be an attractive solution that can
synergize with an appropriate combination of growth factors and cytokines to control
development. However, limited knowledge exists on the molecular composition of the
extracellular matrix which is necessary for establishing its role in developmental biology.
One key component of the extracellular matrix that has been overlooked in its role to
regulate ES differentiation is heparan sulfate glycosaminoglycans. (HSGAG) HSGAG play an
important role in the active extracellular matrix by regulating a wide variety of biological
processes including embryonic patterning, morphogenesis, and disease. (Venkataraman, 2000)
The wide range of responses regulated by HSGAG is due to their diverse sulfate composition,
created by a series of non-template driven enzyme modifications. (Jackson, 1991)The first
modification is by N-deacetylase/N-sulfotransferase, which may control the final sulfation
density because regions of N-sulfation are preferentially modified by subsequent enzymes.
(Kjellen, 2003) The result is an HSGAG backbone containing specific anionic sulfate sequences
that bind to growth factors and elements of the extracellular matrix to influence cell function.
This thesis contributes towards the understanding of the role of heparan sulfate
glycosaminoglycans in vascular development. There are several challenges to the investigation
of structure activity relationships of HSGAG. For example, unlike other biopolymers, HSGAG
cannot be amplified due to their complex biosynthesis and modifications and therefore it is
difficult to characterize their chemical structure. To address this limitation, we have harnessed a
sensitive analytical system that encompasses sequential digestions of the HSGAG polymers
using site-specific enzymes, resolving the constituents based on charge and mass using
capillary electrophoresis. In this way, we've analyzed the degree of sulfation of HSGAG
disaccharides during the differentiation of stem cells into endothelial cells.
In Chapter 3, we investigated the role of HSGAG in vasculogenesis. An embryoid body
model was used to recapitulate embryonic vasculogenesis in vitro. After determining the
expression patterns of HSGAG sulfation enzymes and characterizing the chemical composition
of cell surface sulfate patterns with endothelial differentiation, we analyzed the affects of
genetically silencing the key HSGAG sulfation enzyme N-deacetylase/N-sulfotransferase-1
(NDST1). Silencing NDST1 reduced HSGAG sulfation and significantly inhibited the generation
of endothelial cells. We explored the possibility that exogenous HSGAG can be used to control
vascular differentiation using HSGAG fragments with various sulfate compositions. These
studies identified the prospect of using exogenous sugar sequences to control cell function for
tissue engineering or therapeutic purposes.
Although the embryoid body is an excellent paradigm of embryogenesis, we utilized the
zebrafish to translate the in vitro results to a more clinically relevant model of vasculogenesis.
As discussed in Chapter 4, we identified the effects of glycome perturbation on blood vessel
development in developing zebrafish embryos. Danio rerio (zebrafish) possess a complex
circulatory system that is similar to that of mammals. (Isogai, 2001) Additionally, zebrafish
overcome several limitations of mammalian in vivo studies due to their fast development,
genetic accessibility and ability to survive significant vascular impairment for several days by
passive oxygen diffusion. For example, mouse embryos null homozygous for HSGAG sulfation
enzyme N-deacetylase/N-sulfotransferase-1 die in utero prior to the development of vasculature
and thus eliminate the possibility of studying the effect of the gene on vessel development.
(Ringvall, 2000) Parallel to our studies with embryonic stem cells, genetic silencing of NDST1 in
zebrafish resulted in impaired vessel formation. This was the first time that N-deacetylase/N-
sulfotransferase inhibition was studied in zebrafish. In order to elucidate some of the
downstream mechanisms associated with glycome perturbation, we performed a global
transcriptome analysis of embryos at three time points corresponding to critical steps in vessel
development. We used multiple stringent statistical tests to eliminate errors associated with
microarray analysis and identified novel mechanisms that modulate HSGAG-mediated
vasculogenesis. The insights gained from the analysis of the glycome-transcriptome crosstalk
in development can be used to identify many currently uncharacterized mechanisms of vascular
development.
One of the pathways we characterized as being differentially regulated between control
and NDST1 knock-down embryos was the insulin-like growth factor (IGF) pathway. In Chapter
5, we investigated the role of IGF1 and IGF2 in embryonic stem cell vasculogenesis. Previous
studies identified roles for IGFs in maintaining stem cell pluripotency as well as endothelial
progenitor cell homing and angiogenesis. (Bendall, 2007) (Han, 2003) (Thum, 2007) For the first
time, we determined that IGFs promote mesoderm and endothelial differentiation in embryoid
bodies. We linked IGF signaling to downstream stabilization of HIF1 a and increased expression
of VEGF, which is a critical inducer of endothelial differentiation. (Forsythe, 1996)
Overall, this work supports the hypothesis that heparan sulfate glycosaminoglycans are
a critical element of vasculogenesis, and modulation of their sulfation patterns regulates blood
vessel development. These insights can be used to discover more efficient methods of directing
stem cell or progenitor cell function and understand the mechanisms of vasculogenesis for
therapeutic applications.
Chapter 2. Background
(Parts of this chapter are taken from "Piecewicz, S. and Sengupta, S. The Dynamic Glycome
Microenvironment and Stem Cell Differentiation into Vasculature. 2010, Stem Cells and
Development.")
2A. Neovascularization in Health and Disease:
The vascular network is essential to human health because it supplies organs and
tissues with oxygen, nutrients, and other circulating molecules that allow them to grow and
maintain homeostasis. The circulatory network is the first functional organ system in
development and allows for growth of the embryo and complex tissues beyond limits of simple
diffusion. (Flamme, 1997) Endothelial cells line the inner surface of all mature blood vessels,
which are stabilized by a surrounding basement membrane smooth muscle cells, and/or
pericytes. The generation of a functional circulatory system is a major hurdle for tissue
engineering because engineered organs would require blood flow to thrive and coalesce with
the body. Apart from supporting growth and maintaining basic survival, blood vessels are linked
to many of the most devastating diseases including myocardial infarction, stroke, diabetes, and
cancer when their function is impaired. Clearly, the vascular system is critical to health and
disease and uncovering new mechanisms of controlling vessel formation can have far-reaching
consequences.
Vasculogenesis and angiogenesis are the two distinct processes of blood vessel
formation. Prior to the discovery in 1997 that vasculogenesis could occur in the adult,
angiogenesis was regarded as the Holy Grail for controlling vessel growth in ischemic tissues
and tumors in adults, and occurs through the expansion and remodeling of existing vessels. In
response to angiogenic stimuli, endothelial cells protrude and degrade the vessel wall and
basement membrane, proliferate and align to first form a sprout and then connect to generate
new capillary networks. (Folkman, 1986) Multiple angiogenesis factors have now been
implicated in the process, including vascular endothelial growth factor (VEGF) which is up-
regulated in hypoxic cells by hypoxia inducble factor 1 (HIF1). (Forsythe, 1996) Other key
angiogenic factors that support endothelial sprouting include angiopoietin, platelet derived
growth factor (PDGF), TIE receptors, and transforming growth factor P (TGFp). (Jain, 2003)
Angiogenic molecules have been targeted to promote or inhibit vessel growth in vivo but limited
success has been achieved. For example, an adenoviral vector expressing VEGF was used to
treat lower limb ischemia but resulted in the formation of disorganized, leaky vessels.
(Pettersson, 2000) Similarly, attempts to inhibit tumor angiogenesis by blocking VEGF
signaling have not resulted in enduring clinical responses and induce side effects including
impaired wound healing, thrombosis, proteinuria, and hypertension. (Bryan, 2010) Clearly,
novel methods to regulate neovascularization are required, and recently focus has shifted to
elucidate mechanisms of vasculogenesis for therapeutic neovascularization approaches.
Vasculogenesis is the formation of endothelial precursor cells and their assembly into a
primary circulatory network in the developing embryo. (Ferguson, 2005) Recent studies have
shown that circulating endothelial progenitor cells in the adult can contribute to the formation of
new vessels in multiple settings, suggesting that vasculogenesis occurs in the adult as well as
the embryo. Endothelial progenitor cells (EPC), identified as CD34+ mononuclear cells isolated
from blood, adopt endothelial morphology and stain for endothelial specific markers when
cultured in vitro and were found to incorporate into newly formed capillaries for up to 6 weeks in
vivo. (Asahara, 1997) Some controversy exists as to the specific markers that define EPC.
(Urbich, 2004) Nevertheless, labeled EPC have been shown to contribute to neovasculariztion
in hind limb ischemia, myocardial infarction, tumor, and matrigel models. (Ferreira, 2007)
Although incorporation of EPC themselves may be as low as 10%, EPC may secrete growth
factors that promote endothelial regeneration. A recent study compared the functionality of EPC
derived vessels to pre-existing microvasculature by measuring red blood cell velocity,
permeability in response to albumin, and leukocyte adhesion. (Au, 2008) Umbilical cord blood
derived EPC could form robust, functional vessels in mice evaluated up to 4 months. Similarly,
mesenchymal stem cells, multipotent adult stem cells, have also been shown to differentiate into
endothelium when injected into adult heart. (Gojo, 2003)
Pluripotent stem cell differentiation into endothelial precursors is the first step of
vasculogenesis. (Flamme, 1995) (Flamme, 1997) (Ferguson, 2005) Post gastrulation, the
formation of 3 germ layers in the embryo, precursors of endothelium and blood are found in the
mesoderm. FGF, TGF-p, and BMP-4 have been shown to be inducers of mesoderm and
subsequent angioblasts formation from pluripotent epiblast cells. Blood islands are discernable
in the yolk-sac shortly after gastrulation in the lateral edges of the mesoderm that consist of
hematopoietic precursors surrounded by angiogenic precursors (angioblasts). Because they
are so closely linked during differentiation and development, a common hemangioblast
progenitor cell may differentiate into both endothelial and hematopoietic precursors. (Flamme,
1995) The fusing of blood islands in the yolk-sac forms the first primitive circulatory network.
(Wang, 1992) These eventually attach to angioblasts within the embryo that have migrated and
aggregated along the midline to forming the dorsal aorta and cardinal veins. Angioblast
differentiation is triggered paracellularly by contact with the endoderm layer. Vascular
endothelial growth factor receptor 2 (VEGFR2) is the first molecule specifically up-regulated in
angioblasts which indicates that VEGF secreted from endoderm is the critical signal for
angioblast differentiation. (Yamaguchi, 1993) GATA2, Bone Morphogenic Protein (BMP), and
Ets family transcription factors are upstream regulators of VEGFR2 expression in mesoderm
cells that respond to FGF signaling. (Lugus, 2007) (Black, 2009) (Wu, 2005) VEGF is one of the
most important regulators of vasculogenesis and angiogenesis; mice deficient in VEGFR-2 die
in utero with a nearly complete lack of vasculature. (al. S. e., 1995) Downstream of initial
lineage commitment events, Tie receptors and their ligands, angiopoietins, are expressed
A) B ) C) 0)
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Figure 1. Molecular Regulation of Vasculogenesis. Although some of the molecules
implicated in vasculogenesis have been determined, many mechanisms remain unknown. A)
Transforming growth factor p (TGFp), Fibroblast growth factor, and Bone morphogenic protein 4
signal to embryonic stem cells to differentiate into mesoderm. B) Mesoderm cells that are
endothelial progenitors, express Vascular endothelial growth factor receptor 2 (VEGFR2/flk-1),
and are thought to be triggered to differentiate by Vascular endothelial growth factor (VEGF)
secretion from adjacent endoderm. C) VEGF and angiopoietin trigger the differentiation into
mature endothelial cells. D) Migration of endothelial cells is stimulated by gradients of VEGF,
stromal derived factor 1 (SDF1), and reactive oxygen species (ROS). Tube formation occurs
through cell-cell junctions by endothelial specific adhesion molecules like Vascular endothelial
adhesion molecule (VECAD) and Platelet endothelial cell adhesion molecule (PECAM).
by angioblasts and are necessary for proper vessel development. The migration of endothelial
cell precursors is thought to be triggered by guidance molecules like stromal derived factor 1
(SDF-1), erythropoietin (Epo), and reactive oxygen species (ROS), and mediated by ephrins,
integrins and ECM proteins to guide cells to the embryonic midline where vascular tubes are
generated. (Schmidt, 2007) Cell adhesion molecules vascular endothelial cadherin (VECAD),
platelet endothelial cell adhesion molecule (PECAM), CD34, and Integrin a5p3 facilitate
intracellular junctions important for lumen formation, cell polarity, and vascular permeability.
(Flamme, 1995) (Figure 1) While these molecules are commonly used to trace endothelial
differentiation and vascular development, we still have limited information about the
mechanisms underlying vasculogenesis. An important first step to achieve this goal was to
develop an appropriate model to mimic this process.
2B. Embryonic Stem Cells as a Model for Vasculogenesis
Pluripotent stem cells, derived from embryonic blastocysts, embryonic carcinoma and
germ cells, or somatic cells induced by chemicals or transcription factors to be pluripotent, have
the capacity to differentiate into all cell lineages. A major focus of the regenerative medicine
field has been to understand and control the differentiation of stem cells toward specific lineages
to recapitulate developmental processes, like vasculogenesis, or generate tissues for
therapeutic purposes. In vitro stem cell models are especially useful for analyzing the effects of
genetic knock-down or chemical treatments on developmental processes that would be lethal to
the embryo, or studying chimeras of cell types cultured together in embryoid bodies. Great
strides have been made toward this goal in recent years, as a number of cell therapies derived
from stem cells have reached clinical trials, including the first two studies using human
embryonic stem cell therapy to treat spinal cord injury and macular dystrophy. (Park, 2010)
Murine embryonic stem cells (ES) cultured in suspension spontaneously differentiate
into cystic embryoid bodies (EB) which regionally differentiate into each of the three embryonic
germ layers and mirrors embryogenesis. (Itskovitz-Eldor, 2000) Doetschman et al. were the first
to discover in 1985 that ES isolated from the inner cell mast of murine blastocysts remain
pluripotent when cultured on fibroblast feeder layers but sponteously form embryoid bodies
containing blood islands when cultured in suspension. (Doetschman, 1985) Shortly thereafter,
EB were used to study the mechanisms of blood island formation and vasculogenesis. (Wang,
1992) (Risau, 1992) (Risau, 1988) These blood islands, which eventually fuse to form vascular
channels, mirror the blood and endothelial cell precursors that give rise to the capillary network
in the developing embryo, and can generate functional blood vessels in vivo and in vitro,
suggesting that vascular development factors are intrinsic to the EB system. Endothelial cells
derived from ES express a full range of specific lineage markers, including VECAD and
VEGFR2/Flk-1. The EB model has been used to delineate the sequential maturation stages of
developing endothelial cells that recapitulates temporal in vivo expression profiles of vascular
markers, including early expression of VEGFR2/Flk-1 followed by PECAM, TIE-2, MECA-32,
VECAD, and MEC-14.7. (Vittet, 1996) VEGF knockdown in EB, a mutation lethal in the embryo,
revealed endothelial progenitor cells that were Flk-1 and PECAM positive but unable to organize
into blood-islands, thus identifying the differentiation stage dependent on VEGF. (Bautch 2000)
Other methods of generating EB include culturing ES in small hanging drops on tissue culture
plates, in bulk semi-solid media or in bioreactors with continuous spinning.
Human embryonic stem cells also form cystic embryoid bodies in suspension culture
which spontaneously differentiate into endothelium correlating with increased expression of
PECAM, CD34, and VECAD. (Levenberg, 2002) Endothelial progenitors can be isolated from
EB by fluorescence activate cell sorting for PECAM+ or other endothelial markers and are
capable of maturing in culture to functional endothelium expressing the appropriate surface
markers and having the ability to take up Acetylated Low Density Lipoprotein. While ES
cultured in vitro appear to possess the capacity for endothelial differentiation that mirrors
vasculogenesis in vivo, they cannot recapitulate the precise special organization of the primitive
vascular plexus of the embryo.
Many studies have focused on methods of directing endothelial differentiation in vitro
that result in higher efficiency yields than the spontaneous EB model and subsequent
endothelial isolation. The most common methods to induce differentiation include exposing
cells to combinations of growth factors or controlling the culture substrate, with or without first
inducing EB formation. Additional methods, like controlling cell-seeding density or physical
factors like shear stress have been used to effectively induce endothelial differentiation.
(Gerecht-Nir, 2003) (Shen, 2003) By far, the most potent pro-vasculogenic factor is VEGF.
Early studies exploring in vitro models of vasculogenesis determined that the addition of VEGF
to culture could increase the number of PECAM+ differentiated cells by 10% and the addition of
other growth factors (FGF-2, interleukin-6, erythropoietin) increased PECAM+ cells by another
5%. (Vittet, 1996) VEGF is also required for the proliferation of endothelial progenitor cells
isolated from EB or bone marrow. (Hirashima, 1999) (Shi, 1998) A combination of VEGF, FGF-
2, insulin like growth factor 1 (IGF1), and epidermal growth factor (EGF) induced rhesus
monkey ES to adopt an endothelial morphology and formed capillary networks when seeded on
matrigel. (Kaufman, 2004) Interaction with neighboring cells stimulates differentiation, as
demonstrated by using mouse bone marrow cells, yolk sac endothelium and fibroblasts to
provoke differentiation of early hematopoietic progenitors. (Kaufman, 2001) Guidance cues are
also provided by defined two and three dimensional matrices. Collagen IV is to date the most
efficient ECM coating to promote mesodermal differentiation and generate increased expression
of Flk1. (Nishikawa, 1998) (Yamashita, 2000) In contrast, fibronectin is most efficient to induce
later stages of differentiation from isolated endothelial progenitors. (Kanayasu-Toyoda, 2003)
(Wijelath, 2004) Three dimensional substrates are advantageous because they mimic the
physiological ECM context and can encourage the formation of larger tissue networks.
(Levenberg, 2007)
Synthetic materials such as polymers have also been explored as substrates for
directing cell differentiation because of their tunable mechanical and chemical properties.
Popular synthetic matrices include polyacrylamides, polyacrylates, poly hydroxyl acids and
natural materials such as agarose and chitosan which can be modified to contain particular
binding motifs or conjugated with ligands. (Saha, 2007) Porous solids, nanofibers and
hydrogels are typically used to generate three dimensional culture systems that more closely
mimic the fibrous, hydrated ECM. ES cultured on alginate scaffolds produce embryoid bodies
that eventually give rise to tissue structures including endothelial tubes. (Gerecht-Nir, 2004)
Levenberg and colleagues have used degradable PLLA/PLGA scaffolds seeded with EPC
isolated from embryoid bodies as implants in mice and demonstrated the generation of a newly
formed vascular network that connects with host vasculature. The same scaffold was used with
EPC and myoblasts to create a vascularized muscle construct. (Levenberg, 2005) Ferreira et
al. observed a 20-fold increase in endothelial differentiation compared to EB when hES were
encapsulated in a dextran based hydrogel tethered with VEGF. (Ferreira, 2007) A dramatically
efficient differentiation method was achieved by McCloskey et al. by growing ES on collagen IV
coatings, FACs isolating Flk+ cells and treating with VEGF, and finally isolating and expanding
cells based on endothelial-like morphology for up to 25 doublings. Although this method is
elaborate, the study reported a final differentiation efficiency of greater than 96% endothelium.
(McCloskey, 2006) While these techniques have been shown to increase endothelial
differentiation, isolated systems such as these are labor intensive do not mimic the complex
physiological interplay of the extracellular niche.
2C. The Extracellular Matrix and Differentiation
The potential of stem cells to generate specific tissue types in a controlled manner is
contingent upon identifying the physiological factors that influence cell fate. A complex interplay
of growth factors and cell-cell interactions are mediated in a dynamic three dimensional
extracellular matrix that triggers molecular transcription pathways controlling cell fate. It is
especially critical to understand the affects of the extracellular milieu when considering stem cell
therapies in diseased or tissue specific environments. While significant progress has been
made in elucidating the paracrine and autocrine mediators of differentiation and pluripotency,
limited attention has been given towards determining the role of extracellular matrix
components.
The extracellular matrix (ECM) supports cell function by surrounding the cell with a
specific combination of structural and soluble proteins and proteoglycans. (Rosso, 2004) The
most abundant structural protein in the ECM is collagen, and its physical properties can
influence cell spreading, morphology, and interaction with other cells. (Prasad, 2002) (Gordon,
2010) Adhesive glycoproteins, like laminin and fibronectin, induce cell-cell and cell-matrix
interactions by binding integrins and cell adhesion molecules. (Hynes, 2009) Proteoglycans like
heparan sulfate proteoglycans (HSPGs) influence cell signaling by binding to soluble signaling
molecules and influencing ligand-receptor interactions. (Park, 2000) The extracellular
microenvironment of stem cell and progenitor cell populations is referred to as a 'niche' that
provides a particular gradient of growth factors and cytokines, paracrine factors, structural and
physical cues that contribute to stem cell stability, proliferation and differentiation. (Schofield,
1978) (Watt, 2009) (Scadden, 2006) A niche can provide signals for stem cell recruitment to
damaged tissues or for precise spatial differentiation in a developing embryo. Components of
the extracellular niche vary from tissue to tissue and developmental stage. (Daley, 2008) In
addition to the molecules comprising the ECM, the molecules associated with remodeling the
matrix play a critical role in the niche. ECM properties are constantly sensed and altered by
internal feedback mechanisms. For example, tension induced signaling through RhoA,
stimulates the unfolding of fibronectin fibrils to synthesize new ECM. (Zhong, 1998) Remodeling
of ECM facilitates cell motility and branching morphogenesis by removing restrictive barriers,
providing cell adhesion sites, mechanical stimuli, and gradients of growth factor exposure.
(Rozario, 2010) It is clear that the ECM has an active role in determining cell behavior.
One of the early studies implicating the importance of ECM proteins in the stem cell
niche discovered that specific structures of heparan sulfate proteoglycans were required for
supporting hematopoietic lineage differentiation. (Gupta, 1998) More highly sulfated heparan
sulfate glycosaminoglycans bound hematopoietic signaling molecules including interleukin-2
and thrombospondin as well as hematopoietic progenitor cells more efficiently than unsulfated
structures. The hematopoietic niche is the most broadly characterized to date; specific locations
of bone marrow have been shown to support various stages of progenitor differentiation.
(Gordon, 1988) Hematopoietic stem cells have been revealed to bind to osteoblast cells that
secrete osteopontin, a proteoglycan that links HSCs with extracellular matrix and proteins that
maintain quiescence and suppress expansion. (Nilsson, 2005) (Vermeulen, 1998) This
highlights how a combination of cell-cell interactions, secreted proteins, and extracellular matrix
interact to create a supportive stem cell niche. An increasing number of studies are now
exploring the mechanisms linking extracellular components and intracellular signaling.
Cells are linked to the ECM through integrins, which also transmit physical stress
signals to the cytoskeleton to regulate ECM maintenance, thus establishing a crosstalk of
information. Integrins assemble fibronectin fibrillar matrices which are crucial to embryonic
development and wound healing, but can bind laminin, collagen, and vitronectin among other
proteins of the niche. (Hynes, 1992) (George, 1993) (Mao, 2005) Specific fibronectin-integrin
interactions have been shown to be critical for vasculogenesis. (Francis, 2002) They have
been implicated in regulating cell proliferation and survival in neuronal stem cells, differentiation
of keratinocytes and other cell types. (Leone, 2005) (Zhu, 1999) Remodeling of ECM is
influenced by tension-mediated integrin signaling through the RhoA-ROCK pathway. (DeMali,
2003) Rho-A signaling can direct mesenchymal stem cells to osteogenic and myogenic
lineages. (McBeath, 2004) (Sordella, 2003) Changes in cellular morphology and tensile
stresses consequence of varying matrix stiffness can have dramatic effects on stem cell
differentiation. (Guilak, 2009) Culture on two dimensional dishes promotes flattened cells rich in
actin-myosin stress fibers, which can shift a chondrogenic phenotype to a fibroblast-like
phenotype. (Holtzer, 1960) Chondrocytic differentiation requires culture in three dimensional or
pellet cultures that can maintain rounded cell morphology. (Hwang, 2006a) (McBride, 2008)
Conversely, mesenchymal stem cells cultured on laminin display elongated phenotypes and
differentiated into smooth muscle, whereas differentiation was inhibited in cells cultured in
rounded morphologies. These effects appear to be mediated by differential of RhoA signaling
due to integrin interactions with the ECM. (Beqaj, 2002) Substrate can direct mesenchymal
differentiation to neuronal, myogenic, and osteogeneic lineages with respective increase in
stiffness. (Engler, 2006) While myotube formation was not dependent on stiffness of collagen
substrate, the development of typical myosin striations occurred only under physical conditions
similar to physiological muscle. (Engler, 2004) Studies probing the effects of mechanical strain
have resulted in mixed results depending on cell type and state of differentiation but
nonetheless demonstrate the influence of mechanical stimuli on developmental processes.
Cyclical mechanical strain can induce mES to differentiate in vascular smooth muscle cells but
has also been shown to inhibit differentiation of hES through upregulation of TGFp1, activin A,
nodal and smad2/3 phosphorylation. (Shimizu, 2008) (Saha, 2008a) It has been suggested that
the mechanosensitivity of stem cells is highly dependent on differentiation stage, as evidenced
by the ability of ES to upregulate cartilage specific genes following mechanical compression
only subsequent of TGFp1 exposure. (Terraciano, 2007)
ECM molecules function through interactions with one another and with soluble factors
that are constantly changing and therefore, it is difficult to study the effects of a single ECM
protein on cell behavior. Nevertheless, many studies have proved that various components of
matrix can have diverse effects on differentiation. The effect of ECM stimuli on embryonic stem
cells may begin as early as the defining trophoblastic versus blastocyst lineage- blastocysts
derived from the inner cell mass cultured on collagen IV, but not collagen I, fibronectin, or
laminin acquired trophoblast markers. (Schenke-Layland, 2007) The consequences of exposure
to various ECM can be diverse depending on cell type and stage of differentiation. Collagen 1,
vitronectin and laminin-332 can induce mesenchymal stem cells to osteogenic differentiation
through activation of the ERK signaling pathway. (Salasznyk, 2007) (Klees, 2005) Laminin was
shown to induce differentiation of neurons, astrocytes, and glia from human and mouse neural
progenitors, as well as smooth muscle differentiation from mouse multipotent lung progenitors.
(Flanagan, 2006) (Nguyen, 2006) (Relan, 1999) The presence or absence of ECM molecules
can be linked to disrupting specific signaling cascades in differentiating cells: Tenascin-C
modulation of Wnt signaling in glial cell differentiation and integrin-mediated ECM regulation of
EGF signaling in tendon differentiation are two examples. (Ruiz, 2004) (Martin-Bermudo, 2000)
Various three dimensional constructs comprised of varying levels of ECM molecules have been
engineered to identify the precise compositions that will guide ES differentiation. (Flaim, 2005)
(Battista, 2005) Although efforts have been made to understand to role of various ECM
components in cell differentiation, the contribution of key elements of the ECM, including
heparan sulfate glycosaminoglycans, remains unknown.
2D. Heparan Sulfate Glycosaminoglycans
Heparan sulfate glycosaminoglycans (HSGAG) are one element of the ECM that
regulate multiple signaling cascades and have been shown to change composition in certain
cancers, during development and cell death. (Sasisekharan, 1994) (Johnson, 2004)
(Nurcombe, 1993) Because of their complex compositions, the specific contributions of specific
HSGAG structures are only beginning to be elucidated. However, recent studies suggest that
the chemical compositions of HSGAG are a dynamic component of the cellular
microenvironment by their ability to temporally and spatially bind important signaling molecules.
HSGAG are the linear polysaccharide component of proteoglycans expressed on the
cell-surface or in the ECM, and are evolutionary conserved from drosophila to vertebrates.
(Bernfield, 1999) (Esko, 2002) There are four core protein classes: syndecans and glypicans,
which are anchored in the cell membrane by a glycosyl-phosphatidylinositol linker, and agrin
and perlecan, which are excreted into ECM. Mutations in these proteins have been associated
with developmental defects. (Perrimon, 1999) Once assembled, these core proteins are
transported to the Golgi apparatus where HSGAG chains are attached and structurally modified
by a series of enzymes. First, a common tetrasaccharide is attached to a serine residue on the
protein core, followed by repeated units of glucuronic acid and N-acetyl glucosamine linked via
1-4alpha linkages to create a chain of 50-150 disaccharides. (Lind, 1993)
Once the disaccharide chain has been assembled, the nascent chains are post-
synthetically modified through sulfation. It is assumed that these modifications are introduced
by sulfotransferase enzymes that function sequentially. Exotosin enzymes EXT1 and EXT
synthesize the HSGAG chains made repeating of N-acetylglucosamine and glucuronic acid
disaccharides. The first alteration is by N-deacetylase/N-sulfotransferase (NDST), which forms a
complex with EXT1 and EXT2 during the formation of the disaccharide chain. The expression of
EXT enzymes was also found to affect NDST expression which supports the notion of a
precisely controlled "GAGosome" enzyme complex which controls sulfate modifications. (Presto,
2008) (Esko, 2002) Because subsequent chain modifications occur at specific sites adjacent to
N-sulfation, NDST controls the final HSGAG sulfate composition. After NDST functions, C5-
epimerase converts glucuronic acid residues adjacent to N-sulfated groups to iduronic acid.
Finally, sulfate groups are added to specific 2-0, 3-0, and 6-0 positions of the sugars by their
respective sulfotransferases (2-OST, 3-OST, 6-OST) using a 3'-phosphoadenosine 5'-
phosphsulfate donor. (Esko, 2002) (Figure 2) The iduronic acid unit has one possible sulfation
site, the 2-0 group, and the glucosamine unit has 3 possible sulfation sites, the 3-0, 6-0 and
free amine groups. Therefore, 32 possible disaccharide units linked linearly in an HSGAG chain
generate an enormous array of chemical compositions that contributes to cell signaling and
function. (Nurcombe, 2006) (Bernfield, 2000) HSGAG modulate cell interactions with critical
signaling molecules and ECM, and therefore play a documented role in many diseases
including atherosclerosis, virus infections, diabetic retinopathies, glomerular injury, and tumor
growth and spreading. (Jackson, 1991)
The stoichiometry of enzymes in the complex may control the final sulfate composition.
Isoforms of the various enzymes add an additional level of complexity. For example, four N-
deacetylase/N-sulfotransferase (NDST) isoforms exist in vertebrates which appear to have
different substrate affinities. NDST1 and NDST2 are expressed in every cell type whereas
NDST3 and NDST4 are only expressed during development or in specific tissues. (Grobe,
2002) (Aikawa, 2001) Generally, sulfation occurs in clusters of disaccharides along the chain
creating regions of rigid negatively charged sites among flexible unmodified regions to allow for
specific binding of proteins near the cell surface. (Maccarana, 1996) (Wilson, 2002) Binding of
ligands is of relatively high affinity, Kd-1-1OOnM, while binding to ECM is somewhat lower,
Kd-1uM. Soluble proteins interacting with HSGAG chains can be stored for future release,
protected from degradation, or presented to a cell surface receptor to facilitate binding. (Varki,
1999) It is unknown whether sulfate sequences are specific for a particular proteins or families
of proteins. The activity of specific enzyme isoforms may be responsible for consistent
differences in sulfation and spacing of sulfated regions in various cell types. (Eriksson, 1994)
(Brandan, 1988) (Toma, 1998) (Sanderson, 1994) For example, successive stages of
Figure 2. Heparan Sulfate Glycosaminoglycan Enzymatic Modifications. Specific HSGAG sulfate
modifications occur in the Golgi Apparatus. A) Once a tetrasaccharide linker is attached to the core
protein, a backbone of repeating glucuronic acid and N-acetyl glucosamine disaccharide units is
generated. The first backbone modification is by N-deacetylase/N-sulfotransferase, which removes the N-
acetyl unit and replaces it with a sulfate group. B) The next modification is by C-5 epimerase, which
converts occasional glucuronic acid units to iduronic acid. C) Finally, 2-0, 3-0, and 6-0 sulfotransferase
enzymes add sulfate groups at their respective positions on iduronic acid (2-0) and glucosamine (3-0 and
6-0) units to generate the final HSGAG sulfation pattern.
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developing neuroectodermal cells produce HSGAGs which favor specific binding to FGF-1 or
FGF-2. (Nurcombe, 1993) The result of this complex, non-template driven synthesis of sulfated
HSGAG chains is a unique HSGAG "glycome" environment surrounding the cell. Changes in
the cellular glycome contribute to the dynamic extracellular niche which controls stem cell
maintenance and differentiation. The variable sulfation of the disaccharide chain creates the
HSGAG diversity that is associated with assorted biological functions because signaling
molecules and ECM components like fibronectin, collagen, and thrombospondin bind to anionic
sulfation sites. Specific sequences of HSGAG bind to molecules like FGF, LDL lipoproteins,
and antithrombin. (Nurcombe, 2006)
2E. HSGAG in Development
While analysis of HSGAG has been a challenge, many studies have used genetic
approaches to implicate them in embryonic development. (Haeker, 2005) The most well
characterized pathways affected by HSGAG alterations are Wnt/Wg and FGF families.
Drosophila mutants sugarless and sulfateless, expressing mutations in UDP-glucose
dehydrogenase (responsible for glucuronic acid synthesis) and in N-deacetylase/N-
sulfotransferase, respectively, display abnormalities in segment polarity and ventral patterning
which have been associated with disrupted Wg (Wnt-1) signaling. (Perrimon, 1999) (Haeker,
1997) These mutants were found to be similar to drosophila mutants with diminished FGF
signaling functionality which leads to disrupted tracheal development, mesodermal cell
migration and determination of particular cell fates. It is now well established that HSGAG
sulfation is required for proper FGF ligand/receptor complex formation which plays a crucial role
in developmental cell migration and differentiation. (Ornitz, 2000) (McKeehan, 1998) (Krufka,
1996) Specific 6-0, N, and 2-0 sulfate patterns bind different FGF isoforms to receptors. (al. P.
e., 2000) (Kreuger, 2004) (Princivalle, 2002) In the mouse, mutation of the 3-OST using a gene
trap method was demonstrated to be lethal to the development of the kidney (Bullock, 1998)
while NDST1 mutation produced embryonic lethal embryos with immature lung formation.
(Ringvall, 2000) And in the zebrafish, Chen et al demonstrated that 6-OST1 but not 6-OST2
exhibited abnormalities in the branching morphogenesis of the caudal vein during embryonic
development. (Chen, 2005) Because of the critical role that HSGAGs play in development by
controlling critical signals, it will be interesting to uncover their functions in stem cell
differentiation and progenitor cell fate.
Emerging studies have begun to associate HSGAG compositions as important for stem
cell differentiation potential or differentiation into specific lineages. (Nairn, 2007) (Nurcombe,
2006) Embryonic stem cells lacking HSGAG are unable to differentiate because FGF signaling
disruption causes pluripotency transcription factors to remain active. Embryonic stem cells
primed for differentiation but deficient in HSGAG chains maintained markers of pluripotency
significantly longer than controls. (Kraushaar, 2009) Knockdown of phospho-adenosine
phospho-sulfate, the donor of sulfate moieties to HSGAG chains, results in a stunting of
mesodermal differentiation and an increase in ectodermal differentiation. (Sasaki, 2009)
Signaling molecules important for neural progenitor development and axonal guidance,
including netrins, slits, and their receptors, are modulated by HSGAG. (Serafini, 1994) (Wang,
2005) (Wilkinson, 2001) Irie et al. demonstrated that the addition of exogenous HSGAG disrupts
axonal targeting and discovered that specific sulfate compositions of the HSGAG backbone are
critical for controlling signaling, and not simply the degree of sulfation. (Irie, 2002) Another study
using HSGAG epitope-specific antibodies reported that the sulfation motifs in pluripotent
embryonic stem cells are different from those of neural progenitors. (Johnson, 2007) HSGAG-
specific antibodies have also been used to identify a unique and transient sulfate epitope
expressed in stem cells differentiating along a mesodermal lineage. Separated cells possessing
this epitope had a dramatically increased potential to form endothelial colonies. (Baldwin, 2008)
Thus, HSGAG-specific epitopes can be used as a novel means to identify and sort cell types as
well as determine signaling molecules that bind to transient epitopes during developmental
pathways. These observations raise the possibility that unique HSGAG epitopes could be
harnessed to control the differentiation of stem cells into specific lineages.
2F. HSGAG Modulation of Vasculogenic Factors
Heparan sulfate glycosaminoglycans are capable of modulating the niche by generating
gradients of growth factors and modulating ligand receptor binding by providing specific binding
motifs along the sulfated backbone. Heparan sulfate may act to sustain the threshold activation
of cell surface receptors required for signaling or simply prevent the diffusion of growth factors.
(lozzo, 2001) The importance of HSGAG in vasculogenesis is clear from a number of genetic
studies in which modulation of HSGAG patterns inhibits vascular development. (Chen, 2004)
(Harfouche, 2009) For example, morpholino inhibition of HSGAG core proteins syndecan-2, or
perlecan causes abnormal development of vessels in zebrafish embryos that could be partially
rescued by overexpressing VEGF. (Zoeller, 2009) In many cases, the disruption of HSGAG
sulfation patterns can be linked to specific vasculogenic mechanisms. A small molecule
antagonist of HSGAG, surfen, interrupts FGF-2, VEGF 165 and fibronectin interactions with
endothelial cells and prevents sprouting. (Schuksz, 2008) In fact, several of the first
vasculogenic growth factors were isolated by their affinity to heparin and heparinases were
shown to inhibit neovascularization. (Folkman, 1986) (Sasisekharan, 1994) Specific HSGAG
patterns can be exploited to control the activity of vasculogenesis signals.
VEGF 165 is the most potent mitogen for vessel formation and is dependent on binding to
specific HSGAG sequences. Ono et al. used chemically modified HSGAGs to determine that a
high content of 2-0 sulfation is not required for VEGF binding and 2-0-desulfated HSGAGs
could sequester VEGF from proliferating endothelial cells in culture whereas 6-0 and N-S
desulfated fragments could not. (Ono, 1999) The requirement of 6-0 sulfation for VEGF
binding was confirmed by Chen et al. who demonstrated that knockdown of 6-0 sulfation
enzymes in zebrafish impeded caudal vein morphogenesis and had a synergistic effect with
VEGF knockdown. (Chen, 2005) The effect was linked to defects in late endothelial
differentiation events as demonstrated by decreases in TIE-1 and TIE-2 receptors. By using a
library of HSGAG isolated from different cell types and selectively de-sulfated, Robinson and
colleagues reinforced that all sulfate positions played a role in VEGF binding affinity, but 2-0
sulfation was less important than N-S or 6-S. (Robinson, 2005) Varying disaccharide lengths
were also explored and led to a proposed model where two separate highly sulfated domains
along the HSGAG chain at least six disaccharides in length and containing a central 6-0
sulfated glucosamine residue results in extremely stable binding to VEGF165. Heparan sulfate
interacts with the exon-7 coding region of VEGF 165 and interacts with VEGFR2 to increase
endothelial proliferation and tube formation. (Ashikari-Hada, 2005) Various sulfate binding
motifs have been shown to have differential effects on specific cell types and may be
synthesized to control threshold signaling levels or act as both decoys and co-receptors for
growth factors and determining respective sulfate sequences confers another level of
complexity in the field. The compositions of HSGAG chains on neuropilin-1, a co-receptor for
VEGFR-2, were different on endothelial and smooth muscle cells and result in different
responses to VEGF. (Shintani, 2006) Differentiating EB derived from NDST1/2 null mice were
found to be defective in HSGAG sulfation and unable to spontaneously generate endothelium
due to lack of VEGF 165-VEGFR2 response. Soluble heparan sulfate was unable to rescue this
phenotype, but chimeric EB containing cells capable of producing sulfated HSGAG could,
suggesting the possibility of intercellular crosstalk in stabilizing receptor interactions.
(Jakobsson, 2006) However, our data demonstrates that soluble heparan sulfate is able to
rescue endothelial differentiation potential from EB with siRNA suppression of NDST1.
(Harfouche, 2009) Neovascularization in tumors derived from mice with an endothelial specific
deletion in NDST1 was dramatically suppressed despite intact pericytes surrounding vessels.
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(Fuster, 2007) Collectively, the results indicate that regulation may be context dependent or
that cells can draw on a variety of HSGAG sources of HSGAG to proceed through
developmental stages.
Fibroblast growth factors are the most well studied protein with respect to their
dependence on HSGAG for receptor signaling and are crucial for mesoderm differentiation and
the generation of angioblasts among other developmental roles. FGFs bind heparan sulfate
with low affinity but high capacity which catalyzes interaction with high-affinity but low capacity
receptors thus acting as a reservoir and increasing the half-life of ligand receptor binding.
(Ornitz, 2000) The receptor and ligand are internalized with the HSGAG binding chain. HSGAG
composition changes during development or in different tissues to accommodate the binding of
various FGFs- FGF-2 preferntially binds to HSGAG harvested from neuronal tissue at
embryonic day 9 while FGF-1 favors HSGAG from day 11. Both isoforms are produced during
this timespan which highlights the importance of HSGAG composition regulation in maintaining
specific developmental signals. (Nurcombe, 1993) 6-0 glucosamine sulfation is required for
FGF ligand-receptor interactions. 6-0 endosulfatase, which removes sulfate groups from the 6-
0 glucosamine position, strikingly reduces FGF2 signaling in ovarian cancer cells, chick and
xenopus embryos. (Nakato, 2002) (Lai, 2003) (Wang, 2004) The first studies to associate intact
HSGAG for proper FGF signaling occurred in D. melanogastar, when mutants of UDP-GIcA-
dehydrogenase, HS polymerase, and N-deacetylase/N-sulfotransferase disrupted mesoderm
development in a manner similar to FGF knockdown. (Lin, 1999) In fact, these mutants
mutations lead to complete disruption of FGF, Wnt/Wg, and hedgehog signaling cascades, all of
which generate gradients to control cell polarity and pattern formation during development.
Isoforms of FGF, along with bone morphogenic proteins (BMP), also play a major role in
maintaining stem cell pluripotency. (Xu, 2005) It is easy to imagine a paradigm where isoform
specific HSGAG are generated to control cell phenotype.
The transforming growth factor-p (TGF-p) family regulates proliferation, migration, and
differentiation of cells. TGF-p secretion in the mesoderm is required for vasculogenesis,
specifically for the organization of endothelial cells into tubes. (Goumans, 1999) It increases the
differentiation of endothelial cells in embyroid bodies yet inhibits angiogenic sprouting indicating
that a high level of signaling control is required for appropriate vessel development. (Mallet,
2006) Approximately one fourth of the proteins in this family have been shown to bind to
heparin and heparan sulfate which allows them to achieve precise site-specific functionality.
(Rider, 2006) Binding of HSGAG to TGF-pl, but not TGF-p2 or TGF-p3, potentiates its action
by preventing its degradation and the formation of inactive complexes with macroglobulin and
therefore affect isoform specific function. (Lyon, 1997) This study identified N-sulfation as
critical for binding of TGF-p. Heparan sulfate proteoglcyans also regulate the storage of TGF-
p in the extracellular matrix through interactions with latent transforming growth factor-p binding
proteins (LTBPs) and fibronectin. (Chen, 2007) Bone morphogenic proteins (BMP) are an
important subgroup of the TGF-p family, and BMP-2 and BMP-4 are the most important
isoforms associated with vascular development. BMP-4 is essential for mesoderm formation
and can induce the differentiation of angioblasts from mesoderm. (Park, 2004) (Nimmagadda,
2005) BMP-4 inactivated mouse embryos possess lethal defects in mesoderm formation, or
survive until the stage of endothelial formation with significantly reduced numbers of blood
islands, indicating that BMP-4 is crucial for differentiation of both mesoderm and endothelial
lineage differentiation. (Winnier, 1995) BMP-2 has been specifically associated with migration
and tube formation of endothelial cells. (Langenfeld, 2004) BMP-2 and BMP-4 are critical to
patterning in primitive embryonic germ layers and thus their action is tightly restricted around the
cells that secrete them; the action range of these proteins is defined by a basic amino acid core
that binds to HSGAG and limits their diffusion. (Ohkawara, 2002) HSGAG directly regulate the
differentiation of mesenchymal stem cells into bone by sequestering BMP; treating cell cultures
with heparinase enzymes significantly increased availability of the cytokine and increased
osteogenic differentiation. (Manton, 2007)
Interactions with other extracellular matrix proteins represent other mechanisms through
which HSGAG regulate signals that control differentiation. As stated above, ECM proteins like
fibronectin and laminin can influence mechanical stimuli and directly bind with cell surface
integrins. The unfolding and polymerization of fibronectin is a requisite for neovascularization.
(Zhou, 2008) This process is stimulated by the binding of heparan sulfate chains which change
the conformation of fibronectin. Specific HSGAGs with 6-0 and N sulfated glucosamine can
expose a fibronectin binding motif for VEGF 165. (Mitsi, 2008) This indicates another level of
HSGAG control over growth factor presentation in the context of vasculogenesis. The examples
presented here highlight HSGAG interactions that mediate critical vasculogenesis cues but
many other factors involved in neovascularization have been shown to interact with HSGAG
including IGF-2, PDGF, and PECAM among others. (Bernfield, 1999)
CHAPTER 3. Heparan Sulfate Glycosaminoglycan Regulation
of Vasculogenesis in Embryonic Stem Cells
(Parts of this chapter are taken from "Harfouche*, Hentschel*, Piecewicz*, et al. Glycome and
Transcriptome Regulation of Vasculogenesis. 2009, 120(19), Circulation.")
Harnessing the vasculogenic potential of embryonic stem cells is an emerging concept
to generate neovasculature. The differentiation of embryonic stem cells into endothelium has
been well documented, however most studies focus on genetic or chemokine regulation.
Limited information exists which implicates the role of the extracellular microenvironment in
stem cell differentiation. Heparan sulfate glycosaminoglycans (HSGAG) are a crucial part of the
"active" extracellular matrix glycome and have been shown to regulate multiple signaling
cascades and therefore dynamically regulate cellular signal transduction. Because HSGAG
bind and sequester many key vasculogenic factors, like FGF and VEGF, we wanted to
determine if HSGAG themselves modulate vasculogenesis. The goal of this section was to
characterize the role of HSGAG during vasculogenesis using embryonic stem cells.
3A. Embryonic Stem Cell Culture
The two defining characteristics of stem cells are pluripotency, the potential to give rise
to any cell type excluding extra-embryonic tissue, and capacity for self-renewal. By varying
culture conditions, embryonic stem cells (ES) can be induced to maintain pluripotent and
proliferate, or to differentiate into diverse cell lineages. ES grown on mitotically inactivated
fibroblast feeder cell layers remain undifferentiated due to cytokines secreted by the feeder cells
that activate intracellular transcription factors like Oct-4 and Nanog that maintain self-renewal
and inhibit differentiation. (Figure 3) Specific cytokines have been discovered that replace the
need for feeder layers to maintain pluripotent ES cultures on gelatin coatings, including
Leukemia Inhibitory Factor (LIF), an interleukin 6 class cytokine upstream of JAK/STAT
pathways, and bone morphogenic protein-4 (BMP-4). (Ying, 2003) While these two factors are
adequate for maintaining murine ES cultures, requirements for maintaining human ES cultures
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are somewhat more complex. 'Feeder-Free' hES cultures can be propogated in media
containing bFGF and various other cytokines when grown on matrigel@ or laminin. (NIH, 2001)
In the absence of the aforementioned cytokines, ES spontaneously differentiate in
culture, proceeding through three germ layers endoderm, ectoderm and mesoderm, to give rise
to diverse cell types. (Keller, 1995) When grown in non-adherent conditions, ES aggregate into
cystic spheroids that mimic the pre-implantation embryo and are called 'embryoid bodies' (EB).
(Figure 3) EB are the best known model for recapitulating embryonic development, specifically
comparable to the egg cylinder-stage mouse embryo, and therefore are very commonly used as
a starting point of ES differentiation models. (O'Shea, 2004) EB are characterized by an outer
layer of endoderm and core of differentiating cells surrounding an epithelial lined cavity. The
outer epithelial-like layer is self-assembled by cell-adhesion molecules like E-Cadherin and the
overall size is dependent on the density of cultured ES. Not surprisingly, the size of EB has
been shown to affect intercellular signaling and differentiation because of changes in ECM
interactions and exposure to soluble molecules. Micropatterned culture plates or polymers can
be used to generate uniform, size specific EB. (Bauwens, 2008)They are an excellent tool for
studying early stage progenitor cells and developmental process that cannot be isolated easily
in vivo. Specific cell types can be isolated from EB directly after disassociation or after plating
EB under various culture conditions to induce differentiation paradigms. The most popular
methods for generating EB include seeding ES on non-adherent, coated dishes, in small
hanging drops of media or PBS, in semi-solid porous gels, or in stirred bioreactors. When
plated on adherent substrates, neuron and endothelial-like projections emanate from the
spherical bodies and other cell morphologies can be easily identified. While the three
dimensional EB model best mirrors embryonic development in vivo, two dimensional culture
conditions are used to ensure precise and uniform exposure of cytokines to ES for directed
differentiation. (Bratt-Leal, 2009)
Regardless of the cell line used or methods of EB formation, vasculogenesis can be
accomplished in vitro. Blood islands containing endothelial progenitors emerge on the surface
of EB after approximately 4-5 days and vascular channels appear within the EB between one
and two weeks, mimicking the formation of a primitive vascular plexus. Endothelial cells derived
from ES express a full range of specific lineage markers, including vascular endothelial cadherin
(VE-CAD), TIE-2 and VEGFR2 (Flk-1). This model has been used to delineate the sequential
maturation stages of developing endothelial cells that recapitulates temporal in vivo expression
profiles of vascular markers. (Risau, 1988) (Wang, 1992) (Vittet, 1996)
3B. Materials and Methods
Cell Culture: Murine 9TR#1 strain 129/Sv+c/+p embryonic stem cells were obtained from
ATCC (Manassas, VA). ES were maintained undifferentiated using a growth medium consisting
of L-glutamine-containing DMEM, 0.1 mM non-essential amino acids, 0.1 mM sodium pyruvate,
0.1 mM 2-mercaptoethanol, all from Invitrogen (Carlsbad, CA), as well as 1000 U/ml leukemia
inhibitory factor (LIF) (Chemicon Inc., Temecula, CA) and 15% fetal bovine serum (HyClone,
Logan, UT) and grown on 0.1% gelatin at a density of 18,000 cells/cm2. When colonies reached
approximately 70% confluency, they were passaged using 1X Trypsin/EDTA up to passage 2.
Differentiation was induced by removing LIF from the medium and seeding cells (passage 2) at
a density of 3000 cells/cm2 on Ultra Low Attachment 100mm dishes or 6-well plates (Corning,
Lowell, MA). For matrigel assays, 3 day embryoid bodies were transferred to polystyrene
culture plates coated with various dilutions of growth-factor reduced BD Matrigel Matrix (BD
Biosciences) and PBS supplemented with VEGF, FGF, HGF, all 5nM (R&D). Cells were fed
over 10 days with complete media with or without growth factors. (Cambrex basal media CC-
3125 supplemented with EGM-MV BulletKit CC-4133).
Quantitative PCR: RNA was isolated from cells at the indicated days using Aurum Total RNA
isolation kit with DNAse digestion step and total RNA reverse transcribed using iScript cDNA
Synthesis kit according to manufacturer's instructions. (Bio-Rad, Hercules, CA) The levels of
mRNA for specific genes were detected by using designed oligonucleotide primers (IDT, Inc.)
and monitoring SYBR Green fluorescence using a Bio-Rad MyIQ iCycler. The normalized
reporter (Rn) was calculated from threshold values, Ct, for each gene as follows: Rn=2 X- CT,
where 8 CT=(average CTtarget-average CTexpermental control) and 18S was used as endogenous
control to normalize quantities of cDNA. Primers used: 18S(5'-aaatcagttatggttcctttggtc-3' and
5'gctctagaattaccacagttatccaa-5'), Oct-4(5'-gttggagaaggtggaaccaa-3' and 5'-ctccttctgcagggctttc-
3'), Tie-2(5'-ggaaacctgttcacctcagc-3' and 5'-ccacttctgagcttcacatctc-3'), VE-Cadherin(5'-
tgcatcctcaccatcacagt-3' and 5'-tccagcgcactcttgctat-3'), VEGFR-2(5'-gctttcggtagtgggatgaa-3' and
5'-ggccttccatttctgtacca-3'), Nanog (5'-ttcttgcttacaagggtctgc-3' and 5'-agaggaagggcgaggaga-3'),
Sox2 (5'-tccaaaaactaatcacaacaatcg-3' and 5'-gaagtcaattgggatgaaaa-3'), PAX6 (5'-
gttccctgtcctgtggactc-3' and 5'-accgcccttggttaaagtct-3'), Brachyury (5'-cagcccacctactggctcta-3'
and 5'-gagcctggggtgatggta-3'), AFP (5'-catgctgcaaagctgacaa-3' and 5'-ctttgcaatggatgctctctt-3'),
VEGF (5'-ggagatccttcgaggagcactt-3' and 5'-ggcgatttagcagcagatataagaa-3'), Ang-2(5'-
catctgcaagtgttcccaga-3' and 5'-aagttggaaggaccacatgc-3'), Foxo5(5'-cgacacagagaggagacacg-3'
and 5'-cgtgatcaacttcgcaattcgt-3'), NDST-1 (5'-cagggaaattcttccacacag-3' and 5'-
cacataggacaacagcagatcg-3'), VWF(5'-gttggcgaggatggagttc-3' and 5'-gatctgacagggctgatggt-3')
Foxo3a (5'-gctaagcaggcctcactcca-3' and 5'-ttccgtcagtttgagggtct-3'), IGF1 (5'-
caaaagcagcccgctcta-3' and 5'-tcgatagggacggggact-3') and IGF2 (5'-actgatgccgaagaagttgc-3'
and 5'-tcagtttcctgccttccatt-3'), 2-OST (5'-tccgactgtgctccagaga-3') and (5'-catctgctccctacattccag-
3'), 3-OST (5'-aaggacaacgtggtgttgc-3') and (5'-aaaggggaggtgtctattcca-3'), 6-OST (5'-
cgaactcaccaactgtgtgc-3').
Immunoblotting: Cells were washed twice with PBS and directly lysed in 3X loading buffer
containing 12% sodium dodecyl sulfate, 15% 2-mercaptoethanol, 1 mM sodium orthovandate
and protease inhibitor cocktail tablets from Roche Applied Sience (Indianapolis, IN). Samples
were then heated for 10 min at 100 0C and equal amounts loaded onto tris-glycine SDS-
polyacrylamide gels. Proteins were electrophoretically transferred onto polyvinylidene difluoride
or nitrocellulose membranes, blocked for 1 h with 10% non-fat dry milk, and subsequently
incubated overnight at 40C with primary antibodies, NDST1 (Affinity Bioreagents), p-actin (Cell
Signaling Technologies). Proteins were detected with horseradish peroxidase-conjugated anti-
rabbit or anti-mouse secondary antibodies and WesternC Peroxidase Substrate (Roche Applied
Sience). The blots were developed using a GeneSnap imaging device and optical densities off
the protein bands quantified using GeneTools (both from SynGene, Frederick, MD).
Predetermined molecular weight standards were used as markers. Proteins were normalized
against p-actin.
Immunocytochemistry: Embryoid bodies were washed with PBS and fixed in absolute
methanol (vwf staining) ir 4% PFA (oct4, tie-2). Cells were permeabilized using 0.1% Triton X-
100 and 0.1% Tween-20 in PBS for 10 min and blocked for one hour with 1% BSA prior to
addition of the primary antibody. VWF(DAKO), Oct4(Santa Cruz), Tie2 (Santa Cruz) primary
antibodies were added to samples overnight at 40C. Samples were incubated with their
corresponding primary antibodies overnight, followed by Alexa Fluor488-conjugated secondary
antibodies (Invitrogen) for 1 hour. Cells were counterstained with propidium iodide. Images were
captured using a Leica LSM510 confocal microscope at a 512x512 pixel resolution.
Fluorochromes were excited with 488 (Alexa Fluor488) nm and 543 (propidium iodide) nm laser
lines and the images captured using 505-53- BP and 565-615 BP filters at a 512x512 pixel
resolution. For matrigel immunostaining assays, day 3 embryoid bodies were transferred to
matrigel substrates and were fixed and stained on day 10.
Flow Cytometry: Cells grown in 100mm dishes were washed with PBS, fixed in ice-cold
methanol and then incubated with rat monoclonal antibody against CD16/CD32 (1:50 dilution,
Pharmingen , BD Biosciences) in order to block Fc receptors. Cells were incubated overnight
with a polyclonal primary antibody directed against VWF or an isotype-matched polyclonal IgG
antibody (Pharmingen) as an internal control. Cells were then washed, incubated with Alexa
Fluor488-conjugated anti-rabbit antibody and counterstained with propidium iodide. Samples
were analysed on a Becton Dickinson FACScan flow cytometer (excitation 488/280 nm).
shRNA Lentivirus Infection: In order to selectively knock-down NDST1 in ES, we infected ES
using NDST1 and control (siGFP) short hairpin RNAs (sHRNAs) in a pLKO.1 puromycin-
resistent vector Mission@ Lentiviral Transduction Particles (Clone ID TRCN0000097920, Sigma-
Aldrich). Briefly, 1 day embryoid bodies were cultured on ultra-low adherent plates (as above)
and infected with 1 or 5 multiplicity of infection (M.O.l) of viruses in the presence of polybrene
transfection reagent (Millipore, Bedford, MA) overnight and in some cases 5ug/mI puromycin
was added to media 24 hours later. Media was replenished every 3 days.
Capillary Electrophoresis Disaccharide Profiles: Cells were washed with PBS and then
incubated with trypsin/EDTA (Invitrogen) for 30 min at 370C in order to harvest cell surface
proteoglycans. Cells were then counted in order to normalize cell number for subsequent
disaccharide analysis. HSGAGs were isolated using a DEAE Sephacel resin (Amersham
Pharmacia Biotech) ion exchange column with 200mM NaCl wash buffer and 1 M NaCl elution
buffer. Samples were washed and concentrated using 3kDa Millipore columns. HSGAGs were
digested by incubating with 3 mlU each heparinase I, heparinase ll, and heparinase 11 (IBEX) at
300C overnight. Digestion products were analyzed using an Agilent 3D capillary electrophoresis
system with a 72 cm extended light path capillary, 75 um inner diameter. Negative polarity
separation was monitored at 235 nm in 50mM Tris, 10 mM dextran sulfate buffer pH 2.5. Peaks
were assigned by comparison to standards, AUA-2S GIcNAc, AUA-2S GIcNS-6S, AUA-2S
GIcNAc-6S, AUA-2S GlcNs, AUA GIcNAc (V-Labs, Inc.) run using the same protocol.
3C. Embryoid Body Vasculogenesis Model
We selected the well characterized EB model to study vasculogenesis in vitro. When
grown under ultra-low adherent conditions in the absence of LIF, ES cells start forming solid
morula-like structures within 2 days, which progressively increase in size and finally become
cavitated consistent with earlier reports. (Figure 3) EB express a specific marker for
pluripotency, Oct4, at day 3 and markers specific for endothelial cells, like TIE-2, by day 7.
(Figure 3) At different time points during the differentiation process, EB were collected, and
RNA was extracted for analysis of endothelial-related gene expression by quantitative PCR (RT-
PCR). Expression level for endothelial cell markers such as VECAD, VEGFR2, Von
Willebarnad Factor (VWF), TIE-2 and Angiopoietin-2 (Ang-2) increased as quantified by RT-
PCR, while expression of the stem cell marker Oct4 decreased progressively over a 10 days
period, consistent with a differentiation paradigm towards vascular endothelial cells. (Figure 4)
This was further validated by quantifying the protein expression of VWF, TIE-2 and Oct-4 using
FACS. The generation of endothelial cells was further characterized by immuno-staining for
VWF, a functional marker of endothelium. Confocal imaging following immunostaining of EB for
VWF revealed negligible signal at day 3, but progressively increasing expression with time. This
finding is consistent with previous reports, where an increase in endothelial cell markers was
observed only after day 3 of differentiation. Hemangioblast precursors are first established at
this time point, coinciding with the onset of vasculogenesis in the mouse embryo. Although the
transcription signals for the endothelial cell markers increased beyond day 7, we opted to
characterize vasculogenesis between days 3 and 7, to avoid the effects of angiogenesis which
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Figure 3. Culture of murine embryonic stem cells 9TR#1 strain 129. A) ES cultured on gelatin
coated plates supplemented with media containing FBS and LIF remain pluripotent and self-renew.
Colonies of ES display a rounded morphology and are captured here using phase contrast
brightfield imaging. Some fibroblasts are present from earlier passaging of cells. B) When colonies
grow large enough and interact, differentiation is triggered. Jagged morphologies of differentiated
cells appear on the perimeter of ES colonies. C) Pluripotent stem cells seeded in non-adherent
coated tissue culture dishes spontaneously aggregate into embryoid bodies. EB are characterized
by an outer layer of endoderm surrounding a core of differentiating cells, and mimic embryonic
development. Various soluble factors can be added to direct differentiation. D) Left: Day 3
embryoid bodies were stained for pluripotency marker, Oct4 (FITC), and counterstained with DAPI.
Right: Day 7 embryoid bodies express endothelial specific marker TIE-2 (TRITC) and DAPI nuclear
counterstain. Images were captured using a Nikon eclipse TI fluorescent microscope using
QCapture Pro software.
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Figure 4. Embryonic stem cells efficiently differentiate into endothelium. A) Embryoid bodies
at days 3, 7 and 10 were fixed and stained for endothelial specific marker, von Willebrand Factor
(green fluorescence), and counter-stained with propidium iodide nuclear stain (red fluorescence).
VWF staining, and thus the appearance of endothelium, progressively occurs in culture after
approximately 7 days. Confocal images were captured using a Leica LSM510 microscope at a
512x512 pixel resolution. B) Quantitative PCR was used to examine mRNA levels of stem cell and
endothelial specific transcripts. Pluripotency marker Oct4 decreases significantly as EB grow and
differentiate, while endothelial specific markers VE-Cadherin, VEGFR2, VWF, Tie2 and Ang2
significantly increase over this period, evidence that endothelial cells are generated and
vasculogenesis is successfully achieved. ***denotes P<0.001 compared to day 3.
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has been reported to initiate beyond day 6. (Nakagami, 2006) Unless otherwise mentioned, this
was the primary model we used for probing the effects of HSGAG and soluble factors on
vasculogenesis.
Culture substrates made of various extracellular matrix proteins like collagen, fibronectin,
laminin and tenascin-c substantially affect ES differentiation and are often selected on this
basis. Substrates effect intracellular signaling by triggering integrin pathways and effecting cell
interactions, growth and morphology. Although substrate and culture conditions for promoting
endothelial differentiation has been thoroughly explored in the literature, we wanted to
investigate the effects of various ECM substrates on our vasculogenesis model. In our studies,
ES seeded directly on collagen type 1, collagen type 4, fibronectin, or laminin did not efficiently
proliferate. When ES were first induced to form embryoid bodies and seeded after several days
on various substrates, we saw no significant effects on vascular differentiation by the various
matrices. Because of this reason, and to be consistent while discerning the effects of various
treatments on vascular differentiation in future experiments, all two dimensional outgrowth and
immunostaining assays were done on a gelatin substrate unless otherwise stated.
We also explored the effects of growth factor-reduced matrigel and various exogenous
combinations of growth factors to produce an efficient in vitro endothelial differentiation
paradigm. The goal was to create a system that could be used to consistently test the effects of
potential vasculogenic inhibitors for possible adverse drug side effects and to explore the
mechanisms of vessel development. We established that matrix physical characteristics
significantly affect endothelial differentiation and sprouting from ES derived EB. Endothelial
differentiation increased as the concentration of matrigel was decreased by dilution with PBS.
Permutations of three known angiogenic factors, vascular endothelial growth factor (VEGF),
basic fibroblast growth factor (FGF), and hepatocyte growth factor (HGF) were tested in cultures
and the combination of all three growth at an effective dose of 5 ng/mL and 1:9 dilution of
matrigel substrate was found to be the most effective for inducing vasculogenesis from 3 day
EB. Quantitative PCR and immunostaining for endothelial specific marker VWF was used to
compare various differentiation conditions. The model was used to explore the effects of
various signal transduction inhibitors including Pan-kinase inhibitor sorafenib, VEGFR2 inhibitor
vatalanib, mTOR inhibitor everolimus, P13 Kinase inhibitor LY294002, and Mitogen-activated
protein kinase inhibitor PD98059. While a majority of the drugs inhibited vasculogenesis, two,
P13 Kinase inhibitor LY294002 and downstream modulator mTOR inhibitor, everolimus, had little
effect on neovascularization. Interestingly, both drugs are known inhibitors of angiogenesis,
signifying our model can be used to detect vasculogenesis-specific inhibitors. (Figure 5)
3D. Expression of HSGAG enzymes and HSGAG sulfate complexity increases with
endothelial differentiation
Once our model of vasculogenesis in EB was sufficiently characterized, we explored the
behavior of extracellular heparan sulfate glycosaminoglycans during endothelial differentiation.
HSGAG are enzymatically modified in the Golgi apparatus, where sulfate groups are added at
specific sites along the sugar backbone to create anionic binding sites for cytokines, receptors
and extracellular matrix molecules. As discussed in Chapter 2, HSGAG have been implicated in
development, and furthermore been shown to have specific interactions with critical
vasculogenic growth factors. We therefore hypothesized that HSGAG composition could
regulate endothelial differentiation. Modulating HSGAG could potentially represent a new
paradigm for efficiently directing stem cell differentiation. Additionally, understanding how the
extracellular glycome controls differentiation can uncover novel mechanisms of vasculogenesis.
We analyzed the temporal expression of sulfotransferase enzymes that add sulfate
groups to the HSGAG backbone in the Golgi apparatus during endothelial differentiation.
Interestingly, we observed that the differentiation of the ES cells into endothelial cells within the
Figure 5. Vasculogenesis Model on matrigel substrate. A) Embryoid bodies at days 3 were
transferred to 0.1% gelatin (no matrigel), matrigel diltuted with PBS and mixed with specified
growth factors at 5ng/mL. At 7 days, differentiated cells were stained for endothelial specific
marker, von Willebrand Factor (VWF, green fluorescence), and counter-stained with propidium
iodide nuclear stain (red fluorescence). B) Quantitative PCR was used to examine mRNA levels
of various endothelial specific transcripts. Represented here is the expression for VWF using
diluted matrigel and various growth factors. Based on A&B, we determined 1:9 matrigel substrate
containing VEGF, FGG, and HGF to be the best model for vasculogenesis. C) The model was
used to test various pathway inhibitors. Everolimus, an mTor inhibitor, did not significantly inhibit
vasculogenesis as the effective dose as measured by VWF immunostaining and QPCR whereas
PD98059 significantly reduced vasculogenesis. The model can be used to discover novel
vasculogenic inhibitors. *# denotes
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embryoid body paralleled an increase in the transcriptional levels of N-deacetylase/N-
sulfotransferase 1 (NDST1), 6-0 sulfotransferase (6-OST), 3-0 sulfotransferase (3-OST), and
2-0 sulfotransferase (2-OST). The increased transcription was translated into an increased
NDST1 protein expression. We chose to focus on NDST1 for future studies, because it is the
rate limiting enzyme for sulfation modification. It has been suggested that 6-OST, 3-OST, and
2-OST only function subsequent and adjacent to N-acetyl modifications. (Grobe, 2002)
To investigate the functional implication of NDST1 expression, we analyzed the
compositional changes in cell surface HSGAG during EB differentiation. Cell surface
proteoglycans were cleaved from cells using trypsin and HSGAG isolated using a DEAE anion
exchange column. HSGAG were digested with heparinases to generate disaccharide
fragments, which were then subjected to reverse polarity capillary electrophoresis, where the
absorbance of the non-reducing end of the disaccharides was monitored. The elution time of
sulphated disaccharides was compared to that of known standards. As we expected, there was
an increase in the higher order sulphated HSGAG fragments as cells differentiated. Very few
sulphated disaccharides were present at day 3 compared to day 7, when endothelial cells are
prevalent in EB. Taken together, these results indicate that the sulfate composition of HSGAG
changes during vasculogenesis and likely plays a role during endothelial differentiation. (Figure
6)
3E. HSGAG are Essential for Vasculogenesis
Although we had established that surface HSGAG sulfate compositions were changing
during embryonic stem cell vasculogenesis, our goal was to determine whether HSGAG were
effectively contributing to controlling this process. We used three methods to modify the
sulfation of HSGAG and analyzed the effects on vasculogenesis. First, treatment with sodium
chlorate indirectly blocks the sulfation of HSGAG by competitively inhibiting the formation of 3'-
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Figure 6. HSGAG sulfate content increases with endothelial differentiation. A) QPCR was used
to examine the mRNA levels of HSGAG sulfate modifying enzymes 2-OST, 3-OST, 6-OST and NDST1.
Enzyme transcripts significantly increased with vasculogenesis B) NDST1 protein levels were
compared at days 3 and 7 and results confirm those of QPCR. C) Extracellular HSGAG were isolated
and the sulfate composition of digested disaccharides was analyzed using capillary electrophoresis and
comparing elution peaks to known standard compositions. Tri-S (Tri-sulfated), Di-S (Di-sulfated), Mono-
S (mono-sulfated) (D) Sulfation at day 7 is higher than day 3, indicating that extracellular HSGAG
sulfate patterns may be regulating differentiation and vasculogenesis. *denotes P<0.05 compared to
day 3 control.
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phosphoadenosine 5'-phosphosulfate (PAPS), the high energy sulfate donor in HSGAG
sulfation reactions. (Delehedde, 2000) Cells treated with sodium chlorate exhibit nascent chains
without sulfate modifications. As shown in Figure 7, the capillary electrophoresis profile of
disaccharides isolated from day 7 differentiated cells are highly sulfated while those treated with
sodium chlorate are significantly less abundant than untreated control. This inhibition was
paralleled by a concentration-dependent decrease in the protein expression of the endothelial
cell marker, VWF, which we measured using fluorescence-activated cell sorting. Interestingly,
the expression of the endothelial cell marker was partially restored by the addition of exogenous
heparin, establishing a causal link between the HSGAG and endothelium formation de novo.
This was further validated by treating the differentiating cells with heparinase I and Ill, which
digests HSGAGs at regions of high and low sulfation respectively (Ernst, 1995), resulting in
significant downregulation of endothelial cell specific markers as measured by quantitative PCR.
(Figure 7)
To further confirm the role of HSGAG in endothelial differentiation, we knocked down the
HSGAG sulfate modifying enzyme, NDST1 by infecting cells with lentivirus containing short
hairpin RNA (shRNA). shRNA is designed to contain a double stranded region of approximately
20 base pairs complementary to the target gene with an overhanging region and linked by a
tight hairpin loop. This sequence is introduced into a plasmid vector containing a ubiquitous
promoter to ensure sustained transcription and is generally passed to daughter cells, especially
when selected for antibiotic resistance. We selected a lentiviral transfection system because it
is one of the most efficient methods for non-adherent cells. After testing various clones and
multiplicity of infections, we selected one which efficiently knocked down NDST1 by up to 80%
as confirmed by quantitative PCR after approximately one week after infection. shRNA induced
inhibition of NDST1 in differentiating cells translated to a significant reduction in endothelial
differentiation. Endothelial markers TIE-2, VWF, and Angiopoietin-2 were significantly reduced
VEGFR2 VE-Cadherin
30- # 750-
201 500-J
10 250D
Day 7 Day 7
30 VWF
20 I
1001
Us e
C) 25
e20
15 -
~10 f
+~fODay7
NaCIO4
Figure 7. Chemical modification of HSGAG sulfation inhibits endothelial differentiation. A) EB
treated with 20mM Sodium Chlorate or Heparinase I or liI exhibited significantly lower levels of
endothelial markers VEGFR2, VE-cadherin, and VWF, demonstrating an inhibition of vasculogenesis.
B) The capillary electrophoresis HSGAG sulfate profile is significantly less from disaccharides isolated
from cells treated with Sodium Chlorate compared to untreated controls at day 7. Tri-S (Tri-sulfated), Di-
S (Di-sulfated) C) Flow cytometry was used to measure the levels of surface VWF protein. When cells
were treated with Sodium Chlorate, there was a dose dependent decrease in endothelial marker VWF.
D) Heparin, a highly sulfated HSGAG, increased the levels of VWF surface protein when added to
sodium chlorate treated cells, meaning that exogenous HSGAG could overcome the inhibition of
vasculogenesis induced by sodium chlorate treatment. # denotes P<0.01 compared to day 3 control, *
denotes P<0.01 compared to day 7 control.
compared to untreated controls, directly implicating NDST1 in the differentiation of ES cells
toward an endothelial lineage. Again, the addition of exogenous highly sulfated HSGAG
(heparin) was able to reverse the inhibition of vasculogenesis. (Figure 8) By preventing HSGAG
sulfation by sodium chlorate treatment, heparinase cleavage, or NDST1 knock-down, we
showed that HSGAG and specifically sulfation of HSGAG are required for embryonic stem cell
vasculogenesis.
3F. Discussion and Conclusions:
In this section, we successfully recapitulated vasculogenesis in vitro using an embryonic
stem cell embryoid body (EB) model. We showed that cells within the EB spontaneously
differentiate and give rise to endothelial cells consistently over one week, as measured by
immunostaining and quantitative PCR. Importantly, we showed that the enzymes which
generate heparan sulfate glycosaminoglycan sulfation sequences significantly increase during
this process. When the sulfation of HSGAG was inhibited by sodium chlorate, or cleavage of
HSGAG from the protein core using heparinase enzymes, vasculogenesis was obstructed as
demonstrated by the reduction of endothelial cells generated within the EB. Furthermore,
specific inhibition of HSGAG sulfation enzyme, N-deacetylase/N-sulfotransferase-1 (NDST1)
using shRNA resulted in inhibition of endothelial differentiation in EB, directly implicating NDST1
and HSGAG sulfation in embryonic stem cell vasculogenesis for the first time. These studies
open the possibility of harnessing HSGAG to control vasculogenesis.
In addition to characterizing the levels of HSGAG enzymes during vasculogenesis, we
analyzed the sulfate compositions of HSGAG disaccharides isolated from ES undergoing
endothelial differentiation to provide a functional link between HSGAG sulfate sequences and
vasculogenesis. Using capillary electrophoresis to identify the degree of sulfation of cell surface
HSGAG we discovered that pluripotent cells possessed very few sulfated HSGAG, which
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Figure 8. Silencing of N-deacetylaselN-sultotransferase-1 inhibits endothelial differentiation. A)
Lentivirus shRNA silencing of NDSTI was confirmed using QPCR. Expression of NDSTI was up to
80% less to that of control, this translated to a significant decrease in expression of endothelial markers.
*denotes P<0.05 compared to control. B) The reduce in endothelial differentiation caused by shRNA
silencing of NDSTI could be rescued and even surpassed when exogenous heparin was added to cells.
# denotes P<0.05 compared to control, * denotes P<0.05 compared to NDSTI shRNA treated cells.
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increased with differentiation. This implies that HSGAG sulfation is one mechanism that cells
use to control the tightly controlled differentiation process.
Other studies have pointed to the importance of HSGAG in differentiation and
development. ES lacking HSGAGs are unable to differentiate because FGF signaling disruption
causes pluripotency transcription factors to remain active. ES primed for differentiation but
deficient in HSGAG chains maintained markers of pluripotency significantly longer than controls.
(Kraushaar, 2009) Signaling molecules important for neural progenitor development and axonal
guidance, including netrins, slits, and their receptors, are modulated by HSGAGs. (Serafini,
1994) (Wang, 2005) (Wilkinson, 2001) Irie et al. demonstrated that the addition of exogenous
HSGAGs disrupts axonal targeting and discovered that specific sulfation patterns caused more
significant changes. (Irie, 2002) This study confirmed that specific sulfate compositions of the
HSGAG backbone are critical for controlling signaling, and not simply the degree of sulfation.
Another study using HSGAG epitope-specific antibodies reported that the sulfation motifs in
pluripotent embryonic stem cells are different from those of neural progenitors. (Johnson, 2007)
HS-specific antibodies have also been used to identify a unique and transient sulfate epitope
expressed in stem cells differentiating along a mesodermal lineage. Separated cells possessing
this epitope had a dramatically increased potential to form endothelial colonies. (Baldwin, 2008)
Although in this study we identified an increase in the degree of HSGAG sulfation and not
specific sequences correlating with vasculogenesis, a logical next step would be to use defined
HSGAG sequences to determine which can induce endothelial differentiation.
We focused on NDST because it is the rate-limiting enzyme for HSGAG sulfate
composition. It first removes acetyl groups from N-acetyl glucosamine residues and replaces
them with a sulfate group. NDST1 is the most ubiquitous isoform expressed in embryonic and
adult tissues. (Grobe, 2002) NDST1 deficient mice die in utero with severe respiratory defects
and overall reduction in HSGAG structure while NDST1 inhibition in drosophila has been
associated with patterning defects. (Perrimon, 1999)
NDST has specifically been studied during differentiation. A similar upregulation of
NDST4 was seen when embryonic stem cell EB were directed to differentiate into a neural
lineage. EB derived from NDST1-'- mice were unable to differentiate at all. (Lanner, 2009)
Specifically, disruption of FGF4 signaling maintained elevated expression of pluripotency factor
Nanog, which could be modulated by exogenous heparin. Knockout of NDST1 disrupted FGF4
but not FGF2 signaling, pointing to specific sulfation epitopes for the FGF isoforms. The
difference between this and our study may be the complete abrogation of N-sulfated HSGAGs
compared to partial knockdown. Reduced N-sulfation was also found to effect pericyte
recruitment during vascular development in a similar model- NDST1 -'- mouse. (Abramsson,
2007) Taken together with our observations, HSGAG sulfation enzymes and specifically
NDST1 are key regulators of differentiation, indicating that sulfation sequences on HSGAG
could be critical for signaling throughout differentiation.
Interestingly, in our study, we found that inhibition of vasculogenesis could be rescued in
with the administration of exogenous HSGAG. This underscores the fact that compositions of
HSGAGs on neighboring cells or in the surrounding matrix can play critical roles in controlling a
cell's fate and opens the door for engineering specific microenvironments to do so. This
concept of heparan sulfate crosstalk in trans was corroborated by Jakobsson et al. who
elegantly demonstrated that suppression of vasculogenesis in ES devoid of surface HSGAGs
could undergo endothelial differentiation when co-cultured with ES possessing typical HSGAGs
but lacking vasculogenic potential. (Jakobsson, 2006) HSGAG modulation disrupted VEGF
gradient formation which is critical for vascular development. Similarly, disruption of FGF-2 and
VEGF binding via endothelial specific NDST1 suppression was also found to selectively reduce
tumor neovascularization, a process increasingly believed to be generated by angiogenesis and
vasculogenesis. (Fuster, 2007)
Like the above studies, we believe that inhibition of vasculogenesis seen with HSGAG
modulation is due to disrupted signaling of molecules that are critical for endothelial
differentiation including FGF and VEGF. These and other vasculogenic growth factors have
been shown to bind to specific HSGAG sequences. Based on the literature, we hypothesize
that the addition of exogenous heparin may provide the binding sites for threshold signaling
events to resume and allow differentiation to proceed. In conclusion, we clearly demonstrate
the involvement of HSGAG, key components of the cell-surface glycome, in vasculogenesis.
Chapter 4. Heparan Sulfate Glycosaminoglycan Regulation
of Vasculogenesis in vivo
(Parts of this chapter are taken from "Harfouche*, Hentschel*, Piecewicz*, et al. Glycome and
Transcriptome Regulation of Vasculogenesis. 2009, 120(19), Circulation." and "Sorathyia,
Jucikas, Piecewicz, Sengupta and Lio' Searching for Glycomics Role in Stem Cell
Development. CIBB 2008, Lecture Notes in Bioinformatics.")
In the last chapter, we established that HSGAG regulate vasculogenesis by analyzing an
in vitro embryonic stem cell model of vasculogenesis. By characterizing the transcription of the
enzymes responsible for HSGAG sulfation as well as examining the functional sulfation profiles
of isolated disaccharide fragments, we found that the sulfation profiles change during
differentiation and were essential for vasculogenesis to occur. In this chapter, we examined the
effects of modulating HSGAG on vasculogenesis using an in vivo zebrafish model. Although
embryoid bodies are an excellent model of embryonic development in vivo, our aim was to
confirm the necessity of HSGAG for vessel development in real time in a developing vertebrate.
Modulating HSGAG sulfation enzyme, N-deacetylase/N-sulfotransferase, resulted in clear
abnormalities in the vasculature. Additionally, we characterized the cross-talk between external
HSGAG sequences and internal transcription profiles using large scale RNA microarray analysis
to identify novel signaling pathways, modulated by HSGAG, which regulate vasculogenesis.
4A. Zebrafish as a Model for Vascular Development
The zebrafish (Danio rerio) is an attractive model for studying vascular development.
The large number of fertilized eggs and ability to monitor transparent embryos using simple light
microscopy makes them particularly appealing for studying development. Their small size and
permeability enable large scale toxicity and drug screening because chemicals diffuse into
embryos for up to several days when added directly to the surrounding aqueous environment.
This approach was used to identify compounds that impeded vasculogenesis and to study
affected downstream signaling pathways. (Chan, 2002) The process of vascular development is
extremely similar in all vertebrates, and zebrafish possess a complex circulatory system similar
to that of mammals. (Isogai, 2001) Most of the genes currently known to be critical for vessel
development have been identified in the zebrafish. Furthermore, the rapid external
development of the transparent zebrafish embryo allows easy visualization of phenotypic
defects and allows for large scale screening techniques. (Roman, 2000) Zebrafish can survive
for several days with severe vascular and cardiovascular defects which make studies of critical
developmental pathways more feasible than in animals where similar mutations result in
embryonic lethality. (Kidd, 2003) Gain or loss of function genetic studies in zebrafish are
effective and significantly less time consuming and costly that studies in mice. Large scale
genetic screens in Boston and Tubingen were the impetus for the identification of many well-
characterized mutant strains that are readily available. The complete zebrafish genome was
sequenced in 2010 and integrated into the National Institutes of health NCBI network.
Paralleling the occurrence of blood vessels in the mouse embryo as described in
previous chapters, endothelial cells first emerge in zebrafish embryos in blood islands contained
in yolk-sac mesoderm. Following differentiation, angioblasts migrate and converge to form
cords that eventually give rise to the major trunk vessels, the dorsal aorta and cardinal vein.
(Fouquet, 1997) Evidence for the existence for a common hemangioblast progenitor for both
hematopoietic and endothelial cells has been identified in the zebrafish cloche mutant, where
knockdown of the cloche gene prevents the formation of both cell types in the embryo. (Stanier,
1995) Angioblasts in the zebrafish arise from the ventrolateral mesoderm, where FGF is critical
for mesoderm development and flk-1 (VEGFR2) required for hemangioblast formation
exclusively. VEGF ligand, suggested to be secreted from primitive endoderm along the midline,
is one of the decisive drivers for angioblast migration. The expression of flk-1 visualized by in
situ hybridization was used to track the migration of angioblasts and formation of the major trunk
vessels. FIk1-expressing angioblasts are visible in the embryo by the 10-somite stage and
migrate along the midline between the 14-20-somite stages. The angioblasts merge to form the
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dorsal aorta and cardinal vein before the 24-somite stage. At approximately the 30-somite
stage (24 hours post fertizilation, hpf) of embryonic development, inter-segmental vessels are
generated from the major trunk vessels by sprouting angiogenesis. (Coffin, 1988)(Fouquet,
1997) The conservation of vascular anatomy among vertebrates suggests that vessel
development occurs through conserved mechanisms and discoveries made using the zebrafish
are applicable to higher organisms and mammals.
The generation of a zebrafish strain that possessed the expression of EGFP driven by
an endothelial specific flil promoter by Lawson and Weinstein in 2002, enabled the continuous
in vivo analysis of vertebrate embryonic vascular development. The transparency of the
zebrafish embryo and the ability to engineer a tissue specific fluorescent expression construct
makes this an ideal system to study vasculogenesis. (Lawson, 2002) We used this transgenic
zebrafish strain, TG(flil:EGFP), to probe the effects of HSGAG modulation on vasculogenesis in
viVO.
4B. Materials and Methods
Zebrafish stocks and injections: Zebrafish (TObingenAB and TG(Fli:GFP) were grown and
mated at 28.50C, and handled in standard E3 solution (5 mM NaCl, 0.17mM KCI, 0.33 mM
CaC2, 0.33 mM MgSO4, 10-5% methylene blue) buffered with 2 mM HEPES (Sigma-Aldrich, St.
Louis, MO). Indicated concentrations of morpholino were injected into 2-cell stage embryos with
a constant volume of 4.6nL using a Nanoject II (Drummond Scientific, Broomall, PA). For
angiograms, 50-55 hours post fertilization tg(Fli-1:GFP) morpholino injected fish as well as wild-
type controls from the same clutch were anaesthetized in a 1:20 to 1:100 dilution of 4 mg/mL
Tricaine (MESAB-ethyl-m-aminobenzoate methanesulphonate, 1% Na2HPO4, pH 7.0) (Sigma-
Aldrich, St. Louis, MO) and positioned on their back in a 1% agarose injection mold. To test the
patency of vessels, 4.6 nL of 10% Tetramethylrhodamine labeled 40 kDa dextran (Molecular
Probes, Eugene, OR) was injected into the cardiac venous sinus. For heparin rescue of NDST1
phenotype, 20 ug/mL heparin was injected into de-chorionated embryos following morpholino
injection. All procedures were approved by Harvard University's Institutional Animal Care and
Use Committee.
NDST1 Morpholino design: A splice-donor morpholino (GTGCATTTAACACTCACCATTCTTC)
was designed by GeneTools, LLC (Philomath, Oregon) to inhibit normal splicing of the gene and
block expression of NDST1. Morpholino sequence was based on the eight 3'-end overlapping
exons of 3 genes with greater than 50% identity to human NDST1, and 60% identitiy to mouse
NDST1, on the most recent zebrafish genome assembly (Zv6 on the Sanger Institute
Ensemble), GenBank accession numbers XP_699032, XP_695253, 5 XP_691043. The exon 3
splice-donor morpholino was predicted to lead to splicing of exon 2 to exon 4. Brightfield and
fluorescence imaging of the embryos was performed with a Nikon SMZ1 500 stereomicroscope
and SPOT Flex camera. Image sequences were obtained with the same set-up and exported as
movies to match live flow patterns. Real time PCR was used to confirm that NDST1 morpholino
resulted in an alternatively spliced fragment. Briefly, primers were designed to amplify a 455
base pair fragment of NDST1 mRNA spanning exons 1 thru 4. PCR reactions on control and
NDST1 morpholino injected embryo cDNA were carried out using Taq DNA polymerase kit
(Qiagen) and run on 2% agarose gel. The cDNA fragments were cut from gels, purified using
GeneClean kit (QBiogene), subcloned into pCS+ plasmid vectors, amplified in a DH5Ct E.coli
strain, purified with Sigma Mini-prep kit, and isolated with restriction enzyme digest. DNA was
sequenced by MGH DNA Sequencing Core, Cambridge, MA.
HSGAG Isolation and Compositional Analysis of Fish Embryos: Fish embryos were
dechorionated at 24hpf and passed through a 30 pm filter into calcium-free Ringer's solution.
Cell suspensions were centrifuged, washed in PBS, and incubated in Trypsin/EDTA (0.05%)
(Gibco BRL) at 370C for 30 minutes. HSGAGs were isolated and analyzed using capillary
electrophoresis as described in the previous chapter.
RNA preparation: Embryos at the 6-somite, 20-somite, and 24 hpf developmental stages were
collected from the pairwise mating of TuebigenAB adult fish. Half of the collected embryos from
each clutch were injected with 4.6 nL 375 molar NDST1 morpholino using a Drummond
Nanoject II. Mutant and wild-type sibling RNA was processed in parallel. Total RNA was
extracted using TriZol reagent (Invitrogen, Carlsbad, CA) and purified using Qiagen RNeasy
columns (Valencia, CA). The quality of RNA samples was confirmed by absorbance ratio at
260nm and 280 nm, gel electrophoresis and by RNA Nano LabChip analysis on an Agilent
Bioanalyzer 2100.
Affymetrix oligonucleotide gene arrays: Hybridization to Affymetrix Zebrafish Genome Arrays
(Catalog #900487) and data acquisition were performed at the Harvard Medical School Partners
Healthcare Center for Genetics and Genomics (Cambridge, MA). Synthesis of cDNA first and
second strand was performed using the GeneChip Expression 3'-Amplification Reagents One-
Cycle cDNA Synthesis Kit. Cleanup of the double stranded product was carried according to
standard Affymetrix protocols using the Affymetrix GeneChip Cleanup Module (Affymetrix). In
vitro transcription (IVT) was performed using the GeneChip Expression Amplification Reagents
kit- 30 reactions (P/N 900449) and was carried out according to the standard Affymetrix
protocols. Hybridization was carried out according the Affymetrix GeneChip@ Manual. Twenty
micrograms of IVT material is the nominal amount used on the GeneChip@ arrays. Affymetrix
hybridization ovens are used to incubate the arrays at a constant temperature of 45oC
overnight. Scanning was carried out on an Affymetrix Model 7000 scanner with autoloader. The
Affymetrix GCOS v1.3 operating system controls the Model 7000 scanner and data acquisition
functions. Quality control using GCOS and dChip applications suggested all hybridizations and
chips were fine. Acquired probe level data was normalized via the Robust Multichip Average
Method (RMA) using Insightful (Seattle) S+@ ArrayAnalyzer 2.0 software and mean log2
expression intensities from triplicate experiments were used in subsequent differential analysis.
Local Pooled Error and ANOVA differential expression testing was performed in S+ @ using a P
statistic cutoff value of 0.05 and Bonferroni and Benjamini-Hochberg corrections, respectively,
to define significant genes and limit false positives. Regulated transcripts were also investigated
using a modified t-test, the R version of the CyberT algorithm. Using this conservative t-test,
transcripts were analyzed as significant with a p value below 0.01 between NDST1 morphant
vs. control and had a Imean fold changel of greater than or equal to 2 between NDST1
morphant vs. control. Differential transcripts analyzed by this method were only considered
when produced from both RMA and Mas5 normalization methods. Gene pathways based on
transcripts regulated for both RMA and Mas5 data at each of the three time points by the cyberT
and fold change criteria described above were defined using Cell Illustrator
(www.cellillustrator.com) and Ingenuity Pathways Analysis @ (http://www.ingenuity.com). Fold
change is defined as the ratio of normalized expression intensities of mutant to wild-type
transcripts for all analyses. Independent component analysis was performed using Matlab
software. Affymetrix probe sets were annotated based on gene symbols available from
Affymetrix Netaffix website, Entrez Gene, Unigene, GenBank and the Boston Trans-NIH
Zebrafish Genome Initiative. Undefined transcripts are identified by Affymetrix probe IDs.
FANOVA analysis and Markov Chain Clustering: Affy and limma packages of the R software
were used for data loading and statistical analysis. RMA method of normalization was used to
correct background. FANOVA analysis was completed as described previously. (Ramsay,
1996) A Markov Clustering script was run in MatLab @. (http://www.arbylon.net/projects/)
Visone social network visualization tool was used to draw networks with Affymetrix ID labels.
(http://visone.info/)
Quantitative PCR: RNA was isolated from cells at the indicated days using Aurum Total RNA
isolation kit with DNAse digestion step and total RNA reverse transcribed using iScript cDNA
Synthesis kit according to manufacturer's instructions. (Bio-Rad, Hercules, CA) The levels of
mRNA for specific genes were detected by using designed oligonucleotide primers (IDT, Inc.)
and monitoring SYBR Green fluorescence using a Bio-Rad MyIQ iCycler. The normalized
reporter (Rn) was calculated from threshold values, Ct, for each gene as follows: Rn=2 X- CT,
where 8 CT=(average CTtargetaverage CTexperimental control) and 18S was used as endogenous
control to normalize quantities of cDNA. For zebrafish, RNA was isolated as described for
microarray studies. GAPDH was used as endogenous control, microarray results confirmed
that levels of GAPDH were constant in all samples. Primers used (Mus musculus): 18S(5'-
aaatcagttatggttcctttggtc-3' and 5'gctctagaattaccacagttatccaa-5'), Tie-2(5'-ggaaacctgttcacctcagc-
3' and 5'-ccacttctgagcttcacatctc-3'), VEGFR-2(5'-gctttcggtagtgggatgaa-3' and 5'-
ggccttccatttctgtacca-3'), NDST-1 (5'-cagggaaattcttccacacag-3' and 5'-cacataggacaacagcagatcg-
3'), Foxo3a (5'-gctaagcaggcctcactcca-3' and 5'-ttccgtcagtttgagggtct-3'), IGF2 (5'-
actgatgccgaagaagttgc-3' and 5'-tcagtttcctgccttccatt-3'). Primers used (Danio rerio): GAPDH-
F(5'-tggaaagtacaagggtgaggtt-3'), GAPDH-R(5' ctctccctgggtcggttg-3'), Foxo5-F(5'-
cgacacagagaggagacacg-3'), Foxo5-R(5'-cgtgatcaacttcgcaattcgt-3').
Immunoblotting: Cells were washed twice with PBS and directly lysed in 3X loading buffer
containing 12% sodium dodecyl sulfate, 15% 2-mercaptoethanol, 1 mM sodium orthovandate
and protease inhibitor cocktail tablets from Roche Applied Sience (Indianapolis, IN). Samples
were then heated for 10 min at 100 *C and equal amounts loaded onto tris-glycine SDS-
polyacrylamide gels. Proteins were electrophoretically transferred onto polyvinylidene difluoride
or nitrocellulose membranes, blocked for 1 h with 10% non-fat dry milk, and subsequently
incubated overnight at 40C with primary antibodies, NDST1 (Affinity Bioreagents), p-actin (Cell
Signaling Technologies). Proteins were detected with horseradish peroxidase-conjugated anti-
rabbit or anti-mouse secondary antibodies and WesternC Peroxidase Substrate (Roche Applied
Sience). The blots were developed using a GeneSnap imaging device and optical densities off
the protein bands quantified using GeneTools (both from SynGene, Frederick, MD).
Predetermined molecular weight standards were used as markers. Proteins were normalized
against p-actin.
Cell Culture: Murine 9TR#1 strain 129/Sv+c/+p embryonic stem cells were obtained from
ATCC (Manassas, VA). ES were maintained undifferentiated using a growth medium consisting
of L-glutamine-containing DMEM, 0.1 mM non-essential amino acids, 0.1 mM sodium pyruvate,
0.1 mM 2-mercaptoethanol, all from Invitrogen (Carlsbad, CA), as well as 1000 U/ml leukemia
inhibitory factor (LIF) (Chemicon Inc., Temecula, CA) and 15% fetal bovine serum (HyClone,
Logan, UT) and grown on 0.1% gelatin at a density of 18,000 cells/cm 2. When colonies reached
approximately 70% confluency, they were passaged using 1X Trypsin/EDTA up to passage 2.
Differentiation was induced by removing LIF from the medium and seeding cells (passage 2) at
a density of 3000 cells/cm2 on Ultra Low Attachment 100mm dishes or 6-well plates (Corning,
Lowell, MA)
shRNA Lentivirus Infection: In order to selectively knock-down NDST1 and Foxo3A, we used
NDST1 and control (siGFP) short hairpin RNAs (sHRNAs) in a pLKO.1 puromycin-resistent
vector Mission@ Lentiviral Transduction Particles (Clone ID TRCN0000097920, Sigma-Aldrich).
Foxo3A shRNA vectors were generously provided by Matthew Roy and Weibo Li (Dr. Nir
Hacohen laboratory, Center for Immunology & Inflammatory Diseases
Massachusetts General Hospital, Charlestown, MA). Briefly, 1 day embryoid bodies were
cultured on ultra-low adherent plates (as above) and infected with 1 or 5 multiplicity of infection
(M.O.1) of viruses in the presence of polybrene transfection reagent (Millipore, Bedford, MA)
overnight and in some cases 5ug/mI puromycin was added to media 24 hours later. Media was
replenished every 3 days.
4C. Morpholino-induced Knock-down of NDST1 Impedes Zebrafish Vascular
Development
To validate our hypothesis that HSGAG modulate vasculogenesis, we used a genetic
approach to knock-down the expression of N-deacetylase/N-sulfotransferase (NDST1) in a
developing zebrafish (Danio rero) embryo model. We specifically used zebrafish strain
TG(flil:EGFP) to monitor vessel development real time in zebrafish embryos. The simplest
method to generate a loss of function of a particular gene in the zebrafish is the use of
morpholino antisense technology to block gene translation. An effective anti-sense technology
should possess a number of characteristics to be effective: selectivity for a particular gene,
stability and non-toxicity in cells, and appropriate concentration and solubility for effective
delivery. Morpholino phosphorodiamidate olignucleotides (MPO) are oligonucleotides of about
25 nucleotides engineered with a morpholine moiety replacing the ribose backbone and a
phosphorodiamidate non-ionic linkage replacing the phosphodiester bond between nucleotides.
These properties make MPO neutrally charged, water soluble, and resistant to intracellular
proteases while maintaining high RNA binding affinity. (Sumanas, 2002) (Partridge, 1996) MPO
inhibit protein translation by blocking interaction of RNA with ribosomal machinery or modulate
pre-mRNA processing by blocking splice donor and acceptor sites. (Kole, 2001) When injected
before the 32-cell stage of embryos into the yolk, MPO can diffuse to all cells in the embryo
without disrupting early blastomeres and is presumably passed to daughter cells. MPO are
found to be most effective at inhibiting RNA translation in the first few days after injection but are
likely diluted after that by cell division or excretion. This is within the timeframe of
vasculogenesis, which occurs within the first 24 hours of embryonic development. During
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evolution, the zebrafish acquired a duplication of approximately 30% of its genome which
resulted in paralog genes which may or may not have functional redundancy. This is important
to consider when designing oligonucleotides and analyzing phenotypic changes. Because of
the success of MPO antisense technology in the zebrafish, we chose to modulate zebrafish
HSGAG by using a NDST1 morpolino knock-down method.
There are four isoforms of N-deacetylase/N-sulfotransferase in vertebrates. NDST1 and
NDST2 are the most abundant isoforms and expressed in all embryonic and adult tissues, while
the expression of NDST3 and NDST4 is limited to development and a few adult tissues.
(Grobe, 2002) There is some overlap of functional isoforms in the Golgi and the forced over
expression of various isoforms of NDST has been shown to result in different HSGAG N-
sulfation patterns. (Pikas, 2000) NDST1 isoform appears to be the most indispensible for N-
sulfation because NDST1-'- mice exhibit embryonic lethality and dramatically reduced HSGAG
sulfation while NDST2-'~ mice are healthy apart from undersulfated mast cells, suggesting that
NDST1 alone cannot be compensated for by the other isoforms. (Ringvall, 2000) NDST3 and
NDST4 have significantly lower enzymatic activity than the other isoforms and low affinity for
non-sulfated HSGAG chains, suggesting that they may amend already modified HSGAG chains.
(Aikawa, 2001) Therefore, NDST1 has a critical role in HSGAG sulfation. As discussed in
previous chapters, it is generally believed that NDST is the key enzyme for all HSGAG sulfation
and therefore subsequent biological interaction because ensuing O-sulfation enzymes function
in relation to N-sulfated domains and limited HSGAG sulfation has been found to occur in the
absence of NDST. (Holmborn, 2004) Inhibiting NDST1 translation is an effective way to impede
sulfation of HSGAG and study the specific effects of sulfation domains on cell function.
Zebrafish display the complete set of enzymes required for HSGAG modification. To
date two C5-epimerases, one 2-0-Sulfotransferase, eight 3-0-Sulfotansferases, and four 6-0-
Sulfotransferases have been identified, at least one for each human orthologue, with two cases
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of gene duplication. (Yost, 2006) However, the expression patterns and loss of function
analysis of NDST1 had not been described previously. BLAST analysis revealed a zebrafish
orthologue for NDST1 on chromosome 21. Three transcripts were identified that contained 60%
identity to mouse NDST1. Given a variety of predicted ATG initiation sites at this locus, a splice
donor morpholino was designed to the third exon of the shared 3'-end because this exon was
contained in all three predicted transcripts. (GTGCATTTAACACTCACCATTCTTC) To confirm
the effectiveness of this morpholino, we designed specific RT-PCR primers to compare the size
of translated NDST1 proteins in morpholino treated and control fish. Sequencing of the
subcloned NDST1 fragments confirmed altered splicing resulting from a premature STOP-
codon. To confirm that the morpholino resulted in the attenuation of HSGAG sulfation, we
harvested the cell surface HSGAG from 24hpf embryos and analyzed disaccharide fragment
sulfation composition using capillary electrophoresis. NDST1 knockdown resulted in significant
reduction in sulfated disaccharides. An antisense probe was generated against NDST1 and
used to monitor the expression of NDST1 mRNA in developing embryos using in situ
hybridization. Interestingly, the strongest expression was found along the midline at the 6-
somite stage, in the region of migrating angioblasts. At the 20-somite stage, the strongest
expression remains at the midline in proximity to the main trunk vessels, as well as in the head
region. (Figure 9)
Morpholino-induced knockdown of NDST1 resulted in concentration-dependent stunting
of tail growth. GFP transgenic embryos TG(Flil:EGFP) exhibited aberrant formation of dorsal
aorta, caudal vein, and inter-segmental vessels that likely contributed to the shortened,
dysmorphic tails. Although higher concentrations of the morpholino resulted in complete ablation
of blood flow beyond the cloacae, lower doses produced more proximal confluence of the dorsal
aorta and posterior cardinal vein. Although lower doses induced vascular abnormalities, no
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Figure 9. zNDST1 morpholino effectively alters RNA splicing and decreases HSGAG sulfation.
A) BLAST analysis of the zebrafish genome revealed 3 possible transcripts with greater than 60%
identity to mouse NDST1. Eight exons are shared in each transcript. B) A morpholino was designed
to target the third exon splice donor site of NDST1 transcripts that would result in pre-mature splicing
of the entire exon (zNDST1). (WT=wildtype). C) Specific primers were designed spanning exons 1-4
(see 7A) and reverse transcription used to determine the size of the transcribed mRNA. As expected,
a shortened transcript was generated dose dependently with morpholino injection dose. D) Gene
sequencing of transcribed NDST1 mRNA was performed to confirm morpholino induced alternative
splicing. As expected, exon three was excluded from mRNA transcript with morpholino treatment. E)
Capillary electrophoresis sulfation profiles of HSGAG disaccharides isolated from 1.15 pmol zNDST1
treated fish are significantly decreased compared to wildtype fish at 24 hours, confirming inhibition of
NDST1 enzyme function. F) In situ hybridization with an oligonucleotide probe designed to target
NDST1 revealed that the major expression occurs along the midline in embryos at 6-somite stage, this
is the region of angioblast migration in vasculogenesis at the same stage. G) In 18-somite stage
embryos NDST1 expression remains in the midline region and head. At this point in vasculogenesis,
angioblasts begin to aggregate along the midline and form the major trunk vessels.
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shortening of the tail was observed, which suggests that a dysmorphic tail was a secondary the
result of primary abnormal vascular development. In the more severe cases, blood cell flow
vessels did not extend beyond the cloacae. In these cases, stagnant blood cells were found in
the space usually occupied by the caudal vein plexus and moved synchronously with the
heartbeat. Occasionally, red blood cells could be observed moving in the otherwise narrower
appearing intersegmental vessels. These findings were consistent in the TOAB as well as tg(Fli-
1;GFP) embryos. (Figures 10,11) (Movies available online, blood circulation in tails of control
(wild-type) vs. N-deacetylase/N-sulfotransferase-1 morpholino treated (NDST1)
embryos:
http://circ.ahajournals.or.libproxy.mit.edu/ci/content/full/CIRCULATIONAHA.1 08.837724/DC1)
Decreased tail blood flow in NDST1 embryos was associated with smaller vessel
lumens. 24 hours post fertilization (hpf) and 48hpf morpholino-injected embryos were compared
with uninjected siblings. The presence of intersegmental tail vessels as determined by Fli1-
EGFP signal was decreased in a dose dependent fashion. This decrease paralleled the dys-
and hypomorphic development of the tail beyond the cloacae. Injection of 40 kD tetramethyl-
rhodamine labeled dextran into 54hpf embryo circulation revealed regions of inter-segmental
vessels with patent, yet smaller lumens. Surrounding vessels appear enlarged, which may
compensate to accommodate blood flow in the region of attenuated vessel formation.
Secondary angiogenic sprouting and complexity of inter-segmental vessels appear to be
impeded in NDST1 knockdown embryos. The caudal venous plexus appeared more like a large
tubule rather than a complex network of capillaries. (Figures 10,11)
To analyze the ability of exogenous HSGAG to rescue the vascular phenotype described
above, we administered heparin to NDST1 knockdown embryos. We observed a partial
recovery of vascular development and tail length in NDST1 knockdown embryos with the
zNDST1-Mo 1.725 pmol zNDST1-Mo 2.3 pmol zNDSTI-Mo
3.5 pmol
Figure 10. Inhibition of NDSTI causes abnormal vessel and body development of 24 hour and 48
hour embryos. A) 24 hours after zNDSTI morpholino injection (zNDST-Mo), embryos possess
shortened, dysmorphic tails and overall impaired development in a dose dependent manner compared to
wildtype fish. Analyzing vessels specifically in tg(Flil:GFP) embryos reveals that NDST1 inhibition causes
severe vascular defects. B) At 48 hours post-injection, embryos are also characterized with dose
dependent shortened bodies compared with wildtype. A closer look at the vessels of 1.725 pmol zNDST1
embryos reveals vessels thinner vessel lumens and abrogation of complex structure in the main axial
vessels. This suggests that dysmorphic tail development is secondary to impaired vascular development.
Brightfield and fluorescent images were captured with a Nikon SMZ1500 stereomicroscope and a SPOT
Flex camera.
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Figure 11. zNDSTI embryos possess compromised vascular structures and impaired
circulation. A) Top, 54 hour post injection tg(flil:GFP) embryos injected with a low dose zNDST1
morpholino (zNDST1) display weaker density of major axial and intersegmental vessels. Bottom, 40kDa
tetramethylrhodamine (TMR) was injected into embryos to monitor circulation. zNDST1 embryos
possess smaller vessel lumens than wildtype embryos. Circulation is significantly lower in
intersegmental vessels of zNDST1 fish. B) Bright field microscopy images of TuebingenAB wildtype
(top) and 1.15 pmol injected 48 hour embryos. In zNDST1 embryos, blood flow is impaired beyond the
cloacae and blood cells accumulate in the tail. (shaded region magnified). In wildtype embryos, no
blood pooling is visible and circulation extends through the entire tail width. This suggests compromised
formation of the major axial vessels with NDSTI inhibition. Brightfield and fluorescent images were
captured with a Nikon SMZ1500 stereomicroscope and a SPOT Flex camera.
administration of heparin. These results confirm the rescue of endothelial differentiation with
external heparin that we saw in NDST1 deficient embryonic stem cells in the previous chapter
and provide further substantiation that exogenous HSGAG can be used to control
vasculogenesis. (Figure 12)
4D. Changes in HSGAG Sulfation Modulate Transcriptome Profiles
The major goals of this work are to define the structure activity function of HSGAG
oligosaccharides for vasculogenesis, translate this relationship to vessel development in vivo,
and elucidate the mechanisms by which the glycome regulates vasculogenesis. By modulating
HSGAG sulfation profiles through the inhibition of critical HSGAG sulfation enzyme NDST1 in
both embryonic stem cells and zebrafish, we established that HSGAG sulfation is crucial for
efficient vascular development. In order to discover the specific mechanisms by which HSGAG
modulate vasculogenesis, we chose to perform an RNA microarray analysis using developing
zebrafish embryos with perturbed HSGAG oligosaccharide sulfation and control embryos with
intact oligosaccharide composition. RNA microarray analysis is a well-established method to
analyze the effects of perturbations on gene transcription, although care must be taken to
perform rigorous analysis of data in order to properly identify differentially expressed gene
transcripts. Comparing the gene transcript profiles, or transcriptome, of embryos with different
glycomic structures, allows us to identify downstream mechanisms that are regulated by
changes in extracellular HSGAG.
4D1. Zebrafish Microarray Technology
Because of their well-characterized genetics and ease of large-scale functional genetic
screens, microarray technologies for zebrafish have made substantial progress in the past
several years. RNA microarrays allow for the analysis of expression profiles of thousands of
transcripts simultaneously compared to traditional molecular biology methods like PCR or in situ
hybridization. Microarrays are especially useful for profiling temporal patterns of gene
Comparing transcript expression profiles can lead to the identification and construction of
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Figure 12. Exogenous heparin partially reverses zNDST1
phenotype. When heparin (highly sulfated HSGAG) was
administered to embryos injected with NDST1 morpholino, they
develop similarly to wildtype, non-injected embryos. Tail length
was used as a measure of phenotype-reversal because we saw
previously that impaired tail length was a secondary effect of
impaired vessel development in zNDST1 embryos. Addition of
heparin to zNDST1 cultures caused a significant increase in tail
length. * denotes P<0.01 compared to wild-type control
embryos, ** denotes P<0.05 compared to NDSTI morpholino
injected embryos.
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expression during development and in response to chemical, physical or genetic perturbations.
molecular pathways that are regulated by a particular experimental perturbation or groups of
genes expressed in similar patterns. (Sipe, 2007) Whole genome sequencing, and advances in
microarray design and scanning technologies have made it possible to profile entire
transcriptomes at once. The process entails isolating high-quality RNA from samples, reverse
transcribing and fluorescently labeling cDNA from collected RNA, hybridizing cDNA to oligomer
microarrays while minimizing background, scanning the microarray to image levels of cNDA
binding by fluorescence and thus expression of various transcripts, and then using multivariate
approaches to analyze expression data.
Oligomer microarrays contain thousands of oligomers spotted on chemically activated
glass slides. Agilent Affymetrix@ GeneChips are developed using an automated
photolithography technique where oligiomers of approximately 25 nucleotides are synthesized in
situ on slides. Affymetrix @ GeneChips contain 'probe-sets' of several oligomers that perfectly
match different regions of a transcript and corresponding single-base mismatch oligomers.
Non-specific binding can be accounted for by adjusting fluorescence levels to account for
mismatches. Several spots of each probe set are present along with other housekeeping and
control spots to ensure accuracy of reported transcript expression. The Affymetrix zebrafish
GeneChip contains 14,953 transcripts with probes designed from RefSeq(2003),
GenBank(2003), UniGene (2003) and dbEST(2003) databases. (Douglas, 2006) Zebrafish
microarrays have been used to study, among other topics, development, hypoxic stress,
disease, temperature perturbations, regeneration, angiogenesis, and response to injury.
The first high-density oligonucleotide zebrafish microarray used to map transcriptome
profiles was in 2005. Transcript expression profiles from 12 developmental stages were
compared and partially validated by RT-PCR. A new cohort of transcribed genes was identified
prior to the mid-blastula transition, a stage where the zygotic genome was believed to be
inactive. (Mathavan, 2005) Covassin et al. isolated endothelial specific RNA by using flow
cytometry to separate GFP positive endothelial cells from the TG(flil:GFP) zebrafish strain and
compare gene expression profiles to those of GFP negative cells. Previously uncharacterized
endothelial markers were identified and confirmed to be specific for the vasculature using in situ
hybridization. (Covassin, 2006) The transcriptome of the zebrafish cloche mutant, characterized
by a nearly complete absence of blood and endothelial cells, was analyzed to discover novel
genes that function early in vasculogenesis. TG(gatal:GFP) strain embryos lacking
fluorescence at the 12-somite stage were considered to have the cloche phenotype. 23 genes
differentially expressed from control embryos were identified in cloche embryos, 13 novel and 7
specific for the endothelium. However, some critical endothelial specific genes like VEGFR2
were missed in analysis because of large variation in experiments and low expression of the
gene, underlying the requirement for rigorous quality control and analysis. (Sumanas, 2005)
Meaningful information from microarray profiles is only extracted through critical
analysis. We used several normalization and analysis methods to ensure the accuracy and
biological validity of data. Microarray data must be filtered, normalized and adjusted for
background, summarized, analyzed for differential expression, and finally annotated according
to genome databases. To eliminate technical sources of variability across replicate arrays, the
mean intensities of the entire array and throughout regions of the array are calculated and
normalized for subsequent analysis. Pre-processing of data also includes correction for
background signal, non-specific binding, and summarizing replicated probe sets and
mismatched probes into one value. Multiple normalization methods exist to adjust hybridization
intensities to one mean intensity value or multiple values based on locally-weighted least
squares regression values (loess normalization) based on location, quantiles based on
distributions, or other methods. The MAS5 method uses a bisquare weight to robustly define
data points based on distance from the mean and identify averaged intensities and exclude
outliers and then transforms data to a log scale to ensure positive intensity values and stable
variance. (Hubbell, 2002) The robust multi-average array (RMA) normalization method log-
transforms intensity values and then calls for global background correction, quantile
normalization of distribution across each array, and a linear model transformation for each
probe set; this method has been shown to extract more insightful data from arrays than other
methods while avoiding outlier values. (Irizarry, 2003) We compared the results of both MAS5
and RMA normalization methods to ensure that gene expression levels were accurate for
downstream analysis.
Once appropriate normalization is complete, statistical testing is done on transcript
intensity values to identify patterns of gene expression across arrays. Most commonly, this
involves calculating a test statistic, for example ratio (fold change) of a transcript among two
experimental groups, and calculating the significance of the statistic. (Slonim, 2002) Common
methods of identifying the significance of a ratio between multiples of different groups are the t-
test or ANOVA, which assume normal distributions and equal variance in data points. More
conservative versions of these tests have been designed to adjust for these assumptions. The
R version of the Cyber t-test incorporates a Bayesian prior based on the variance of transcripts
with similar expression levels to each transcript. (Baldi, 2001) The Local Pooled Error test
(LPE) is another example of test where variance estimates are combined for transcripts with
similar intensities and is especially useful for low-replicate studies where calculated probe
transcript variance is inaccurate. These tests were used to improve the error accuracies for
individual transcripts in our dataset.
When testing for significance of transcript ratios across such a large number of genes, it
is important to control for false positive error rates given the chance of identifying changes in
expression as significant based on chance alone. False positive identified transcripts can be
decreased by adjusting the error rate as a function of the total number of transcripts tested
using the Bonferroni or Benjamini-Hochberg corrections, among others. More accurate
methods for limiting false positive statistical values have been developed. For example,
Significance Analysis of Microarrays (SAM) uses a non-parametric permutation method to
calculate the chance that a gene expression changes designated as significant is a false
positive. It determines how often we would expect to find what appears to be a regulated gene
due to chance alone by determining the average number of genes regarded as significant after
balanced permutations in the data have been made and accounting for the number false
positives in the real data analysis. (Tusher, 2001) By approximating the amount of false
positives in the data set with SAM, we were relatively confident that identified transcripts were
significant.
In addition to the statistical tests described above, we used projection tests to explain
the variance in the data. These tests can eliminate 'noise' that is common in microarray data
and often overlooked by statistical tests, and therefore significantly increase the quality and
biological validity of resulting data. Projection tests like Principle Component Analysis (PCA),
Independent Component Analysis (ICA) and Singular Value Decomposition (SVD) reduce the
dimensionality in the multivariate data and project the reduced variables in two or three
dimensional space to identify major components that contribute to the variance in the data.
(Landgrebe, 2002) (Saidi, 2004) (Holter, 2000) SVD analysis represents temporal gene
expression profiles as a linear combination of 'characteristic nodes' and a matrix of gene
specific coefficients. The variation of gene specific coefficients defines the relative contribution
of nodes to the final gene expression profiles. If coefficients of the experimental replicates
cluster when nodes are plotted against one another, it is evidence that particular nodes
contribute to gene expression profiles of those samples and one can then investigate genes that
positively correlate to those nodes as functionally significant. PCA and ICA are similar
variations to this method, where components are identified by dividing the data into matrices
that represent 'gene signatures' in the data. Clustering of samples along a particular
component in graphical representations signifies that genes that contribute to that component
may be strongly linked to the characteristics of those samples. We used the ICA projection
method which has been shown to significantly increase the validity of analyzed microarray data,
and can identify regulated transcripts that are often overlooked as noise by other methods.
(Saidi, 2004)
Once we identified differentially expressed gene transcripts and confirmed that error
rates were low by using the above tests, we used several clustering methods to visualize data
and identify groups of genes that may be co-regulated. Hierarchal clustering compares the
expression pattern of a gene across sample sets and calculates the similarities using Euclidean
(most commonly) or other metrics to calculate distances between expression patterns. The
gene expression profiles are graphically organized by comparing distances in order to identify
clusters that are changing in similar patterns. (Eisen, 1998) Other methods include partitioning
algorithms, where the number of clusters is pre-determined. The results are dendrograms or
heat maps which display gene data trends that cluster together. Clusters can define critical
genes that are turned "on" or "off' by experimental perturbations.
Regulated transcripts identified by the above methods were grouped into functional
pathways in order to elucidate entire signaling networks that are regulated across samples. Of
course, the expression of gene transcripts is an inter-dependent process and understanding
how groups of transcripts are co-regulated is critical for achieving biological significance from
lists of significantly regulated transcripts. Pathway analysis tools have been developed to group
regulated genes into known functional networks based on an algorithm that determines
connectivity between transcripts supported by literature references. A network graphically
represents molecular relationships between genes depicted as nodes and edges/lines which
depict relationships between nodes. The dependence and conditional independence of the
transcript expression patterns, without considering known functional networks, can be examined
using a Bayesian approach. (Friedman, 2000) Many methods exist which attempt to cluster
genes by expression profiles to visualize regulated networks while limiting statistical errors in
complex data. As described below, we used a Markov Chain Clustering algorithm to obtain
gene regulatory networks because it identifies relationships between transcript expression
profiles while eliminating traditional, often inaccurate assumptions, and noise in the data set.
Using a combination of the methods described above, we identified hundreds of gene
transcripts which were regulated by HSGAG sulfation.
4D2. Glycome Modifications Modulate Transcriptome Signatures in Developing
Zebrafish Embryos
To investigate the effects of HSGAG perturbation on downstream transcriptional
regulators of vasculogenesis, we performed a global gene expression analysis of NDST1
morphant embryos and control siblings during development. We chose to focus on three
developmental time points which correlate to significant stages of zebrafish vessel development:
6-somite, the stage in which angioblasts migrate to the midline axis, 20-somite, the stage in
which the angioblasts associate and form the major axial vessels, and 28-somite (24-hours post
fertilization), when angiogenesis begins with sprouting of inter-segmental vessels. (Jin, 2005)
RNA was isolated from triplicate samples of each experimental condition and microarray
analysis completed using Affymetrix Genechip Zebrafish Genome Array.
Before analyzing microarray data, quality control diagnostics were performed on
fluorescence levels measured to ensure even hybridization and lack of scratches,
contamination, etc. across the arrays. Data was summarized over the array and normalized
using both the Mas5 algorithm and the more robust RMA normalization methods to a mean
expression level of 100 for comparison during downstream analysis. A box plot comparing the
log2 transformed distributions of the intensities across the arrays is a visualization of successful
normalization across all samples. (Figure 13) Transcripts were annotated using 3 sources
which were the most updated references for annotation at the time of analysis. (Affymetrix
annotation file downloaded from Netaffx, Entrez Gene/Unigene/GenBank, and Trans-NIH
Zebrafish Genome Initiative database) For an initial evaluation of the data, we performed a
simple (age group) paired Student's t-test between NDST1 knockdown and control embryos. A
plot of expression values for all genes in knockdown vs. control samples reveals many gene
elements that lie off a straight line of slope 1, representing differential expression of that gene
among the groups. We identified some of the differential transcripts on this plot, including IGF2,
P13Kinase, Foxo5, MDM2, and Cylcin G1. (Figure 14) The 35 genes with the lowest p-values
were classified into functional groups using GOStat@. Functional groups classified from the
data included biopolymer metabolism, nucleic acid metabolism, proteolysis, protein catabolism,
and mitosis. From this initial evaluation, we determined that critical genes were being regulated
by knockdown of NDST1 and continued with more rigorous analysis of the data.
Mean values of the three experiments were log2 transformed for further statistical
analysis. The Local Pooled Error differential expression test pools variance estimates for genes
with similar expression intensities which lowers within gene error estimates. LPE was executed
and identified 218 significant transcripts regulated between NDST1 mutant and control embryos
at all ages after a Bonferroni false-positive correction. Transcripts were considered differentially
regulated if p-value was less than 0.05 and fold change was less than 0.75 or greater than 1.25.
Fold change is defined as the ratio of normalized expression intensities of mutant and wild-type
RNA. The complete list of significantly regulated genes is located in Appendix 1, Tablel.
Hierarchal clustering using a Euclidean distance metric identified distinct temporal expression
patterns in the 50 most significant transcripts. (Figure 15) As evident from the heat map,
clusters of regulated transcripts with similar expression profiles were identified for control
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Figure 13. Normalization of Microarray Data. 18 total Microarray
experiments were used for our study. Samples consisted of RNA isolated
from triplicate NDST1 morpholino injected zebrafish embryos and control
siblings at 6-somite, 20-somite, and 24-hours post fertilization developmental
stages. Samples were hybridized to Affymetrix Zebrafish Genome
GeneChips, and quality control of individual arrays was completed.
Fluorescent intensities representing hybridization to individual gene
transcripts were normalized by Mas5 and RMA methods. Box plots (above)
depict the log2 transformed intensity distributions across all 18 arrays have
been successfully normalized to a mean intensity value for downstream
analysis. (This normalization was used for Cyber-T and ICA analyses, t-test,
LPE, and ANOVA analysis was normalized similarly using Mas5 method)
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Figure 14. Scatter Plot of global transcriptome profiles in NDSTI and control samples. As
an initial analysis, data was log transformed and normalized to a mean intensity value of 100. A
plot of mean transcript intensity values for NDST1 vs. control samples identifies transcript
elements that lie off a linear distribution as differentially expressed or 'regulated' between
experimental groups. Statistical testing identifies the significance of identifying regulated
transcripts. We identified many differentially expressed transcripts including those labeled above.
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samples only, NDST1 mutant samples only, or those expressed later in NDST1 mutants. In
order to identify regulated genes at specific developmental stages, ANOVA analysis was carried
out on normalized data contrasting age with type (control vs. mutant). From this analysis we
were able to identify transcripts that were differentially expressed at each specific age. P-value
threshold was 0.05 and adjusted using a Benjamini- Hochberg false-positive correction.
Interestingly, the largest number of differentially expressed genes, 619, was identified in the 20-
somite age group. (Figure 16) This stage is associated with the aggregation of angioblasts at
the midline and formation of the major axial vessel structures in the zebrafish embryo.
Disruption of vasculogenesis mechanisms at this stage may explain the observed phenotype in
NDST1 knockdown embryos, characterized by an underdeveloped dorsal aorta and pooling of
blood cells in the tail. 119 regulated genes were identified in the 24 hpf group and 67 in the 6-
somite group. Again, this is consistent with the observed NDST1 phenotype in which vessels
are present, angioblasts are formed by the 6-somite time point, but intersegmental vessel
development is compromised, a process which occurs at 24 hpf. 34 transcripts were found to
be significant in all three age groups. All but two, phosphatidylinositol transfer protein and
Dr.5925.1.A1, were also found significant in LPE differential analysis. Several of the
overlapping transcripts were identified in our initial evaluation of the transcript data using a
simple Student's t-test, including Pl3Kinase, MDM2, IGF2, Foxo5, and GADD45. Regulated
significant genes can classified into functional groups associated with cell signaling,
transcription factors, cell proliferation/differentiation, protein stability, apoptosis, and matrix
interactions. The complete list of significant genes identified with ANOVA analysis is in
Appendix 1, Table 2. To add a further level of robustness to our model, a more conservative
statistical test, the R version of Cyber-T, was also used to analyze data normalized by both
Mas5 and RMA methods. Cyber-T considers the error rate of transcripts with similar variance
and expression levels and thus increases the accuracy of identifying significant transcripts
across a wide range of values. Because there were many transcripts found to be regulated
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Figure 15. Hierarchal Clustering of significantly regulated transcripts depicts clusters of genes
specific for experimental groups. The top 50 significant transcripts identified from Local Pooled
Error analysis were clustered using a Euclidean distance measure of gene expression profiles to group
genes with similar patterns. The colored legend represents the intensity values of a gene for a given
sample. Group I depicts genes expressed in control embryos only, Group 11 identifies genes
expressed more in control embryos, Group Ill identifies a cluster of genes expressed later in NDSTI
embryos only, and Group IV identifies a cluster of genes expressed in NDST1 embryos only. Some
transcripts identified in Group IV include IGF2 and Foxo5. (WT 20-somite= wild-type (control) embryo
at 20-somite stage)
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ANOVA analysis of NDST1 mutant vs. control embryonic transcriptomes
Overlapping Significicant Transcripts:
Pleckstrin P13 Kinase
Ribosomal Protein FOS SWI/SNFchromatin regulator
GTP binding Protein 1 GADD4S Thymus specific serine protease
Ras-like family 11 Membrane protein palimoylated 1 PARK
Caspase 8 Foxo 5 NMDA
Vaccinla-related Kinase 2 Forkhead box 1 LC56384
PS Glycosytransferase Dr.S926.A1
Cyclin G2 Zinc finger protein like 1 Dr.14673.2.S1.at
Multi-drug Resistance 5 Pelota homolog Dr.21979A1.at
IGF-2 Replication factor subunit C Dr.26003.1A1.at
MDM2 Phosphatidylinositol transfer protein Dr.2109.1.S.at
Figure 16. ANOVA analysis identfies regulated gene transcripts at specific
developmental stages. Paired ANOVA testing (P<.05) of microarray data identified 67,
619, and 119 regulated genes at 6-somite, 20-somite, and 24-hpf stages, respectively.
The 34 overlapping genes highlighted in the diagram are represented in the table.
Transcripts that have not been identified are represented by Affymetrix ID.
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specific to each normalization method, we only considered differential expression significant if it
was overlapping for both normalization methods. This biased the results toward the RMA
method considering more genes were found as significantly regulated using Mas5
normalization, however we believe this is a more conservative estimate and more likely to
identify results that can be validated biologically. Using this conservative t-test, transcripts were
defined as significantly regulated between mutant and control if they had a P-value below 0.01
and had a Imean fold changel of greater than or equal to two between NDST1 morphant vs.
control. Similar to the results from ANOVA testing, the 20-somite stage had the most genes
"regulated" by the NDST1 knockdown. 26 gene transcripts are regulated for all three time
points, a majority of which were found to overlap at all time points by ANOVA (73%). (Figure
17) (Tables 3A, 3B, Appendix 1) Significance Analysis of Microarrays (SAM) was used to
estimate the false discovery rate of significant transcripts. According to this analysis, 55% of the
significant genes in the 6-somite group may be identified by chance alone, but only 8% and 16%
of the significant genes in 20-somite and 24-hpf groups, respectively. This means that the later
time points contain the most reliable data on which to base functional assumptions.
Finally, Independent Component Analysis (ICA) was executed on the data set to identify
differentially expressed transcripts after elimination of noise in the data, and to identify regulated
transcripts that may have been overlooked by other methods. As described above, ICA splits
expression data into components and can identify transcripts that cluster along components as
having related expression profiles. In our analysis, we classified transcripts of a component
(component 2) with characteristic clustering for NDST1 and control samples. (Figure 18)
'Contributions' of each transcript to the specific component were calculated and the top 0.5%
was considered differentially expressed between the experimental conditions. All except 2
transcripts identified from Cyber-T analysis were identified from this component, along with an
additional 34 'regulated' genes. (Table 4, Appendix 1) Overall, 18 gene transcripts were
Cyber-T analysis of NDST1 mutant vs. control embryonic transcriptomes
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Figure 17. Cyber-T analysis identifies regulated gene transcripts at specific developmental
stages. Scatter plots compare the mean transcript abundance of the triplicate NDST1 samples with
control triplicates. A) The transcripts with cyber-T P<0.01 and Ifold change|22 at the 24-hpf time
point are highlighted in green in graphs for all three time points. It is clear that many of these were
regulated at earlier time points. B) Similarly, transcripts with cyber-T P<0.01 and Ifold change22 at
the 6-somite time point are highlighted in blue in graphs for all three time points. Many were
regulated at the 20-somite and 24-hpf stages as well.
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Independent Component Analysis of Microarray Data
NDST1 Morphant
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Wild Type
SS 20S 24hr
Figure 18. Independent Component Analysis investigates regulated transcripts independent
of the assumptions of traditional statistics by reducing the dimensionality of complex data
networks. The Hinton plot above depicts 'components' or gene signatures derived from expression
intensity data. For each row, or component, the color and magnitude of the square represents the
degree to which a particular sample contributes to that component. Orange is negative contribution
and yellow is positive contribution. We investigated the genes positively associated with component
two, which has specific positive contributions for NDST1 samples only. A majority of the regulated
transcripts identified with previous statistical methods were also in the top 0.5% of transcripts
contributing to component 2.
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confirmed to be differentially regulated from all statistical tests for all developmental stages.
(Table 1)
Networks based on Cyber-T regulated genes were generated using Ingenuity Pathways
Analysis and Knowledge Base software. The genes were overlaid onto a global molecular
network developed from the database based on known functional interactions. Fischer's exact
test was used to calculate the probability of interactions found in the network. Gene products
are represented as nodes that are linked by edges that define the degree of interaction. In this
way, we identified pathways in our data set that were most significantly affected by NDST1
knockdown. Key molecular pathways identified include those associated with IGF2, FOS,
MDM2, BAX, GADD45, and FOXO. (Figure 19) Functional pathways regulate apoptosis,
differentiation, cell matrix, and cell-cell interaction.
4D3. Markov Clustering of Transcriptome Profiles Identifies Robust Clusters of Gene
Interaction following NDST1 knockdown
The analysis methods above identified many significantly regulated transcripts that
function in conjunction with HSGAG regulation during early vascular development in the
zebrafish. While the analysis methods above have been extensively used and validated, novel
network associations and clustering algorithms can be generated that can identify regulatory
associations that evade traditional methods. Supervised clustering methods, like hierarchal
clustering, partition data into a pre-defined number of groups or compared to a given reference.
Unsupervised clustering requires no information about the data set and can more accurately
identify network relationships that are unique to a given biological system. An unsupervised
Markov Chain Clustering (MCL) technique was used identify differentially regulated transcripts
upon NDST1 knockdown in zebrafish that interact through the various developmental stages.
The objective of MCL is to quantify the proximity between elements of data; gene expression
Affymnetrix ID Transcript AOAFl yeTFl
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Figure 19, Molecular Pathways of regulated genes. Cell Illustrator and Ingenuity Pathway
Analysis were used to construct functional pathways of regulated transcripts from 6-somite,
20-somite, and 24-hpf stages according to Cyber-T analysis. A Fisher exact test was used to
calculate the probability of gene association by chance alone. Genes are represented by
nodes and relationships as edges connecting nodes. (See Legend)
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profiles can be described as vectors whose elements are the different expression
measurements of a gene over experimental conditions. Elements with a large degree of
proximity are likely to share a common functional or regulatory mechanism. (Lattimore, 2005)
We developed a novel clustering technique based on differentially expressed genes in
NDST1 knockdown and control embryos based on FANOVA analysis. FANOVA builds on
standard ANOVA by calculating a distribution of values over each measurement that can
provide information about the gene perturbation response. The functions generated with this
methodology account for mean values of each transcript expression for a particular age, specific
variation associated with an age group, and specific variation in a particular transcript within an
age group. The distributions can be evaluated using complex network analysis to determine the
degrees of interaction in the network. In analyzing the characteristics of a network co-
regulation, or connectivity topology, biological networks have been found to lie in between
completely regular or completely random systems. Graph structures of the network are more
complex than the vectors in traditional clustering methods and are represented by nodes, or
elements, which are connected by edges which characterize the degree of interaction between
nodes. They are a better representation of gene expression patterns, where the degree and
complexity of underlying connectivity is relatively unknown. (Lattimore, 2005)
In our system, we suppose that the differentially regulated genes are those that
compensate or react to the inhibition of NDST1 and contribute to the vasculogenic phenotype.
We identified 609 transcripts with varying expression of at least one log fold by FANOVA. A
network graph of 609x609 elements was constructed where each node represented a gene and
each edge represented the degree of interaction. Each element of this matrix was filled with the
interaction value which was calculated as the ratio of expression changes between two genes
from experimental samples and the same genes from control samples. The edge was removed
from a network if the calculated interaction value was lower than a set threshold. This matrix
was the input for a Markov Clustering Algorithm (MCL) to obtain gene regulatory networks. The
matrix undergoes iterative algebraic operations of expansion and inflation. Resulting structural
properties of the matrix are affected by the presence of interacting nodes in the matrix, which
are revealed through the iterative process when the matrix stabilizes. (Lattimore, 2005) The
elements in the input matrix are described as the probabilities of interaction or 'random walks'
between nodes and the process of expansion and inflation will increase the probabilities of
random walks present in clusters without a priori knowledge of cluster presence. (Figure 19)
FANOVA analysis of the NDST1 microarray data revealed 609 gene transcripts of fold
change greater than 1 log scale that were differentially regulated in NDST1 and control
zebrafish embryos. The p-value distributions were distributed according to power laws as
predicted. (Figure 20) The distributions contain two exponential value regions which suggest
that most differential transcripts are partitioned in two groups with different connectivity pattern.
We identified some regulated of the regulated transcripts on the distribution including GADD45,
MMP2, P13 Kinase, MDM2, VEGFR2, IGF, and FOXO5.
MCL Clustering confirmed the presence of connectivity in the network. The magnitude
of edges was calculated as the ratio of expression differences between two genes from
perturbation samples and the same two genes from control samples. Unstable nodes were
identified and removed by introducing 'noise' perturbations into the matrix and removing nodes
with a minimal level of interaction. A large network over the different time points was
constructed from the interactions of differentially expressed genes. (Figure 21) It is clear that
many genes interact between the 6-somite, 20-somite, and 24-somite developmental stages
that contribute to the vasculogenic phenotype present in embryos. Because the initial cluster
was so complex, we tuned clustering parameters to obtain a smaller, more critical cluster.
(Figure 21) The cluster map obtained contained 20 interacting gene transcripts. 13 transcripts
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Figure 20. FANOVA analysis of regulated transcripts. A) The p-value
distribution from FANOVA analysis of all regulated transcripts between NDST1
mutant and control embryos across all time points. The distribution follows a
power-law as expected for biological data. Different slopes (exponents) on the
distribution function indicate partitions in groups of gene transcripts with
expression connectivity following NDST1 perturbation. B) Example of Markov
Chain Clustering of a data matrix. The input matrix (1) is subjected to iterations
of expansion and inflation (2-5) until the matrix stabilizes (6) to reveal interacting
nodes. The interaction values of 609 statistically significant gene transcripts
identified by FANOVA analysis, proportional to the ratio of the gene transcript
from mutant to control values, was the input matrix for MCL clustering.
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Figure 21. MCL Clustering identified large networks of interacting gene transcripts. (Left) The
large network of interacting nodes represents the degree of connectivity in regulated transcript elements
in response to NDST1 inhibition. Gray edges: connectivity in 6-somite-20-somite steps; Black edges:
connectivity in both 6-somite-20-somite and 20-somite-24-hpf steps; Red edges: connectivity in 20-
somite-24-hpf step; Blue nodes: high degree of connectivity; Gray nodes: lesser degree of connectivity.(Right) Clustering parameters were tuned to generate several smaller, more manageable clusters. The
network represents the most significant cluster. Transcripts are identified by Affymetrix ID and have notbeen identified to date. These transcripts may represent novel genes that regulate vasculogenesis.
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have been defined in zebrafish: proteolipid protein 1a, pleckstrin homology domain, synuclein,
ATPase, myocyte enhancer, nitric oxide synthase, glutathione S-transferase, Elav-like family
member, parvalbumin 2, pyruvate carboxylase, anterior gradient homology 2, malic enzyme 3,
and neuronal growth regulator. The other 7 transcripts are identified by the Affymetrix ID or
ETS ID sequence. Although these genes have not been identified as having a specific role in
vasculogenesis, they may represent novel genes that control vessel development. Additionally,
because of global NDST1 knockdown in embryos, they may represent gene networks that
compensate for diminished HSGAG in other systems, for example neuronal growth regulator.
Because the scope of this project is to identify mechanisms of vasculogenesis, we chose not to
explore the effect of NDST1 knockdown on other organ systems. The results demonstrate that
robust gene interaction networks are present in our data and that perturbations in HSGAG
sulfation by NDST1 knockdowns are translated to gene expression profiles that affect
development.
4D4. The FOXO5 transcription pathway is up-regulated following NDSTI knockdown.
Based on the models constructed above, we identified several transcripts that were
repeatedly found to be regulated in NDST1 morpholino injected zebrafish embryos. One
transcript that was up-regulated in all three developmental stages following NDST1 suppression
was the transcription factor FOXO5 (orthologue of murine and human FOXO3A). FOXO3A has
been implicated in apoptosis inhibition of endothelial cells and its silencing has been shown to
enhance the angiogenic activity of endothelial cells. (Potente, 2005) The presence of insulin and
growth factors in the cell microenvironment activate P13 Kinase, upstream of AKT which
phosphorylates FOXO3A and renders it inactive. The increase in FOXO3A levels indicates a
decrease of extracellular activators of the pathway following knock down of NDST1. This
supports our hypothesis that perturbation of HSGAG by inhibiting NDST1 prevents the
availability and binding of extracellular growth factors which are critical for vasculogenesis.
Active FOXO3A migrates to the nucleus and targets pro-apoptotic and cell cycle arrest genes
including: p27, p21, Cylin D1/D2, Cyclin G1, BIM, GADD45, Bc12, TRAIL, and Fas ligand. Some
of these genes are up-regulated in the NDST1 knockdown fish, including: pro-apoptotic gene
BAX( fold-change 2.09), ubiquitin ligase 3(1.37), P13 kinase(3.56), and Cyclin G1 (2.27).
Another transcript that was identified in several statistical tests was Insulin like growth factor 2
(IGF2). IGF2 was linked as an upstream regulator of FOXO and was up-regulated in NDST1
morphants. This may represent a compensation mechanism of cells for lack of growth factor
signaling.
We confirmed the increase in FOXO5 and IGF2 mRNA levels in NDST1 morphant
embryos compared to control using quantitative PCR. Because this may represent a novel
pathway that regulates vasculogenesis, we decided to explore it further using our embryoid
body vasculogenesis model as described in the previous chapter. We used short hairpin
FOXO3A RNA contained in lentivirus vectors to infect differentiation embryoid bodies and
effectively inhibit expression of FOXO3A. (Figure 22) Interestingly, we found that the
expression of functional endothelial markers was dramatically increased in embryoid bodies that
where FOXO3A was inhibited compared to controls. At the same time, we observed a
significant decrease in IGF2 expression. We also observed that expression levels of FOXO3A
decrease as cells undergo differentiation into endothelium. This demonstrates that FOXO3A,
possibly mediated by IGF, regulates vasculogenesis and may represent a novel pathway to
target for inhibiting or promoting neovascularization.
4E. Discussion and Conclusions
The work presented in this chapter demonstrates that the sulfate composition of HSGAG
affects vascular development in vivo. A reverse genetic RNA interference technique was used
to probe the role of an HSGAG enzyme in zebrafish vessel development. Injecting zebrafish
embryos with a morpholino for N-deacetylase/N-sulfotransferase1 (zNDST1) effectively
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Figure 22. The IGF2/Foxo3A Pathway Regulates Vasculogenesis. (A) Quantitative PCR was used to
confirm significant changes in Foxo5 and IGF2 expression in zebrafish control and NDST1 knockdown
embryos. Similar to microarray analysis, levels of Foxo5 and IGF2 expression were significantly increased
in NDST mutant embryos. (6S WT= 6-somite wild-type (control); 6S zNDST1=6-somite NDST1 mutant;
*=P<0.05) (B) Parallel to results in zebrafish, the expression of Foxo3A was significantly increased in
embryoid bodies treated with NDST1 shRNA (shNDST1). * denotes P<0.05 compared to respective
controls. Protein levels of NDSTI were also increased in NDST1 shRNA treated embryoid bodies as
depicted in the Western blot below. (C) shRNA against Foxo3A (shFoxo3A) was designed to probe the
effects of the transcription factor on endothelial differentiation and confirmed to statistically reduce mRNA
levels (**) compared to control. The expression of IGF2 was significantly decreased (***) in shFoxo3A
treated embryoid bodies compared to control, indicating that IGF2 is a downstream target of Foxo3A. (D)
Silencing of Foxo3A results in significantly increased levels of endothelial markers Tie2 and VEGFR2,
indicating increased endothelial expression, evidence that Foxo3A inhibits vasculogenesis.
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decreased the expression of the enzyme which translated to HSGAG synthesized with
significantly decreased sulfation for more than 24 hours, which is the duration of
vasculogenesis. Vasculogenesis and angiogenesis in zNDST1 embryos were significantly
impaired. The major axial vessels of the zNDST1 embryos lacked patent lumens which resulted
in blood pooling in the tail. There was an overall decline in angiogenic branching of the caudal
plexus and robust inter-segmental vessels. In addition to linking HSGAG sulfate structure to
vasculogenesis, we performed a global analysis of the transcription profiles of zNDST1 and
control embryos during vasculogenesis to identify several molecular mechanisms affected by
HSGAG perturbation. A series of robust statistical models were used to identify many gene
transcripts and several functional pathways that are significantly 'regulated' by NDST1 inhibition.
This 'cross-talk' of extracellular HSGAG sulfation patterns to intracellular gene expression
regulation demonstrates the critical role that HSGAG play in vasculogenesis. It builds on the
work of the previous chapter by studying vessel development, structure, and anatomy in vivo
and identifying some of the critical pathways downstream of HSGAG that regulate these
processes.
As with the embryonic stem cell studies (See Chapter 3), we chose to inhibit NDST1 as
a method of studying the effects of HSGAG sulfation on development. NDST1 is the first in the
series of enzymes that add sulfate groups to HSGAG chains in the Golgi. It has been shown,
by us and others that inhibition of NDST1 results in the generation of cellular HSGAG with
significantly decreased sulfation and thus decreased capacity for interacting with the
microenvironment. Indeed, we demonstrated by isolating cell surface HSGAG from zebrafish
embryos and separating disaccharide moieties using capillary electrophoresis that inhibition of
NDST1 significantly reduces chemical sulfation of HSGAG. In previous studies, genetic
perturbation of HSGAG synthesis resulted in early developmental defects, including failure of
mesoderm differentiation and embryonic lethality, which prevented further characterization of
vasculogenesis. (Lin, 2000) (Stickens, 2005) This limitation was overcome with the zebrafish
97
model, which survived for several days following oligonucleotide-induced knockdown of NDST1.
Zebrafish are an especially useful organism for studying impairment of vascular development
because passive oxygen diffusion enables embryos to survive for several days without
functional vasculature. Knock down of NDST1 resulted in a phenotype of attenuated vascular
development. Specifically, the functional integrity of major axial and inter-segmental vessels
was impaired and there was a significant decline in branching along the caudal vein plexus.
Taken together with data from the previous chapter, where we demonstrated that NDST1 and
HSGAG are critical for endothelial differentiation, these results demonstrate a causal link
between glycome composition and blood vessel formation.
Variation in heparan sulfate fragments isolated from zebrafish at different time points
indicates that HSGAG are dynamically modulated during development. (Zhang, 2009)
Zebrafish possess orthologues of each of the enzymes that sequentially sulfate heparan sulfate
chains in the Golgi, including NDST, C5 glucuronic acid epimerase, and 2-0, 3-0, and 6-0
sulfotransferases. The expression patterns of 2-0, 3-0, 6-0 and epimerases have been
identified in the zebrafish. (Yost, 2006) (Yost, 2006) (Yost, 2007) Although the number of
isoforms vary in these enzymes among species, human, mouse and zebrafish all express 4
isoforms of NDST with NDST1 being the most ubiquitous. To our knowledge, our study is the
first to look at the effects of NDST1 inhibition in the developing zebrafish. HSGAG have
complementary roles in development across species. (Kramer, 2010) For example, the
requirement of HSGAG for FGF signaling in branching morphogenesis has been well
characterized in mouse, zebrafish and Drosophila. (Norton, 2005) (Lin, 1999) Axon pathfinding
is compromised in zebrafish and mice with mutations in HSGAG enzymes. (Lee, 2004) (Pratt,
2006) 6-0 Sulfotransferase (6-OST) has been shown to be critical for the development of
muscle in zebrafish embryos, another mesodermal lineage. (Bink, 2003)
Studies in zebrafish have specifically looked at the HSGAG regulation of
vasculogenesis and angiogenesis. Morpholino-induced silencing of HSGAG proteoglycan
syndecan-2 resulted in inhibition of angiogenic sprouting, which was correlated with decreased
VEGF signaling in vivo. (Chen, 2004) Another proteoglycan, perlecan, was found to be critical
for VEGF-induced angiogenesis and specifically endothelial cell migration and proliferation.
Angiogenic blood vessel development of the intersegmental vessels, dorsal anastomotoic
vessels and subintestinal vessels were inhibited while vasculogenesis was not. (Zoeller, 2009)
In a similar study, vascular branching was decreased in zebrafish embryos deficient in 60ST 1
but not 6-OST 2. Morpholino-induced silencing of 60ST resulted in abrogation of the fine
mesh-like, organized structure of the caudal vein plexus at 30 hours post fertilization. (Chen,
2005) This phenotype is similar, but less severe, to the one we observed with NDST1 knock
down. Expression of endothelial marker flk-1 (VEGFR2) was not significantly reduced in 60ST
morphant embryos while expression of late endothelial marker tie-2 was significantly decreased,
indicating that the inhibition of 60ST affects late stages of vascular development. This supports
the notion that 6-0 sulfation is critical for VEGF binding, and is necessary for spatial restriction
of the growth factor to regulate vascular branching pattern. (Ruhrberg, 2002) Zebrafish
embryos treated with VEGFA morpholino exhibit a similar phenotype characterized by lack of
caudal plexus and intersegmental vessel formation. (Kawamura, 2008) These results may
partially explain the analogous vascular defects we observed in NDST1 morphant embryos.
However, we hypothesized the more severe phenotype we saw is the result of inhibition of
several signaling pathways due to reduced HSGAG sulfation at all sites.
Analogous to embryonic stem cells, the addition of exogenous heparin could partially
rescue the vascular phenotype induced by NDST1 knockdown in zebrafish embryos. Heparin
was used because it is a highly sulfated heparan sulfate analogue that contains all possible
sulfate groups that were inhibited by silencing of NDST1. Although there was a significant
increase seen in tail length, measurements did not reach those of control. This can be due to
the imprecise sulfate compositions present in heparin that can disrupt cytokine gradients or
more likely due to inadequate diffusion of the sugar to all cells during development.
Nevertheless, it is clear that HSGAG can restore key signaling pathways that promote vascular
development. To explore this notion, we decided to study the transcriptional changes that occur
upon NDST1 silencing.
Several different robust analytical methods were used to analyze microarray
transcriptional data to ensure the accuracy of our findings. Not surprisingly, a large number of
genes that were differentially regulated were involved in morphogenesis. For example, we
observed changes in the expression of Wnt receptor Frizzled, and another morphogen, Sonic
Hedgehog (Shh). Previous studies in zebrafish have indicated vascular defects in Shh mutant
embryos. (Chen, 1996) Endoderm secreted Shh is necessary for angioblasts to assemble into a
vascular network and to undergo vascular tube formation. (Vokes, 2004) Shh has also been
shown to be an indirect agent of vessel formation by upregulating growth factors like BMP-4,
angiopoeitins, and VEGF. (Pola, 2001) (Astorga, 2007) This supports our hypothesis that the
global inhibition of HSGAG sulfation can provide biological information that is relevant in the
context of the interaction of distinct cell types, and therefore may not be evident through cell-
selective modulation of the gylcome. Nicalin, a highly conserved transmembrane protein and
Nodal signaling agonist was also up-regulated after HSGAG modulation. Nodal proteins are in
the TGFp superfamily and play a key role in mesodermal patterning. (Haffner, 2004)
Many transcripts associated with apoptosis and cell death or proliferation were
significantly regulated between NDST1 morphant and control embryos including FOS, GADD45,
BAX, MDM2, and Caspase 8, among others. Apoptosis plays a critical role on vessel formation;
increased expression levels of apoptotic transcripts may also indicate cell death due to lack of a
functional vasculature. (Duval, 2007) Enzymes implicated in protein stability and matrix
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restructuring were also significantly regulated. For example, prolidase, which catalyzes the final
step in collagen degradation, was down-regulated in NDST1 morphant embryos. Prolidase has
been linked to angiogenesis through defective wound healing in patients with inherited
deficiency for the protein. (Surazynski, 2008) Plasminogen, MMP2 and cathepsin L, essential
for invasive angiogenesis and integration of circulating endothelial progenitor cells into ischemic
tissues, were also down-regulated.
Interestingly, despite the interaction of HSGAG with VEGF, FGF, and PDGF, none of
these growth factors were found to be directly modulated by NDST1 silencing. However, the
expression of insulin like growth factor 2 (IGF2) was significantly increased. IGFs play a key
role in embryonic growth and development and reported to regulate BMP expression and
patterning formation in the zebrafish. (Eivers, 2004) HSGAG binding insulin like growth factors
have been implicated in endothelial progenitor cell homing and angiogenesis but, interestingly,
have also been implicated in maintaining embryonic stem cell pluripotency. IGF binding
proteins bind HSGAG and regulate the levels of circulating ligand. This dichotomy suggests
that precise regulation, by HSGAG and other processes, is important for IGF function. (LeRoith,
1997) (Paye, 2006) Other notable signal transduction component transcripts that were
modulated include vaccinia related-kinase 2, pleckstrin, an analogue of angiopoietin 3, and
stromal derived factor 1 (SDF1). Secreted SDF triggers recruitment of endothelial progenitor
cells to ischemic tissues. (Yamaguchi, 2003)
Several transcription factors were identified as being up-regulated in NDST1 knockdown
embryos. For example, spleen tyrosine kinase (SYK) was up-regulated in NDST1 knock down
embryos. SYK suppresses cell motility by inhibiting P13 kinase and urokinase-type plasminogen
activator, which are critical in neovascularization. (Mahabeleshwar, 2003) The transcription
factor FOXO5 (orthologue of human and mouse FOXO3A) was consistently up-regulated by
approximately 5-fold. FOXO3A has been implicated in migration and apoptosis inhibition in
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endothelial cells, and its down-regulation was shown to enhance angiogenic activity. (Potente,
2005) Insulin and growth factor signaling leads to downstream phosphorylation and inactivation
of FOXO3A, lack of signaling enables FOXO3A to migrate to the nucleus and promote the
expression of pro-apoptotic genes. An up-regulation of FOXO3A with NDST1 inhibition is
further evidence for disrupted growth factor signaling following glycome perturbation. Because
this transcript was identified as significantly regulated in all statistical tests and pathway
analyses, we chose to further characterize its role in endothelial development.
Using our embryonic stem cell model (See Chapter 3), we observed that expression of
FOXO3A decreased significantly as cells differentiated into endothelium. We confirmed that
shRNA-mediated silencing of NDST1 increased both transcript and protein levels of FOXO3a,
suggesting that the transcription factor is a downstream target of HSGAG modification.
Furthermore, shRNA-mediated inhibition of FOXO3A in embryoid bodies resulted in a significant
decrease in IGF2 expression, which suggests that IGF2 is regulated by FOXO3A. There is
evidence of bidirectional signaling between IGFs and FOXO family transcription factors. (Liu,
2007) Although additional pathways can be coordinating the HSGAG-transcriptome cross-talk
in vasculogenesis, these results clearly implicate the FOXO/IGF signaling axis in this process.
In summary, we have clearly demonstrated the involvement of HSGAG in vessel
development. It is realistic to assume that the impaired vascular development observed in
zebrafish embryos upon silencing of HSGAG sulfation enzyme N-deacetylase/N-
sulfotransferase 1 are due to mechanisms that are conserved in mammalian vasculogenesis
and angiogenesis. We uncovered some key downstream pathways that may be implicated in
mediating the glycome regulation of vessel development using high throughput transcriptome
analysis and investigated the role of one pathway, FOXO3A, on endothelial differentiation in our
murine embryoid body model and confirmed its regulation of vasculogenesis. Our findings that
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HSGAG regulate vessel development and morphogenesis in vivo support the clinical relevance
of regulating HSGAG structure for vascular therapies in patients.
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CHAPTER 5. Insulin Like Growth Factors Regulate
Embryonic Stem Cell Vasculogenesis
The ability of embryonic stem cells to differentiate into endothelium and form functional
blood vessels has been well established and can potentially be harnessed as therapy for
various cardiovascular diseases. However, after almost two decades of investigation in this
field, very few clear-cut procedures exist for directing endothelial differentiation. A better
understanding of the cellular mechanisms regulating vasculogenesis is required for the
development of embryonic stem cell based models and therapies. In the previous chapters, we
identified heparan sulfate glycosaminoglycans (HSGAG) as being crucial for vasculogenesis in
embryonic stem cells and corroborated these results by demonstrating that sulfated HSGAG are
essential for blood vessel development in zebrafish. Microarray analysis of the transcription
profiles of zebrafish with perturbed HSGAG sulfation compositions revealed many downstream
pathways regulated by glycomic changes. We identified several molecules that are known
regulators of vessel development and discovered the Foxo3A transcription factor was negatively
regulating vasculogenesis, linking this pathway to endothelial differentiation for the first time. In
our analysis, we observed a link between levels of Foxo3A and expression of insulin like growth
factor 2. The role of the insulin-like growth factor signaling axis in stem cell vasculogenesis is
conflicted. Recent studies have shown that insulin-like growth factor 2 (IGF2) signaling can
stimulate endothelial progenitor cell homing and may contribute to postnatal vasculogenesis and
angiogenesis. (Thum, 2007) On the other hand, IGF2 signaling was reported to play a direct
role in maintaining stem cell self-renewal and survival. (Bendall, 2007) In this chapter, we
elucidated the role of IGFs and IGF receptors in vasculogenesis using an embryonic stem cell
model. The addition of IGF1 or IGF2 to differentiating stem cell cultures predisposed them
toward a mesodermal lineage, the endothelial precursor germ layer, at early differentiation
stages, as well as the generation of significantly more endothelial cells at later stages. Inhibition
of IGFR1 signaling using neutralizing antibody and a specific inhibitor, picropodophylin,
104
significantly reduced IGF-induced mesoderm and endothelial precursor cell formation.
Treatment with picropodophyllin blocked downstream AKT and MAPK signaling. Additionally,
we linked IGF to stabilization of HIFla and downstream up-regulation of VEGF at various
stages in vasculogenesis. Understanding the mechanisms that are critical for vasculogenesis
will bring us one step closer to directed stem cell differentiation and cell based therapies for
neovascularization.
5A. Insulin Like Growth Factors
Insulin like growth factor (IGF) signaling mediates many critical cell responses including
mitogenesis, proliferation, growth, differentiation, and angiogenesis. (Nakao-Hayashi, 1992)
(Kleffens, 1998) (Petley, 1999) (LeRoith, 1997) (Schmid, 1995) IGFs circulate in the
bloodstream at nanomolar concentrations and are generally bound to one of six IGF binding
proteins (IGFBPs), which regulate their availability to cell surface receptors. (Paye, 2006)
Glycosaminoglycans may play a critical role in liberating the ligands from their binding proteins
and making them available to bind receptors. (Arai, 1994) (Moller, 1994) Insulin-like growth
factors 1 and 2 (IGF-1 and IGF-2) share about 50% of amino acid sequence with insulin and
have some affinity for the insulin receptor, but have distinct physiological functions from insulin
mediated by signaling through the IGF-1 receptor. (Rinderknecht, 1978)Binding to this tyrosine
kinase receptor activates downstream P13K and MAPK cascades that stimulate growth and
survival of particular cell types. IGF1R binds IGF1, IGF2, and insulin with decreasing affinity.
The IGF-2 receptor (Man-6-P) is not a tyrosine kinase, and whether it elicits unique downstream
signaling pathways or acts as a 'sink' for IGF-2 is relatively unknown. (Siddle, 2001)
(Blanchard, 1999) (Chang, 2008) (EI-Shewy, 2007) (Hawkes, 2004) (Ikezu, 1995) (Osipo, 2001)
Insulin growth factors are essential for embryonic development. Both IGF1 and IGF2
are necessary to maintain normal embryonic growth rates in mice and do not compensate
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completely for one another. (Baker, 1993) Indeed, IGF2 has been shown to play specific roles in
adult development and disease. (Reik, 2000) (Chao, 2008) IGF1 mutant mice display
developmental bone defects and reach only 70% the size of wild-type mice. In contrast,
overexpression of IGF2 leads to fetal overgrowth and phenotypes similar to Beckwith-
Wiedemann Syndrome. (Sun, 1997) Complete absence of IGF1R or of both IGF1 and IGF2 is
embryonic lethal.
IGF1 is a well known inducer of angiogenesis. (Nakao-Hayashi, 1992) However, its
specific role in vasculogenesis is largely unknown. Clinical correlations have been made
between IGF1 and neovascularization, most notably in retinopathy models. (Hellstrom, 2001)
(Smith, 1999) IGF1 has been shown to induce neovascularization and endothelial proliferation
in cornea and retina models. (Grant, 1993) Similarly, IGF1R signaling has been shown to
mediate neovascularization in human lung development and in zebrafish cardiovascular
development. (Han, 2003) (Hartnett, 2010) Previous studies have implicated IGFs in stimulating
endothelial progenitor cell differentiation, migratory capacity, homing and incorporation into
existing vascular networks. (Maeng, 2009) (Thum, 2007) Mesoderm, the precursor of blood
vessels, muscle, bone and other specific lineages, have also been shown to be dependent on
insulin-like growth factors. (Morali, 2000)
While the above studies have shown that IGFs stimulate specific cell lineage
differentiation, studies have also established a role for the insulin-like growth factor pathway in
maintaining stem cell pluripotency. (Bendall, 2007) (Huang, 2009) In this study, we investigated
the role of insulin-like growth factors 1 and 2 in embryonic stem cell vasculogenesis. Our
previous study had revealed a correlation between impaired vascular development in zebrafish
and expression of IGF levels. (Harfouche, 2009) As a first step, we examined the expression of
IGF1 and IGF2 as well as their receptors in differentiation stem cells. Interestingly, the
expression of IGF1 was extremely high in undifferentiated cells and then dropped and gradually
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rose with endothelial differentiation, while IGF2 expression increased temporally with endothelial
differentiation. (Figure 23) The expression of IGFR1 and IGFR2 paralleled that of IGF1 and
IGF2 ligands. These results are consistent with studies in the literature that have implicated the
signaling pathway in promoting stem cell pluripotency as well as differentiation. We also looked
at transcription levels of IGF binding proteins as differentiation progressed. Binding proteins
significantly increased with differentiation, suggesting that they play a role in regulating cell
lineage commitment. Interestingly, IGF binding protein 3 (IGFBP3) expression was highest at
day 3, which corresponds to mesoderm generation and the onset of endothelial commitment in
embryoid bodies. (Figure 23) Studies have pointed to a role for IGFBP3 in mediating vessel
development and endothelial cell homing, and been linked to VEGF and TGF-p signaling.
(Kielczewski, 2009) (Dahlfors, 2000) Further studies to explore the role of IGFBPs and
endothelial differentiation in stem cells are required.
Based on the results that IGF1 and IGF2 have distinct expression patterns during
endothelial differentiation, we investigated the role of both isoforms in vasculogenesis. Our
results show that both IGF1 and IGF2 promote vasculogenesis from and embryoid body model
acting through the IGFR1 pathway.
5B. Materials and Methods
Cell Culture and Materials: Mouse embryonic stem cell line 9TR#1 strain 129 was obtained
from ATCC. Embryoid bodies were induced by seeding cells at a density of 3100 cells/cm2 on
neutrally charged tissue culture plates (Corning) in differentiation media composed of 15% FBS
(Hyclone) in high glucose DMEM (Gibco). Mouse recombinant IGF-1 and IGF-2 (R&D) were
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Figure 23. Expression of Insulin Like Growth Factors, Receptors, and Binding Proteins with
Embryonic Stem Cell Differentiation. A) mRNA levels of IGFR-1, IGFR-2, IGF1, and IGF2 increase
with time in differentiating embryoid bodies measured from days 1-7, although IGF1 appears to remain
steady, pointing to its role in both pluripotency and differentiation. B) The expression levels of IGF
Binding Proteins 1-6 also increase with EB differentiation. IGFBP3 has a complex pattern of
expression, peaking at day 3, the stage of mesoderm differentiation. * denotes P<0.05, Rn denotes
normalized reporter.
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reconstituted in sterile PBS and diluted to desired concentrations immediately before use.
Picropodophyllin (Enzo Life Sciences) was reconstituted in DMSO and diluted to desired
concentration immediately before use. For all experiments, IGF and PPP treatment doses were
reconstituted to desired dose in differentiation media and added to cells for 3 hours, after which
time media was removed and replaced with fresh differentiation media. Cells were treated daily
with IGF-1 and IGF-2 beginning at day 1, and treated on alternate days with PPP, or as
indicated in the text. Neutralizing antibodies for IGFR-1 and IGFR-2 (R&D) were added to EB
(2ng/mL) and incubated at 370C for one hour before addition of 5ng/mL IGF. For Western Blot
experiments, cells were cultured on Aggrewell @ Microwell plates (Stem Cell Technologies) to
control the size and amount of protein in EB samples.
Quantitative PCR: RNA was isolated from cells at the indicated days using Aurum Total RNA
isolation kit with DNAse digestion step and total RNA reverse transcribed using iScript cDNA
Synthesis kit. (Bio-Rad, Hercules, CA) The levels of mRNA for specific genes were detected
by using designed oligonucleotide primers (IDT, Inc.) and monitoring SYBR Green fluorescence.
The normalized reporter (Rn) was calculated from threshold values, Ct, for each gene as
follows: Rn=2 X- cT, where 6 CT=(average CTtarget-average CTexpejmenta ontro) and 18S was used
as endogenous control to normalize quantities of cDNA. Primers used: 18S(5'-
aaatcagttatggttcctttggtc-3' and 5'gctctagaattaccacagttatccaa-5'), Oct-4(5'-
gttggagaaggtggaaccaa-3' and 5'-ctccttctgcagggctttc-3'), Tie-2(5'-ggaaacctgttcacctcagc-3' and
5'-ccacttctgagcttcacatctc-3'), VE-Cadherin(5'-tgcatcctcaccatcacagt-3' and 5'-
tccagcgcactcttgctat-3'), VEGFR-2(5'-gctttcggtagtgggatgaa-3' and 5'-ggccttccatttctgtacca-3'),
Nanog (5'-ttcttgcttacaagggtctgc-3' and 5'-agaggaagggcgaggaga-3'), Sox2 (5'-
tccaaaaactaatcacaacaatcg-3' and 5'-gaagtcaattgggatgaaaa-3'), PAX6 (5'-gttccctgtcctgtggactc-3'
and 5'-accgcccttggttaaagtct-3'), Brachyury (5'-cagcccacctactggctcta-3' and 5'-
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gagcctggggtgatggta-3'), AFP (5'-catgctgcaaagctgacaa-3' and 5'-ctttgcaatggatgctctctt-3'), VEGF
(5'-ggagatccttcgaggagcactt-3' and 5'-ggcgatttagcagcagatataagaa-3').
Immunohistochemistry: EB were transferred to 0.1% gelatin coated glass coverslips on day 3
and differentiated as indicated above and with various treatments as indicated. On day 7, cells
were fixed with 4% PFA, solubilized for 10 minutes in 0.1% Tween, and blocked for 1 hour in
1 % BSA. Primary and secondary antibodies [ 1:500 TIE-2 (Santa Cruz), 1:5000 Alexafluor@488
goat anti-rabbit (Invitrogen) were incubated with cells for 1 hour at room temperature. Cells
were counterstained with DAPI (Sigma) for 30 seconds. Images were obtained using a Nikon
Eclipse TI microscope and QCapture Pro software.
Western Blotting: For signaling studies, cells were serum-deprived overnight for signaling
experiments. Indicated doses of PPP (1.2nM, 12nM, 120nM), PHA, or vatalanib (50 pLM each)
were added to cells and incubated for 4 hours, at which time cells were stimulated with 300
ng/mL IGF-1 and collected after 15 minutes in ice cold lysis buffer. For the analysis of HIF1
protein levels, cells were serum-deprived overnight, pre-treated with Rapamycin, LY294002, or
PD98059 (30 IM each) for 2 hours, and stimulated with IGF-1 (50-300ng/mL) for 4 hours.
Nuclear protein lysate was isolated using NE-PER® Nuclear Extraction Reagents. (Pierce
Biotechnology) Proteins were isolated and transferred to nitrocellulose membranes. Primary
antibodies Phosphorylated-IGFR1 Y1 136, IGFR1, Phosphorylated AKT S473, AKT, P44/42
MAPK, VEGFR2, Phosphorylated VEGFR2, p-actin (Cell Signaling), and ERKI/ERK2, HIFla
(Santa Cruz) were incubated on membranes overnight at 4*C. Quantification of protein levels
were a using GeneTools @ software. Background was subtracted from protein raw values and
then normalized to levels of actin.
Statistical Analysis: All experiments were done in triplicate and repeated to ensure consistent
results. Statistical analyses were performed by Prism @ software (GraphPad Software, San
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Diego, California) using one-way ANOVA and Newman-Keuls post-test correction with
acceptance level p<0.05. Data is presented as mean +/- SEM.
5C. IGF Treatment Increases Mesoderm Development and Endothelial Differentiation
Embryonic stem cells permitted to aggregate into cystic embryoid bodies (EB)
spontaneously differentiate into the three germ layers from which diverse cell lineages
differentiate. Vascular channels form in EB after approximately one week and have been
shown to recapitulate in vivo vascular development steps and are thus a robust model for
studying vasculogenesis. To ascertain the effects of insulin-like growth factors on
vasculogenesis, we treated differentiating EB with increasing doses of IGF1 and IGF2. After 3
hours, media containing IGFs was removed and replaced with fresh media, as we saw that
continuous exposure to the growth factor causes receptor down-regulation. (Figure 24)
Treatment with IGF1 or IGF2 significantly increased the differentiation of ES into mesoderm
compared to control, as measured by mRNA levels of mesoderm-specific marker, Brachyury, by
quantitative PCR at day 3. The mRNA levels for pluripotency markers, OCT4, Nanog, and Sox2
were not significantly affected by IGF treatment. (Figure 25) Because insulin-like growth
factors are known survival factors, we wanted to ensure the effect was mesoderm specific.
IGFs did not significantly up-regulate endoderm and ectoderm specific markers, APF and Pax6,
leading us to conclude that the proliferating effects of IGF1 and IGF2 were mesoderm specific.
(Figure 25) The increase in mesoderm generation peaked at approximately 5ng/mL for IGF1
but increased with doses up to 50 ng/mL for IGF2. The biphasic concentration response seen
with IGF is consistent with similar observations in the case of other angiogenic agents.
To look at whether IGF treatment increases differentiation of ES into mature endothelial
cells, we considered the mRNA levels of endothelial specific markers, like VEGFR2, TIE2, VE-
CADH, and eNOS, in day 7 EB. EB treated with IGF1 or IGF2 expressed significantly higher
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levels of endothelial markers compared to untreated control. (Figure 26) Markers for functional
endothelium, like eNOS and VWF, were upregulated along with markers associated with
endothelial progenitor cells, meaning that IGFs have the ability to promote development of a
mature, functional vasculature. The optimal dose of IGF1 or IGF2 to enhance vasculogenesis
was approximately 2-5ng/mL, which resulted in expression of endothelial markers is as high as
7-fold compared to control. For future experiments, we used 5ng/mL as the optimal dose of
IGFs to induce endothelial differentiation.
5D. Inhibition of IGFR-1 blocks the effects of IGF1 and IGF2 treatment and suppresses
endothelial differentiation
To look closer at IGF signaling, we investigated the effects of blocking Insulin-like
Growth Factor Receptor 1 (IGFR1), the major receptor through which IGF1 and IGF2 signal. A
neutralizing antibody for IGFR1 significantly inhibited the effects of IGF1 and IGF2 on
differentiating EB. Levels of endothelial specific markers are substantially reduced when EB are
treated with IGFR1 antibody, as seen by cultures immunostained for endothelial-specific marker
TIE2. Differentiated 7 day EB treated with 5 ng/mL IGF1 and IGFR1 neutralizing antibody
exhibited minimal TIE2 staining compared to control cultures wherein regions of TIE2 staining
appear within vascular structure outgrowths. (Figure 27). This was confirmed by quantitative
PCR, where IGFR1 neutralizing antibody significantly decreased the endothelial enhancing
effects of IGF1 and IGF2, as measured by levels of VEGFR2 and TIE2. (Figure 27) IGFR2
neutralizing antibody was also administered to cell cultures in conjunction with IGFs, and no
significant reduction in vascular differentiation was seen. (Figure 27) Taken together, the
results indicate that the effects of IGFs on mesoderm development and vasculogenesis are
mediated specifically through IGFR1 signaling.
Picropodophyllin (PPP), is a selective inhibitor of IGFR1 which binds to its Tyrosine 1136
residue and blocks its capacity for autophosphorylation and downstream signaling. We
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demonstrated that PPP inhibits phosphorylation of IGFR1 at the expected phosphorylation site
as well as inhibits phosphorylation of downstream pathways, AKT and ERK. Quantification of
Western Blot bands reveals that signaling is decreased by at least 50% following treatment with
PPP. (Figures 28, 29) Inhibition was effectively achieved at doses of 12nM and higher of PPP.
Although PPP specifically inhibits IGFR1 signaling by binding to a specific tyrosine residue on
the protein, we confirmed that the drug was specific for the IGF pathway. PHA is an inhibitor of
MET receptor and was used as a pharmacological control and shown to have no effect on
IGFR1 signaling. We also confirmed that PPP had no effect on the VEGFR signaling. As
shown in Figure 28, PPP doses used to inhibit IGFR-1 have no effect on VEGF stimulated
VEGFR-2 phosphorylation, while VEGFR specific inhibitor vatalanib effectively inhibits signaling.
Treatment of EB with PPP inhibited ES mesoderm differentiation as measured at day 3. Levels
of pluripotency markers Nanog and Sox2 were significantly increased, whereas mesoderm
marker Brachyury was decreased. (Figure 30) At one week, PPP significantly inhibited
endothelial differentiation, as indicated by levels of VEGFR2, TEK, and VE-CADH. (Figure 31)
Immunostaining additionally confirmed that treatment with 12nM PPP severely decreased the
number of cells positively stained for TIE2 and organized into vascular structures compared to
control cultures. (Figure 31)
5E. IGFs promote EB differentiation at various stages in the vasculogenesis pathway
Based on the above results, we wanted to further investigate whether IGFs increase
endothelial development by simply increasing mesoderm differentiation, or play a role at other
vasculogenic stages. Indeed, EB treated with IGFs at early stages of differentiation before
mesoderm development, i.e. on days 1 and 2 only, displayed increased numbers of endothelial
cells after one week as measured quantitatively by levels of VEGFR2 mRNA. However, EB
treated post-mesoderm development with IGF-1 and IGF-2 also contained increased levels of
endothelial cells compared to controls but a higher dose of IGF was required to see this effect.
(Figure 32) This leads us to believe that one of the major means by which IGFs enhance
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Figure 26. IGFI and IGF2 promote endothelial differentiation. Day 7 embryoid bodies pulse-
treated daily with increasing doses of IGF1 (A) and IGF2 (B) possess increased levels of endothelial
specific markers VEGFR2 and TIE2 as measured by quantitative PCR. # denotes P<0.05, Rn
denotes normalized reporter.
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vasculogenesis is by stimulating mesoderm development but that IGFs also enhance
endothelial development at later stages in differentiation. Treatment with PPP before day 3 also
severely decreased the number of endothelial cells at one week, as did treatment after
mesoderm development. (Figure 32) Taken together, the data indicates that IGFs enhance
both differentiation of mesoderm, as well as other stages of endothelial lineage differentiation.
5F. IGFs stabilize HIFIa and increase expression of Vascular Endothelial Growth Factor
Because we demonstrated that IGF1 and IGF2 affect vasculogenesis at various stages
in the endothelial differentiation pathway, we hypothesized that they may regulate expression of
VEGF, a growth factor that is critical for many stages in vascular development. As we
expected, VEGF expression was significantly increased at day 3 and day 7 following treatment
with IGF1 or IGF2, while pre-treatment of EB with PPP lowered levels of VEGF expression.
Figure 33 depicts representative examples of the quantitative increase of VEGF following IGF1
treatment (left), IGF2 treatment (center), or following PPP treatment (right). HIFla is an
important regulator of VEGF expression in neovascularization, which has been shown to be
stabilized by IGF1. (Treins, 2005) We explored whether IGF-mediated stabilization of HIFla
and subsequent up-regulation of VEGF was one of the mechanisms by which IGFs were
increasing vasculogenesis in embryoid bodies.
We demonstrated that total levels of cellular HIFla protein were increased following
stimulation with IGF1, which was inhibited by rapamycin. (Figure 34) Rapamycin specifically
inhibits the pathway associated with growth factor induced stabilization of HIF a. Stabilization
and translocation of HIFla to the nucleus is one of the major stimuli for VEGF transcription.
(Semenza, 2002) Although protein levels of HIFla were increased in total cell lysates by only
22%, we found that HIFa protein levels in the nuclear fraction was increased by more than 2-
fold which is evidence of stabilized HIFla translocation to the nucleus. Treatment of
differentiating cells with rapamycin inhibited the effects of IGF1 and IGF2 on VEGF
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Figure 27. Inhibition of IGFRI, but not IGFR2, inhibits vasculogenesis in differentiating
embryoid bodies. A) Tie-2 staining of control and IGF1 treated EB is significantly more
pronounced than in EB treated with IGFR1 neutralizing antibody (nAb IGFR1) or IGFR1
neutralizing antibody and IGF1 (nAb IGFR1+IGF1). Tie-2 staining (FITC), DAPI nuclear
counterstain. B) IGFRI neutralizing antibody treatment (Antibody/Ab) combined with IGFs
significantly reduces levels of endothelial markers VEGFR2 and Tie-2 compared to treatment
with IGF1 and IGF2 alone. C) IGFR2 neutralizing antibody (Antibody/Ab) treatment combined
with IGFs had no significant effects on levels of VEGFR2 or Tie-2 compared to treatment with
IGF1 or IGF2 alone. * denotes P<0.05, Rn denotes normalized reporter.
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Figure 28. Picropodophyllin treatment decreases IGFRI signaling while having no
effect on VEGFR2 signaling. A) Phosphorylation of IGFR1 Y1 136 was inhibited in EB pre-
treated with picropodophyllin (PPP) and stimulated with IGF1 as measured by the ratio of
Phosphorylated IGFR1 to total IGFR1 receptor. Inhibition was effective at doses of 12nM
and higher. A random pharmacologic control drug, PHA, had no effect on IGFRI
phosphorylation. Quantification of protein levels is shown at right. B) PPP treatment had no
effect on VEGFR2 signaling, while a specific inhibitor of VEGFR2, vatalanib, significantly
decreased receptor phosphorylation with VEGF stimulation. Quantification of protein levels
is shown at right.
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Figure 29. Picropodophyllin treatment decreases AKT and ERK signaling in IGFI
treated embryoid bodies. A) PPP treatment prior to IGF1 stimulation leads to a
significant decrease in downstream AKT S473 phosphorylation. Quantification of protein
levels is at right. B) PPP treatment prior to IGF1 stimulation leads to a significant
decrease in downstream ERK p44/p42 phosphorylation. Quantification of protein levels
is at right.
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expression as measured by quantitative PCR at day 3. Downstream mediators of IGFR1
signaling, P13 Kinase and MAP Kinase, inhibited using LY294002 and PD98059, respectively,
also decreased levels of VEGF expression and mesoderm differentiation. (Figure 35) Taken
together, the results support a mechanism wherein IGF treatment triggers signaling through P13
Kinase and MAP Kinase pathways leading to stabilization of intracellular HIF1a, which in turn
increases transcription of VEGF, the critical endothelial cell differentiation factor. (Figure 36)
Our results indicate that this is one of the major pathways by which IGF induces endothelial
progenitor cell differentiation from mesoderm and then mature endothelial differentiation from
EPC.
5G. Discussion and Conclusions
We have determined, for the first time, the direct effects of IGF1 and IGF2 on embryonic
stem cell vasculogenesis. Our results demonstrate that treatment with IGF1 or IGF2 increase
the generation of endothelial cells in a spontaneously differentiating embryoid body model.
Daily pulse treatment of EB with IGFs beginning on day 1 caused a significant increase in
mesoderm generation which translated to increased differentiation into endothelium compared
to control. Interestingly, we did not see a significant increase in mRNA levels for Pax6 or AFP,
markers of ectoderm and endoderm, meaning that the effect is specific for the mesoderm
lineage, and importantly, is not simply due to proliferation of all cell types. To see if this was the
reason for the increased number of generated endothelial cells, we treated EB with IGFs only
after mesoderm formation. Treatment with IGFs after day 3 also caused a significant increase
in endothelial differentiation at one week. These results suggest that insulin-like growth factors
play a role in both of these stages. IGFs have been shown to induce differentiation of several
cell types, including neurons, osteoblasts, myoblasts, cardiomyocytes and chondrocytes.
(Padin-Iruegas, 2009) (An, 2010) (Coolican, 1997) (Koch, 2005) (Kouroupi, 2010) IGF in
combination with other growth factors like VEGF and FGF, has been shown to induce optimal
endothelial differentiation culture conditions from stem cells, but to our knowledge ours is the
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first study to look directly at IGF-1 and IGF-2 treatment alone using an embryoid body stem cell
vasculogenesis model. (Sun, 2009) (Kaufman, 2004)
Bendall et al. discovered that IGF2 (30 ng/mL) was sufficient in maintaining human ES
self-renewal and pluripotency and postulated that a subset of ES generate a source of the
ligand to maintain undifferentiated cultures. (Bendall, 2007) Chen and Khillan demonstrated
that retinol signaling through IGFR1 led to maintenance of self-renewal and pluripotency in
mouse ES. (Chen, 2010) Both studies proposed that the downstream P13K/AKT pathway was
critical for these effects. Indeed, stem cells balance a large number of signaling pathways and
subtle shifts in signaling can effectively cause a cell to remain pluripotent or progress along a
particular differentiation pathway. Proliferation and differentiation of myoblasts upon IGF
treatment (1-3 ng/mL) were shown to utilize separate downstream pathways. The MAPK
pathway was critical for optimal proliferation after IGF-1 stimulation, while P13K signaling was
required for differentiation. (Coolican, 1997)
The treatment specifics and context definitely play a large role in determining the
downstream effects of IGF treatment on ES. For example, we saw a large difference in mRNA
levels when cells were treated continuously with IGF or picropodophyllin compared to 'pulse'
treatment where media was replaced with fresh control media after specified times. Continuous
treatments caused a significant down-regulation of IGFR1 and IGFR2. Differential expression of
various IGF binding proteins could also influence the effects of IGF at various cellular stages.
Additionally, in our studies, treatment with IGFs or PPP began after 24 hours of culturing cells in
low-adherent conditions, when they have likely gained some differentiation capacity. Taken
together, these results indicated that the availability of insulin like growth factors is tightly
regulated to control their cellular affects. HSGAG have been established as regulating the
availability of IGF1 and IGF2. 2-0 and 3-0 sulfated heparan sulfate inhibit the formation of
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Figure 30. Picropodophyllin treatment inhibits mesoderm formation in
differentiating embryoid bodies. Day 3 embryoid bodies treated with PPP have
unchanged or increased levels of pluripotency markers Oct4, Nanog, and Sox2 and
significantly decreased levels of Brachyury mRNA compared to control EB. * denotes
P<0.05, Rn denotes normalized reporter.
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Figure 31. Picropodophyllin treatment Inhibits endothelial differentiation in
embryoid bodies. A) PPP treatment decreases expression of vascular markers
VEGFR2, Tie-2, and VE-Cadherin (VECADH) at day 7 compared to control. B)
Differentiated EB cultures treated with PPP and stained for Tie-2 (FITC) and counter-
stained with DAPI had strikingly less regions of Tie-2 staining compared to control
cultures. *denotes P<0.05, Rn denotes normalized reporter.
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complexes of IGFs with IGFBP2, IGFBP3 or IGFBP5, making IGF1 more available to bind with
its receptor. (Arai, 1994) (Moller, 2006) The link between HSGAG and IGF induction of
vasculogenesis supports the results of the previous chapters, which demonstrated inhibition of
vasculogenesis with elimination of HSGAG structures.
We propose that one of the mechanisms by which IGF promotes vasculogenesis is by
HIF1a mediated up-regulation of VEGF. We demonstrated significant up-regulation of VEGF
mRNA after treatment with IGF1 or IGF2. The doses that produced optimal VEGF upregulation
corresponded with those that stimulated the most endothelial differentiation. Picropodophyllin,
the specific inhibitor of IGFR1, significantly decreased VEGF mRNA levels. Picropodophyllin
(PPP) is a cyclolignan that inhibits IGFR1 activation by sterically hindering phosphorylation of
adjacent 1135 and 1136 tyrosines on the intracellular receptor domain, while having no effect on
the phosphorylation of closely related insulin receptor or non-related tyrosine kinase receptors
including FGFR, PDGFR, and EGFR, nor did it down-regulate insulin, VEGFR, EGFR, or
PDGFR. (Girnita, 2004) (Vasilcanu, 2008) PPP was shown to inhibit IGFR1 signaling in a
multiple melanoma mouse model leading to reduced levels of VEGF and a significant reduction
in angiogenesis and increased survival. (Menu, 2006) IGF induced up-regulation of VEGF
secretion was also blocked by PPP in choroid tumors and Kaposi sarcoma. (Economou, 2008)
(Catrina, 2005) IGF1 has been shown to upregulate VEGF in many cell types, including colon
cancer, pancreatic cancer, fibroblasts, and osteoblasts. (Stoeltzing, 2003) (Akeno, 2002)
(Miele, 2000) (Fukuda, 2002) (Goad, 1996) We have shown that IGF1 and IGF2, signaling
through IGFR1, increase levels of VEGF in embryonic stem cells. Inhibition of IGFRI signaling
with picropodophyllin (PPP) decreases VEGF levels and thus inhibits vasculogenesis.
HIF1u is a major transcriptional activator of VEGF and VEGF receptors and a major
stimulus for embryonic vasculogenesis. (Han, 2010) In normoxic conditions, the protein is
degraded by
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Figure 32. IGFs induce endothelial differentiation at early and late stages of
vascuiogenesis. A) VEGFR2 and Tie-2 mRNA levels at day 7 are significantly increased
compared to controls in EB treated on days 1 and 2 only or on days 4-7 only, pre- and
post- mesoderm formation, respectively. B) PPP treatment on days I and 2 only or on
days 4-7 only at the effective dose of 12nM significantly reduce levels of endothelial
markers VEGFR2 and Tie-2 at day 7.
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Figure 33. IGFI and IGF2 increase VEGF expression levels in differentiating emnbryoid
bodies. Levels of VEGF as measured by quantitative PCR increase with IGF1 (A) and IGF2 (B)
treatment, and decrease with PPP treatment (C), at day 3.
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Figure 34. IGFI increases HIFIa protein levels in differentiating embryoid bodies. A) Protein
levels of HIFla were measured in whole cell lysates at day 7. HIFlalevels increase by
approximately 25% following treatment with IGF1 for 4 hours. Rapamycin, an inhibitor of
HIF1 a synthesis, reduces protein levels when added to cell cultures prior to IGF1 stimulation. B)
Nuclear levels of HIF1a (nuci HIFia ) were significantly increased subsequent to IGF1 treatment,
evidence of HIFi a stabilization and translocation to the nucleus. Protein quantification is at right.
128
A)
HIFla
-. 0
actin 0-
control +IGF1 +rapamycin I0
+IGF1 #
B)
nuci HIFla 11
0.5-
actin wlie 0.0-
control +1GF1
Iff
Figure 35. Inhibition of HIFia with rapamycin decreases VEGF expression and in
embryoid bodies treated with IGF1. (right) Day 3 EB treated with IGF1 express
significantly higher levels of VEGF compared with control (# denotes P<0.05 compared with
control), which is significantly inhibited by treatment with HIFIa inhibitor rapamycin or
LY294002 and PD98059, inhibitors of P13 Kinase and MAP Kinase. (* denotes P<0.05
compared to IGF1 treatment). (left) LY294002 and PD98059, inhibitors of P13 Kinase and
MAP Kinase inhibit expression of mesoderm marker Brachyury when administered with IGF1
treatment.
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Figure 36. IGF1 and IGF2 promote vasculogenesis in embryonic stem cells through
stabilization of HIFMa and subsequent VEGF up-regulation. Based on the
accumulated data, we propose that IGF1 and IGF2 signal through IGFR1 to downstream
AKT and MAPK pathways, stabilizing HIFia and facilitating increased VEGF expression,
and therefore promote vasculogenesis in differentiating cells.
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the ubiquitin pathway, but is stabilized in hypoxic conditions and goes on to transcribe genes
critical for vasculogenesis, metabolism and cell survival. Inhibition of HIF1 a in ES dramatically
inhibits levels of VEGF and results in reduced vascular development. (Ryan, 1998) (lyer, 1998)
Hypoxia promotes endothelial differentiation and neovascularization in embryoid bodies.
(Ramirez-Bergeron, 2004) In addition to hypoxic activation, HIFIa synthesis is activated by
various oncogenes, cytokines, and growth factors. (Semenza, 2002) IGF-1 has been
established as a posttranscriptional stimulator of HIFla accumulation, nuclear translocation,
and activity. (Treins, 2005) IGF1 increases HIFla protein levels and VEGF transcription in
Kaposi Sarcoma which is inhibited by treatment with PPP. (Catrina, 2006) IGFR1 signaling
mediated through downstream AKT and MAPK pathways leads to increased levels of HIF1a
and VEGF in pancreatic, colon, and other cancers and therefore was investigated as an anti-
angiogenic target. (Fukada, 2002) (Stoeltzing, 2003) We have shown that IGF-1 stimulation of
embyroid bodies causes and increase in levels of HIF1 a protein in embryoid bodies. Treatment
with HIFla inhibitor rapamycin inhibits intracellular protein levels of HIFla and blocks IGF-
induced increase in VEGF transcription. This suggests that the HIF1aNEGF axis is one of the
key mechanisms through which IGF1 and IGF2 increase endothelial differentiation. Further,
HIFla has been shown to increase transcription levels of IGF2, resulting in an autocrine IGFR1
activationNEGF expression loop. IGF2 expression and IGF2 induced VEGF expression was
shown to be increased in hepatocarcinogenesis and proliferative hemangiomas. (Feldster,
1999) (Kim, 1998) (Ritter, 2002)
Our study establishes a convincing role for both IGF1 and IGF2 in stimulating
vasculogenesis in embryonic stem cells. Treatments at various stages of differentiation
revealed that IGFR1 signaling pushes differentiation of stem cells toward a mesodermal lineage,
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as well as endothelial progenitor cells into mature endothelial cells, indicating that IGFs can
emerge as a powerful tool for enabling vascular regeneration therapies.
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CHAPTER 6. Conclusions and Future Directions
A functional vasculature is critical to maintain the health of every organ and tissue of the
body. Blood vessels play a role in most diseases, from ischemia to inflammation and
uncontrolled proliferation. Additionally, the incorporation of a functional blood supply is a major
barrier in the development of artificial tissues. Understanding the mechanisms of
neovascularization is a necessary step toward developing new approaches for treating diseases
like coronary artery disease and cancer. The formation of new blood vessels occurs through
two processes: vasculogenesis, or the de novo formation of vessels from progenitor cells, and
angiogenesis, the sprouting and remodeling of existing vessels. While much is known about the
mechanisms of angiogenesis, less is known about the process of vasculogenesis.
Understanding the processes associated with de novo vessel development is increasingly
important considering evidence that endothelial progenitor cells contribute to the growth of new
blood vessels in adults. (Asahara, 1997) It is also useful for a basic understanding of the
development of the circulatory system in the embryo.
This thesis makes novel contributions toward understanding vasculogenesis by
exploring the role of heparan sulfate glycosaminoglycans (HSGAG) in the process of blood
vessel formation. HSGAG mediate critical signals from the extracellular environment to internal
transcription pathways that influence vasculogenesis. In Chapter 3, we examine the critical
function of HSGAG sulfation patterns in embryonic stem cell endothelial differentiation, the first
step of vasculogenesis. The spontaneous generation of endothelial cells and vasculogenesis in
embryonic stem cell embryoid bodies is a well established model of in vivo embryonic
vasculogenesis. This was one of the first studies to implicate HSGAG in embryonic stem cell
differentiation and specifically in endothelial differentiation. We identified that the expression of
the enzymes responsible for HSGAG sulfation increases with endothelial differentiation and
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focused on the rate-limiting sulfation enzyme N-deacetylase/N-sulfotransferase-1 (NDST1).
Genetically silencing NDST1 effectively reduced HSGAG sulfation and significantly decreased
endothelial differentiation. Inhibiting HSGAG sulfation by chemical or enzymatic means
confirmed that the presence of specific sulfate groups is necessary for endothelial cell
differentiation. One of the key findings from this chapter is that the addition of exogenous
HSGAG can restore vasculogenesis in cells possessing under-sulfated HSGAG, suggesting that
the effects of glycome-mediated signaling can be controlled externally. It will be interesting to
build upon this finding by determining specific sequences of HSGAG that can be incorporated
into cell culture paradigms to control embryonic stem cell differentiation, progenitor cell
differentiation, or cell function in general. Vasculogenic growth factors have been shown to bind
to specific sulfate compositions, and HSGAG analogues can serve as a depot to sequester
specific soluble factors that are required for various developmental stages or present them to
their specific receptor. We have completed preliminary studies of integrating specific HSGAG
analogues into physiological extracellular matrix as scaffolds for embryonic stem cell
differentiation. Further investigation is required to determine the mechanisms by which various
HSGAG analogues mediate cell function.
The study of HSGAG chemical composition is difficult because they do not possess a
structural template and therefore cannot be amplified. To identify the chemical composition of
HSGAG during endothelial differentiation, we harnessed a CE-based method to isolate cell
surface HSGAG and identify the degree of sulfation of the disaccharide fragments by using
capillary electrophoresis. Using this technique, we determined that undifferentiated stem cells
are under-sulfated and the degree of sulfation increases with differentiation. We also used this
technique to confirm that chemical and genetic methods of inhibiting HSGAG sulfation enzymes
were translated to cell surface chemical compositions.
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To validate that the results from Chapter 3 were clinically relevant, we used a zebrafish
model to study the effects of HSGAG sulfation compositions on vasculogenesis in vivo. We
designed an antisense oligonucleotide morpholino to inhibit expression of NDST1 in zebrafish
embryos, and characterized the phenotype for the first time. Inhibition of NDST1 expression led
to impairment in functional vessel formation in vivo. As with the embryonic stem cell model,
vessel development could be influenced by the addition of exogenous heparin to the
microenvironment, which is strong evidence for the clinical utility of using HSGAG to control
neovascularization. Further experiments need to be done to determine particular sulfate
compositions, with or without the addition of growth factors and/or proteins that can control
vessel formation in vivo.
HSGAG regulate a large number of signaling pathways and analysis of the
transcriptome profiles of zebrafish embryos possessing impaired circulatory systems following
HSGAG modulation allowed us to home in on specific pathways regulated by HSGAG
perturbation that mediate vessel development. We used several different statistical methods
and a novel clustering algorithm to eliminate errors in identifying gene transcripts regulated by
HSGAG composition at three critical stages in vessel development. Many regulated transcripts
were identified as transcription factors, regulators of apoptosis, intra-cellular signaling
molecules, or yet to be identified gene transcripts. The transcription factor Foxo3A was
identified as one of the pathways modulated by HSGAG. We biochemically confirmed that
Foxo3A was indeed up-regulated following HSGAG modulation and was linked to an inhibition
of endothelial differentiation in embryonic stem cells. This is the first time that Foxo3A has been
implicated in vasculogenesis.
In Chapter 5, we explored the role of another HSGAG modulated pathway in
vasculogenesis. Insulin Like Growth Factors (IGF) 1 and 2 had been previously shown to
modulate both pluripotency and angiogenesis and our objective was to determine the specific
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effects of the growth factors on endothelial differentiation in embryonic stem cells. We
discovered that IGFs promote both mesoderm and endothelial differentiation, two critical stages
in vasculogenesis. Based on downstream signaling analysis, we propose a model wherein
IGFR1 signaling to downstream AKT and MAPK mediators stabilizes intracellular levels of
HIF1cc, causing an up-regulation of VEGF, the critical inducer of vasculogenesis. The effects of
IGFs on embryonic stem cell differentiation to specific lineages have not been widely explored,
partly due to the complexity of IGF interactions with various IGF binding proteins (IGFBPs). We
found that the expression patterns of IGFBP1-IGFBP6 significantly increased with differentiation
which is evidence that they are involved in regulating the functions of IGFs during development.
Interestingly, IGFBP3 was upregulated at various stages critical for mesoderm differentiation
and has been linked to VEGF production and vascular repair. (Kielczewski, 2009) (Rosenzweig,
2004) (Arnquist, 2000) Future studies are warranted to investigate the roles of IGFBPs in
embryonic stem cell differentiation and neovascularization.
This thesis lays the groundwork for utilizing heparan sulfate glycosaminoglycans as a
means of controlling neovascularization. Elements of the extracellular microenvironment,
including HSGAG, have dynamic roles in regulating cell signaling. Our work demonstrates the
necessity of HSGAG sulfate sequences in vascular development. We revealed a complex
interaction between extracellular HSGAG sequences and embryonic transcriptome profiles.
Modulation of extracellular HSGAG compositions allowed us to identify novel pathways
implicated in vasculogenesis. Importantly, we discovered that exogenously administered
HSGAG controls vessel development which can lead to the cultivation of glyco-based therapies
for neovascularization. As a whole, the results presented here provide a better understanding
of vasculogenesis which can have important applications for clinical therapy.
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Appendix 1. Gene Transcript Tables
Acquired probe level data was normalized via the Robust Multichip Average Method (RMA)
using Insightful S+@ software and mean log2 expression intensities from triplicate experiments
were used in subsequent differential analysis. Local Pooled Error differential expression testing
was performed in S+ using a P-statistic cutoff value of 0.05 and Bonferroni false-positive
corrections, to define significant genes between wild-type and NDST1 mutant embryos at all
ages. Fold change is defined as the ratio of normalized expression intensities of mutant and
wild-type RNA. Affymetrix probe sets were annotated based on gene symbols available from
Affymetrix Netaffix website, Entrez Gene, Unigene, GenBank and the Boston Trans-NIH
Zebrafish Genome Initiative. Using a P-value cutoff of 0.05, 218 genes were found to be
statistically significant between control and mutant in LPE differential analysis with fold changes
less than 0.75 or greater than 1.25. The complete list of significant genes passing the P-value
cutoff is available in Supplementary Table 1.
Table I LPE Transcripts P<0.05
Probe Names Gene Name Fold Change Adj. p- mean.NDSTI mean.WT
Value
Dr 21935_1_Alat wu:fc84a08 6.36437701 0.OOE+00 6.38 3.71
Dr_23587_1_Alat growth arrest and DNA- 6.060302048 0.OOE+00 6.7 4.1
damage-inducible, alpha like
Dr_11242_1_Alat pleckstrin homology-like 7.182212308 0.OOE+00 8.8 5.96
domain, family A, member 3
Dr 12986_1_Ala at v-fos FBJ murine 5.793980785 0.OOE+00 7.63 5.09
osteosarcoma viral oncogene
homolog
Dr_17659_1_S1_at membrane protein, 5.791439966 0.OOE+00 7.48 4.95
palmitoylated 1
Dr_10334_1_S1_at caspase 8 5.104340247 0.OOE+00 7.36 5.01
Dr_11479_1_Alat wu:fb96a1O 3.831546196 0.OOE+00 6.45 4.51
Dr_7787_1_SIat Dr77871Si at 4.355761013 0.OOE+00 11.2 9.03
Dr_2953_1_SIat zgc:55750 3.238291819 0.OOE+00 7.86 6.17
Dr_11481_1_Alat zgc:92153 3.050011115 0.OOE+00 5.61 4
Dr_10914_1_Alat wu:fc49dOl 2.724083262 0.OOE+00 5.76 4.31
Dr_12986_1_Alat v-fos FBJ murine 3.422601675 0.OOE+00 6 4.23
osteosarcoma viral oncogene
homolog
Dr_5129_1_S1_at zgc:56722 2.876147371 0.OOE+00 10.9 9.41
Dr_8209_1_S2_at forkhead box 05 4.821829373 0.00E+00 9.4 7.13
Dr 23406_1_S1_at wu:fd50hl2 2.871588649 0.OOE+00 7.06 5.53
Dr_845_1_Alat fibrinogen alpha chain 0.443879627 1.02E-19 5.56 6.74
Dr_2168_1_Alat wu:fd20gO7 0.474995516 3.32E-17 5.66 6.73
Dr_542_1_S1_at murine double minute 2 4.10587982 1.15E-12 10.3 8.29
homolog
Dr_21399_1_Alat wu:fj64h06 2.849291844 2.17E-12 5.93 4.42
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Dr_16669_1_SIat nuclear receptor subfamily 2, 0.698289895 2.23E-12 3.92 4.44
group F, member 1, like
Dr_5434_1_S3_at proteolipid protein Ia 0.356658732 2.55E-12 5.83 7.32
Dr_2795_1_Alat zgc:110001 0.225837207 5.23E-12 6.52 8.66
Dr_1689_2_Al_a_at Dr_1689_2_Ala at 0.554165038 1.84E-11 4.97 5.82
Dr_15150_1_Alat poly (ADP-ribose) polymerase 2.844134713 4.56E-11 6.48 4.97
family, member 3
Dr_5925_1_Alat wu:fi04f09 3.67998172 1.04E-10 7.38 5.5
Dr_19402_1_Alat Dr_19402_1_Alat 0.4519241 1.93E-09 7.17 8.31
Dr_6820_1_Alat GTP binding protein 1, like 3.621415719 3.76E-09 8.21 6.35
Dr_21089_1_SIat wu:fb59aOl 0.468923667 4.04E-09 4.29 5.38
Dr_20495_2_Alat selenoprotein W, 2a 0.279968224 5.83E-09 7.95 9.78
Dr_20198_1_SI_a_at heat shock cognate 70-kd 2.356038966 1.19E-08 6.89 5.65
protein
Dr_26003_1_Alat Dr_26003_1_Alat 3.091251211 1.39E-08 6.63 5
Dr_21979_1_Alat wu:fc92elO 3.485378171 1.78E-08 7.11 5.31
Dr_2052_1_SIat tumor protein p53 2.693042504 2.55E-08 10.6 9.21
Dr_20850_1_SIat fatty acid binding protein 7, 0.513486695 3.23E-08 5.84 6.81
brain, a
Dr_2408_2_SIat matrix metalloproteinase 2 2.245903748 4.50E-08 8.97 7.8
Dr_12386_2_S1_a_at mesogenin 1 0.481954214 4.65E-08 8.29 9.35
Dr_20495_1_SIat selenoprotein W, 2a 0.321949073 4.79E-08 6.13 7.77
Dr_19552_1_S1_at zgc:76878 0.28847332 5.77E-08 7.91 9.7
Dr_6709_1_S1_at wu:fjlOeO8 3.212800502 7.46E-08 10.2 8.53
Dr_3663_1_Alat wu:fb55bl1 0.381177535 7.46E-08 9.01 10.4
Dr_12986_3_S1_a_at v-fos FBJ murine 3.339625661 7.79E-08 7.12 5.38
osteosarcoma viral oncogene
homolog
Dr_25536_1_Alat heat shock protein 90-alpha 2.586552545 1 .19E-07 9.27 7.9
Dr_22517_1_S1_at Dr_22517_1_Si at 2.101415288 2.01E-07 5.21 4.14
Dr_5411_1_SIat zgc:55364 0.618179021 2.37E-07 5.42 6.11
Dr_19794_1_Alat Dr_19794_1_Alat 2.585147861 2.83E-07 5.94 4.57
Dr_8145_1_S1_at insulin-like growth factor 2 2.911405517 2.85E-07 8.29 6.74
precursor
Dr_1212_1_SIat cyclin G1 2.316700104 3.50E-07 12.5 11.2
Dr_24890_1_S1_at Dr_24890_1_SI at 0.556641779 4.73E-07 4.89 5.73
Dr_10257_1_Alat peptidase D 0.387194912 5.49E-07 5.82 7.19
Dr_2408_1_Alat matrix metalloproteinase 2 2.188895833 7.21 E-07 7.04 5.91
Dr_15033_1_S1_at Dr_15033_1_S1 at 3.237500241 1.16E-06 10.3 8.6
Dr_4925_1_S1_x_at cytoglobin 0.627062174 1.59E-06 4.12 4.8
Dr_6419_1_Alat wu:fc19gO3 2.871820146 1.96E-06 8.44 6.91
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Dr_11310_2_SI_x_at tubulin, alpha 1 0.540150859 2.04E-06 9.32 10.2
Dr_24871Si at ureidopropionase, beta 2.186389748 2.18E-06 7.21 6.08
Dr_5434_1_S2_at proteolipid protein 1a 0.473705721 2.38E-06 5.26 6.34
Dr_519_1_Alat wu:fb50eOl 0.341032893 2.79E-06 6.84 8.4
Dr_5434_1_S4_at proteolipid protein Ia 0.520823951 2.89E-06 5.47 6.41
Dr_11310_2_SIat tubulin, alpha 1 0.482372043 2.97E-06 8.72 9.77
Dr_58_1_Alat zgc:73230 2.899824119 3.14E-06 8.3 6.76
Dr_15781_1_S1_at vaccinia related kinase 2 2.813746779 5.54E-06 7.22 5.73
Dr_21808_1_Alat wu:fc44g03 0.526916295 7.61E-06 7.19 8.12
Dr_7668_1_Alat wu:fi04dlO 0.368006588 1.05E-05 6.43 7.87
Dr_6377_1_Alat zgc:63486 0.420215651 1.19E-05 5.53 6.79
Dr_137501_SI at Dr_13750_1_SI at 0.587083372 1.35E-05 5.79 6.56
Dr_13633_1_Alat zgc:92287 1.997032899 1.35E-05 7.38 6.38
Dr_26372_1_Alat zgc:112425 2.413314102 1.44E-05 6 4.73
Dr_20276_1_Alat wu:fb8lh03 2.172066992 1.45E-05 5.54 4.42
Dr_3880_1_S2_at bcl2-associated X protein 2.266626846 1. 51 E-05 9.1 7.92
Dr_4812_1_SI_s_at myosin, heavy polypeptide 2, 0.643431468 2.06E-05 8.25 8.88
fast muscle specific
Dr_2601_1_SIat NMDA receptor-regulated 0.382835149 2.1OE-05 7.72 9.1
gene 1a
Dr_2452_2_Al_x_at wu:fd50eO4 0.673963983 2.22E-05 5.47 6.04
Dr_610_2_SIat heat shock protein 90-alpha 2.553096378 2.42E-05 8.83 7.48
Dr_54343_SIat glycoprotein M6Aa 0.611318868 3.28E-05 5.68 6.39
Dr_7771_1_SIat zgc:111858 2.03979858 3.61E-05 5.78 4.75
Dr_54791_SI at retinol binding protein 4, 0.680788891 3.61E-05 8.6 9.15
plasma
Dr_9353_1_S1_at zgc:55733 0.549431146 4.OOE-05 7.15 8.02
Dr_12458_1_Alat poly (ADP-ribose) polymerase 0.398482314 5.20E-05 6.51 7.84
family, member 2
Dr_6814_1_SIat fatty acid binding protein 3, 0.610511341 6.38E-05 10.2 10.9
muscle and heart
Dr_4160_1_Alat Dr_4160_1_Alat 0.626179247 6.75E-05 6.57 7.24
Dr_25767_1_SIx at Dr257671_S1 x at 2.445181573 7.44E-05 8.85 7.56
Dr_24285_1_Alat Dr_24285_1_Alat 0.727707407 7.62E-05 4.23 4.69
Dr_7722_1_Alat sb:cb26 0.66232017 7.71E-05 5.6 6.19
Dr_10141_1_Alat zgc:101687 0.423692501 8.51E-05 5.06 6.3
Dr_19223_1_S2_at aldolase c, fructose- 1.729788079 1.05E-04 7.45 6.66
bisphosphate
Dr_14160_1_Alat Dr_14160 1_Alat 1.94289603 1.23E-04 5.94 4.98
Dr 18230_1_Alat Dr_18230_1_Alat 0.563808057 2.12E-04 4.65 5.47
157
DrAffx_2_16_SIat DrAffx_2_16_Siat 1.598740072 2.19E-04 5.31 4.63
Dr_7638_1_S2_at calmodulin 2, gamma 0.480826462 2.27E-04 5.33 6.39
Dr_16350_1_Alat Dr_16350_1_Alat 0.496988819 2.54E-04 5.87 6.88
Dr_371_1_SIat sb:cb339 0.651993461 2.80E-04 8.01 8.63
Dr_20198_2_SI_x_at heat shock cognate 70-kd 2.14750427 3.18E-04 6.53 5.43
protein
Dr_1142_1_Alat zgc:66068 0.422923315 3.82E-04 8.92 10.2
Dr_17100_1_Alat Dr_17100_1_Alat 0.449495102 4.88E-04 7.18 8.33
Dr_11244_1_SIat glucose phosphate isomerase 1.524079226 5.1OE-04 8.6 7.99
a
Dr_5660_1_SIat cysteine-rich protein 2 0.624894003 5.42E-04 8.15 8.83
Dr_2914_1_SIat myosin, light polypeptide 2, 0.64290559 6.09E-04 8.44 9.08
skeletal muscle
Dr_13826_1_Alat Dr_13826_1_Alat 1.893960969 6.68E-04 5.45 4.53
Dr_26207_1_Alat inhibin, beta A 1.193009722 6.94E-04 3.82 3.56
Dr_1288_1_Alat wu:fa94a03 1.467106599 6.94E-04 4.48 3.92
Dr_13863_2_Alat Dr_13863_2_Alat 1.857603892 7.65E-04 5.56 4.67
Dr_25624_1_SIat wu:fc44h05 0.682602972 8.09E-04 4.27 4.82
Dr_18631_2_Alat Dr_18631_2_Alat 1.710567103 8.29E-04 5.71 4.94
Dr_1015_2_SI_x_at Dr_1015_2_S1 x at 1.481668702 8.29E-04 12.4 11.8
Dr_11240_1_Alat Dr_11240_1_Alat 1.332402716 9.22E-04 5.29 4.87
Dr_1658_1_Alat Dr_1658_1_Alat 1.791011623 1.15E-03 7.82 6.98
Dr_10389_1_Alat zgc:101106 1.779780223 1.15E-03 5.66 4.82
Dr_21187_1_Alat wu:fb92c06 0.696130842 1.24E-03 5.64 6.16
Dr_20136_1_SIat wu:fdl4gO4 1.795570626 1.31E-03 6.68 5.84
Dr_404_1_Al_x_at wu:fa11a12 0.591146576 1.33E-03 4.08 4.84
Dr_372_1_SIat -isoaspartyl protein carboxyl 0.575447892 1.50E-03 5.49 6.29
methyltransferase
Dr_25767_1_S1_at Dr_257671_S1 at 2.198157103 1.60E-03 9.87 8.73
Dr_25527_1_Alat ribosomal protein L10a 1.464447932 1.71 E-03 5.31 4.76
Dr_9294_1_Alat wu:fcl4cOl 0.731887799 1.71E-03 4.32 4.77
Dr_16127_1_SIat Dr161271_S1 at 0.560471959 1.74E-03 8.2 9.04
Dr_23385_1_Alat Dr_23385_1_Alat 1.647965111 1.88E-03 4.7 3.98
Dr_6337_1_S1_at cytochrome P450, subfamily 0.419017005 1.90E-03 6.72 7.98
XIA, polypeptide 1
Dr_201_1_Alat wu:fb34c03 0.545439316 1.94E-03 5.39 6.27
Dr_4907_1_S1_at fibrinogen, gamma 0.636259369 2.03E-03 7.43 8.08
polypeptide
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Dr_24521_Alat wu:fb60b05 0.68393641 2.42E-03 6.13 6.68
Dr_47971_Si at Dr_47971_S1 at 0.626425697 2.52E-03 7.37 8.05
Dr_22937_1_Alat wu:fc23c09 0.709763899 2.73E-03 5.14 5.64
Dr_20969_1_SIat forkhead box 11 1.933739288 3.09E-03 7.07 6.12
Dr_381_1_Alat wu:fal2cl2 0.647868716 3.13E-03 4.28 4.91
Dr_20131_2_Alat clusterin (complement lysis 0.636975549 3.20E-03 4.9 5.56
inhibitor, SP-40,40, sulfated
glycoprotein 2, testosterone-
repressed prostate message
2, apolipoprotein J)
Dr_2260_1_S1_at pelota homolog (Drosophila) 0.477704377 3.52E-03 7.99 9.06
Dr_2634_1_Alat Dr_2634_1_Alat 0.565978282 3.54E-03 6.22 7.04
Dr_236_1_SIat Dr2361_Si at 2.009115634 3.75E-03 8.81 7.8
Dr_19380_1_S1_at thymosin, beta 0.723489357 4.1OE-03 6.37 6.84
Dr_13863_1_SIat Dr_13863_1_Siat 1.999401488 4.13E-03 6.91 5.91
Dr_18350_1_Alat Dr_18350_1_Alat 1.491033942 4.71E-03 4.83 4.26
Dr_40021_Alat wu:fb30eO6 0.719555264 4.95E-03 8.99 9.47
Dr_3645_1_S1_at plasminogen 0.606313983 4.95E-03 6.99 7.72
Dr_23067_1_S1_at myosin, heavy polypeptide 1, 0.599672367 5.05E-03 7.1 7.83
skeletal muscle
Dr_9180_1_Alat zinc finger protein-like 1 0.505191685 5.08E-03 5.28 6.26
Dr_4838_1_A1_at wu:fb5lg06 0.729218516 6.01E-03 4.62 5.08
Dr_14673_2_SIat zgc:92830 2.056854724 6.01 E-03 7.09 6.05
Dr_8379_1_SIat cardiac myosin light chain-1 0.642318164 6.07E-03 6.23 6.87
Dr 24764_1_S1_at Dr247641_SIat 0.697096409 6.09E-03 4 4.52
Dr_18151_1_S1_at Dr181511_Si at 0.727390506 6.18E-03 4.12 4.58
Dr_5670_1_Alat wu:fcO4eO5 0.794545972 6.24E-03 3.48 3.81
Dr_25534_1_SIat secreted frizzled-related 0.632143544 6.39E-03 6.57 7.23
protein 1
Dr_25140_5_SI_x_at Dr251405_Si x at 0.729486761 7.39E-03 9.56 10
Dr_1250_1_Alat wu:fb39dOl 0.709997672 7.44E-03 6.66 7.15
Dr_25679_1_SIat solute carrier family 1 (glial 0.650240851 7.69E-03 7.46 8.08
high affinity glutamate
transporter), member 3
Dr_19223_1SIat aldolase c, fructose- 1.486466654 7.86E-03 6.77 6.19
bisphosphate
Dr_4628_1_S1_at ATPase, H+ transporting, 0.503116845 8.12E-03 5.15 6.14
lysosomal accessory protein 1
Dr_6174_1_Alat wu:fj39b01 0.675532273 8.20E-03 4.1 4.67
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Dr_9556_1_SIat multiple substrate lipid kinase 0.722901656 8.60E-03 3.75 4.21
Dr_5404_1_SIat calymmin 0.686417101 8.60E-03 6.58 7.12
Dr_3799_1_SIat zgc:64012 0.854927864 8.70E-03 3.3 3.52
Dr_18349_1_Alat Janus kinase 1 1.542355251 9.OOE-03 4.89 4.26
Dr_1435_1_SIat caveolin 3 0.639536498 9.OOE-03 7.02 7.66
Dr_1194_1_SIat zgc:76908 1.420875157 9.74E-03 8.16 7.65
Dr_20010_7_SIat ATPase, Ca++ transporting, 0.686110524 1.04E-02 8.28 8.82
cardiac muscle, fast twitch 1
Dr_4859_1_Alat Dr_4859_1_Alat 0.643660392 1.04E-02 6.38 7.02
Dr_18212_1_SIat Dr_18212_1_SI at 0.631416165 1.04E-02 5.11 5.78
Dr_11532_1_SIat F-box protein 32 1.305221539 1.07E-02 4.92 4.53
Dr_12108_1_Alat wu:fb48e04 0.698360758 1.09E-02 4.75 5.26
Dr_12986_2_SIat v-fos FBJ murine 2.212990565 1.14E-02 7.12 5.98
osteosarcoma viral oncogene
homolog
Dr_16654_1_S1_at Dr_16654_1_SI at 1.274185566 1.25E-02 6 5.65
Dr_2043_1_Alat AU RNA binding 0.576532883 1.26E-02 5.7 6.49
protein/enoyl-Coenzyme A
hydratase
Dr_11520_3_SI_a_at si:ch211-51e12.7 0.512967205 1.46E-02 8.6 9.56
Dr_210681_SI_s_at POU domain gene 1 0.595156175 1.53E-02 6.17 6.92
Dr_7638_1_SIat calmodulin 2, gamma 0.506553692 1.61 E-02 5.19 6.17
Dr_309_1_SIat wingless-type MMTV 1.600021732 1.61 E-02 7.35 6.67
integration site family,
member 8a
Dr_16749_1_Alat Dr_16749_1_Al at 0.525458161 1.77E-02 7.45 8.38
Dr_24292_3_Al_a_at zgc:103619 0.632571253 1.96E-02 4.77 5.43
Dr_4572_1_SIat thrombospondin 4 0.511544588 2.02E-02 6.81 7.78
Dr_14414_2_S1_at zgc:112165 1.680382889 2.09E-02 6.35 5.6
Dr_1015_1_Alat Dr_1015_1_Al at 1.579631782 2.18E-02 7.86 7.2
Dr_11310_1_SIat tubulin, alpha 1 0.534672062 2.23E-02 8.72 9.63
Dr_17683_1_S1_at im:7138651 0.770807172 2.23E-02 5.99 6.37
Dr_1377_1_Alat collagen, type 1, alpha 2 0.661184862 2.27E-02 6.55 7.15
Dr_11520_1_S1_at si:ch211-51e12.7 0.507637552 2.29E-02 7.27 8.25
Dr_4867_1_Alat wu:fb64eOl 0.726327949 2.33E-02 5.77 6.23
Dr_18238_1_Alat Dr_18238_1_Alat 0.509448847 2.35E-02 6.08 7.05
Dr_17891_1_SIat zgc:110715 0.594250287 2.53E-02 9.14 9.89
Dr_5278_1_Alat protein tyrosine phosphatase, 0.566356003 2.59E-02 6.2 7.02
receptor type, N
Dr_20821_1_Alat plasminogen 0.623927066 2.61 E-02 5.75 6.43
Dr_8124_1_S1_at crestin 0.639549087 2.62E-02 7.72 8.36
Dr_23480_2_SIat bactin2 0.666980644 2.73E-02 5.13 5.71
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Dr_546_1_SIat visual system homeobox 2 0.669636327 2.83E-02 4.42 5
protein
Dr_356_1_SIat GATA-binding protein 2 1.349641462 2.84E-02 8.06 7.63
Dr_2794_1_Alat engrailed lb 0.715080962 2.86E-02 6.02 6.5
Dr_7815_1_SIat synaptosome-associated 0.731470608 2.86E-02 5.07 5.52
protein 25a
Dr_17890_2_Alat zgc:85723 0.733785041 2.90E-02 3.97 4.42
Dr_26414_1_SI.x_at id:ibdl087 0.552208883 2.92E-02 8.37 9.23
Dr_1448_1_SIat zgc:77231 0.666681269 2.95E-02 7.84 8.43
Dr_17146_1_Alat Dr_17146_1_Alat 1.672412579 2.98E-02 6.61 5.86
Dr_179_1_S2_at T-box gene 16 0.733325799 2.98E-02 5.31 5.75
Dr_3984_1_Alat kelch repeat and BTB (POZ) 0.682864907 2.98E-02 7.63 8.18
domain containing 10
Dr_4925_1_SIat cytoglobin 0.656596288 3.OOE-02 4.2 4.8
Dr_13058_1_Alat sb:cb734 1.850429409 3.29E-02 6.91 6.02
Dr_6285_1_SIat zgc:92732 0.696413753 3.29E-02 5.14 5.66
Dr_10504_1_Alat zgc:91802 1.654808301 3.29E-02 6.22 5.5
Dr_441_1_SI at procollagen, type IX, alpha 2 0.674804266 3.30E-02 7.58 8.15
Dr_71111SIa at hm:zehOl76 0.591097736 3.46E-02 6.52 7.28
Dr_26119_1_SIat Dr261191Si at 1.312188061 3.46E-02 4.59 4.2
Dr_1298_1_Alat zgc:110611 0.740830551 3.60E-02 3.7 4.13
Dr_14854_1_SIat zgc:92910 0.749496372 3.65E-02 9.48 9.9
Dr_5462_1_SIat fibrinogen, B beta polypeptide 0.659801517 3.71 E-02 6.74 7.34
Dr_25659_1_SIat Dr_256591_SI at 0.738497018 3.72E-02 4.11 4.55
Dr92881_SIat wu:fc21hO8 1.433357715 3.74E-02 6.78 6.26
Dr_4905_1_SIat uncoupling protein 4 0.687456675 3.95E-02 5.95 6.49
Dr_12833_1_Alat zgc:64213 1.284716559 4.07E-02 4.91 4.55
Dr_20214_1_Alat tubulin, alpha 8 like 3 0.63621249 4.28E-02 7.57 8.23
Dr 5403 1_Alat sb:cb88 1.60671016 4.28E-02 9.64 8.95
Dr_8118_1_Alat orthopedia protein 0.665862224 4.32E-02 4.5 5.09
Dr_35601_Alat cystathionase (cystathionine 0.612135482 4.33E-02 7.5 8.2
gamma-lyase)
Dr_4751_1_SIx at aldehyde dehydrogenase 2 0.720539037 4.44E-02 6.73 7.2
family (mitochondrial)
Dr_17394_1_Alat Dr_17394_1_Alat 0.611143552 4.56E-02 6.19 6.9
Dr_13168_1_S1_at nuclear cap binding protein 0.500920236 4.59E-02 8.69 9.69
subunit 2
Dr_208151_SIat alpha-tropomyosin 0.643554931 4.80E-02 8.35 8.99
Dr_17357_1_Alat H2A histone family, member 0.559795618 4.93E-02 7.1 7.94
I X
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Acquired probe level data normalized by Robust Multichip Average Method (RMA) was
investigated by ANOVA differential expression testing using Insightful S+@software. ANOVA
analysis contrasted age within condition factors to find significant transcripts regulated at the
different developmental stages. P-value cutoff was 0.05 and adjusted using a Benjamini-
Hochberg correction. Fold change is defined as the ratio of normalized expression intensities of
mutant and wild-type RNA. Expression values and fold changes are expressed in log2 values.
Affymetrix probe sets were annotated based on gene symbols available from Affymetrix Netaffix
website, Entrez Gene, Unigene, GenBank and the Boston Trans-NIH Zebrafish Genome
Initiative. 34 transcripts were found to be significant in all three age groups. All but two,
phosphatidylinositol transfer protein and Dr.5925.1.A1, were also found significant in LPE
differential analysis. An additional 11 transcripts are significant between 6S and 20S
developmental stages and an additional 59 transcripts are significant between 20S and 24HPF
developmental stages. The complete list of 633 regulated gene transcripts is available in Table
2.
Table 2. ANOVA transcripts P<0.05
mean mean mean mean mean
Raw p- Adj. p- NDST1 mean NDST1 WT.20 NDST1 WT
Affymetrix ID transcript Value Value 6S WT 65 20S S 24hpf 24hpf
spleen tyrosine 3.92E-
DrAffx_1_11_Siat kinase 1.37E-03 02 3.68 3.37 3.47 3.36 3.51 3.51
1.71E-
DrAffx_2_64_S1_at wu:fd23d07 3.75E-04 02 6.09 6.43 5.48 6.38 5.75 6.31
3.29E-
Dr_10051_1 Alat cyclin G2 1.09E-03 02 6.88 7.16 6.44 7.28 6.75 7.4
1.71E-
Dr 10085 2 S1_a at cyclin I 3.82E-04 02 9.22 9.49 8.82 9.75 9.33 10.3
serine (or
cysteine)
proteinase
inhibitor, clade
E (nexin,
plasminogen
activator
inhibitor type 6.41E-
Dr 10097 1 Slat 1), member 2 7.89E-05 03 9.16 8.69 9.4 8.39 8.61 8.34
actin related
protein 2/3
complex, 3.23E-
Dr_10136_2_S1_at subunit 3 1.03E-03 02 9.93 9.89 10.5 10.4 10.7 10.3
4.52E-
Dr_10141_1_Alat zgc:101687 5.07E-05 03 4.77 5.98 5.42 6.77 4.99 6.14
1.91E-
Dr 10196 2 S1_a at zgc:77025 4.55E-04 02 8.38 7.61 8.34 7.66 7.88 7.57
selenoprotein 2.09E-
Dr 10201 1 S1 at W 1 5.37E-04 02 9.72 9.35 9.9 9.61 9.97 9.65
4.80E-
Dr_10216_1_S1_a-at zgc:112015 1.89E-03 02 7.11 6.87 7.37 7.07 7.23 6.87
1.56E-
Dr_10216_2_Slat zgc:112015 3.13E-04 02 7.29 6.99 7.45 7.03 7.13 6.74
death effector
domain- 2.62E-
Dr 10244 1 S1 at containing 1 7.48E-04 02 8.24 7.59 8.16 7.27 7.61 6.9
4.93E-
Dr 10257 1 Alat peptidase D 5.62E-05 03 5.69 6.56 5.53 7.39 6.25 7.62
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proteasome
(prosome,
macropain) 265
subunit, non- 4.49E-
Dr_10290_1 Al at ATPase, 10 1.69E-03 02 8.93 8.42 8.99 8.54 8.82 8.37
2.37E-
Dr_10334_1_Siat caspase 8 1.37E-08 05 6.93 5.13 8.09 4.93 7.05 4.96
thyroid
transcription 2.99E-
Dr 10342 1 51 at factor la 2.76E-05 03 5.94 6.38 5.68 6.18 5.59 6
Dr 10359_1_Al 1.39E-
Dr 10359 1 Al at at 2.62E-04 02 8.76 9.33 8.85 9.44 8.94 9.23
Dr 10359_2_S1 1.71E-
Dr 10359 2 51 at at 3.76E-04 02 8.71 9.12 8.68 9.21 8.81 9.06
3.27E-
Dr 10389 1 Alat zgc:101106 1.07E-03 02 5.05 4.63 6.18 5.05 5.74 4.79
actin related
protein 2/3
complex, 2.05E-
Dr 10390 1 51 at subunit 5B 5.14E-04 02 8.59 8.41 9.28 8.84 9.68 9.25
4.60E-
Dr_10400_1_Alat zgc:110333 1.79E-03 02 8.85 8.51 8.38 7.96 8.22 8.01
homeo box (H6 3.29E-
Dr 10448 1 S1 at family) 3 1.09E-03 02 3.36 3.34 3.18 3.45 3.46 3.75
thymidylate 1.28E-
Dr_1047_1_Slat synthase 8.09E-06 03 9.45 8.53 9.31 9.12 9.71 9.15
4.90E-
Dr 10492 1 51 at deltaA 1.96E-03 02 8.7 8.75 8.61 8.99 9.01 9.53
3.09E-
Dr_10504_1_Alat zgc:91802 1.04E-06 04 5.52 5.18 6.76 5.5 6.39 5.82
4.1OE-
Dr_1050_1_Slat zgc:110113 4.41E-05 03 10.4 10.6 9.73 10.5 10.3 10.8
8.88E-
Dr 10602 1 Al at hm:zeh0176 1.33E-04 03 8.25 8.64 7.54 8.7 8.75 9.5
3.49E-
Dr 10624 1 Slat zgc:110343 1.17E-03 02 6.48 5.89 7.67 6.57 7.68 6.98
2.29E-
Dr_10624_2_S1_a-at zgc:110343 6.10E-04 02 7.53 7.06 8.63 7.74 8.54 7.89
carbonyl 3.28E-
Dr 10648 1 51 at reductase 1-like 3.24E-05 03 7.2 7.09 8.96 8.02 8.47 7.64
eomesodermin 1.90E-
Dr 10724 1 S1 at homolog 4.48E-04 02 5.17 5.3 5.76 6.08 6.33 6.86
4.30E-
Dr 10742 2 S1_a at zgc:55259 1.57E-03 02 8.04 7.6 8.49 7.47 7.68 7.18
DnaJ (Hsp40)
homolog,
subfamily B, 4.52E-
Dr 1075 1 Al a at member 1 1.74E-03 02 6.25 5.91 6.39 5.93 6.09 6.05
1.83E-
Dr 10914 1 Al at wu:fc49dOl 1.33E-05 03 4.33 4.24 6.81 4 6.14 4.69
COP9
constitutive
photomorphoge
nic homolog 4.47E-
Dr 11003 1 S1 at subunit 7A 1.70E-06 04 8.22 8.83 8.27 8.93 8.11 8.55
2.91E-
Dr 1104 1 Alat zgc:110794 8.70E-04 02 6.11 6.78 6.11 6.32 6.16 6.29
Dr_11190_1_Al 2.03E-
Dr 11190 1 Al at at 5.01E-04 02 5.21 5.31 6.02 5.4 5.82 5.49
5.OOE-
Dr 1123 1 Al at wu:fa99ell 2.03E-03 02 6.68 6.44 6.82 6.33 6.44 6.2
Dr_11240_1_Al 1.63E-
Dr_11240_1_Alat _at 3.35E-04 02 6.14 5.91 5.34 4.57 4.38 4.14
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pleckstrin
homology-like
domain, family 1.67E-
Dr 11242 1 Al at A, member 3 4.38E-09 05 8.71 6.15 9.05 5.83 8.65 5.9
carboxypeptidas
e N, 3.39E-
Dr_1128_1_S1lat polypeptide 1 1.13E-03 02 9.24 9.23 9.16 8.67 8.96 8.41
1.31E-
Dr_11310_1_S1_at tubulin, alpha 1 2.36E-04 02 7.56 8.56 8.85 9.93 9.76 10.4
1.71E-
Dr_11310_2_S1_at tubulin, alpha 1 3.70E-04 02 8.08 8.96 8.5 10.1 9.58 10.3
1.91E-
Dr 11310 2 S1 x at tubulin, alpha 1 4.55E-04 02 8.56 9.36 9.27 10.5 10.1 10.8
1.91E-
Dr 11356 1 Alat zgc:92193 4.56E-04 02 8.1 7.62 8.1 7.51 7.61 7.51
1.86E-
Dr_1142_1_Alat zgc:66068 5.16E-07 04 8.81 9.88 8.69 10.4 9.28 10.2
Dr 11447_1_Al 7.93E-
Dr_11447_1_Alat at 1.13E-04 03 5.8 5.36 6.53 5.64 6.01 5.56
Dr 11452 1 Al 5.07E-
Dr 11452 1 Al at at 2.04E-06 04 8.03 7.95 8.36 7.91 8.11 7.72
Dr 11464 1 Al 5.18E-
Dr_11464_1 Al at at 6.05E-05 03 5.32 5.74 5.7 6.36 6.38 6.66
2.26E-
Dr_11479_1_Alat wu:fb96alO 6.57E-07 04 5.45 4.58 6.85 4.47 7.05 4.49
2.90E-
Dr 11481 1_Alat zgc:92153 3.78E-08 05 4.64 4.16 6.17 3.91 6.03 3.94
heterogeneous
nuclear
ribonucleoprote 4.55E-
Dr 1149 2 Al at in AO 1.76E-03 02 12 12.2 11.4 12 12 12.1
polo-like kinase 1.71E-
Dr_11503_1_Slat 4 (Drosophila) 3.83E-04 02 7.5 7.58 6.8 7.47 7.35 7.61
4.OOE-
Dr_11508_3_Alat bcl2-like 1.42E-03 02 7.03 6.89 7.71 6.93 7.11 6.76
si:ch2ll- 3.19E-
Dr 11520 1 S1 at 51e12.7 3.09E-05 03 7.53 8.46 6.91 8.18 7.37 8.1
si:ch2ll- 2.56E-
Dr 11520 2 S1 a at 51e12.7 2.26E-05 03 8.22 8.97 7.48 8.55 7.94 8.74
si:ch2ll- 1.39E-
Dr_11520_3 S1 a at 51e12.7 2.60E-04 02 8.73 9.63 8.23 9.4 8.84 9.67
Dr 11536_1_Al 4.70E-
Dr_11536_1_Alat _at 1.84E-03 02 4.17 3.95 4 3.81 4.06 3.84
Dr_11590_1_Al 1.70E-
Dr 11590 1 Al s at _s at 3.67E-04 02 7.29 6.18 6.49 7.17 7.69 8.39
MCM5
minichromosom
e maintenance
deficient 5 (S. 7.62E-
Dr_11651_1 51 at cerevisiae) 3.74E-06 04 10.2 10.4 9.5 10.3 9.83 10.4
dihydrofolate 4.54E-
Dr 11722 1 S1 at reductase 1.75E-03 02 8.57 8.54 7.53 8.38 7.92 8.21
Dr_11789_1_S1 4.81E-
Dr_11789_1_S1_at _at 1.90E-03 02 8.17 8.17 8.54 8.14 8.21 7.83
proteasome
(prosome,
macropain)
subunit, beta 3.29E-
Dr_11843_1_S1lat type, 6 1.09E-03 02 11.1 10.9 11.3 11 11.1 10.8
4.78E-
Dr 12046 1_Slat zgc:86647 1.88E-03 02 7.96 7.56 8.13 7.75 8.3 7.92
Dr_12072_1_Al 7.49E-
Dr_12072_1_Alat at 1.03E-04 03 4.64 4.44 5.13 4.45 4.67 4.47
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8.31E-
Dr_1212_1_S1lat cyclin G1 1.75E-07 05 12.1 11.3 12.7 11.1 12.6 11.3
1.89E-
Dr 12365 1 Alat zgc:56006 4.40E-04 02 7.42 7.31 8.61 7.44 8.03 7.53
2.54E-
Dr_12373_1_Slat zgc:92178 7.10E-04 02 8.59 8.14 8.91 8.6 8.63 8.27
sal-like 1 2.71E-
Dr 12380_1_Slat (Drosophila) 2.45E-05 03 6.85 6.98 6.17 6.55 6.55 7.07
2.65E-
Dr_12386_2_S1_a at mesogenin 1 7.65E-04 02 10.1 10.8 7.42 9.26 7.39 8
5.OOE-
Dr 12425 5 S1 at wu:fj24cOl 2.04E-03 02 3.95 3.85 4.05 3.89 4.17 3.92
poly (ADP-
ribose)
polymerase
family, member 1.20E-
Dr 12458 1 Al at 2 2.94E-07 04 6.58 7.82 6.28 7.8 6.68 7.9
Dr 12497_1_S1 6.90E-
Dr_12497_1_Slat at 8.81E-05 03 3.7 3.74 4.08 3.6 3.61 3.52
Dr 12509_1_S1 1.39E-
Dr 12509 1 S1 at at 2.58E-04 02 8.71 8.49 8.52 8.15 8.12 7.63
1.95E-
Dr 12514 1 Al at wu:fil6hO7 4.70E-04 02 6.99 7.12 6.19 6.95 6.67 6.91
8.67E-
Dr_12522_1 Alat zgc:111988 1.26E-04 03 5.24 5.19 6.3 5.65 5.8 5.52
4.13E-
Dr 12555 1 S1 at wu:fk6lcO6 1.47E-06 04 7.72 8.18 7.54 8.52 8.09 8.75
Kruppel-like 3.09E-
Dr 12593 1 S1 at factor 12 9.63E-04 02 7.39 6.91 7.29 6.95 6.8 6.72
angiopoietin- 3.OOE-
Dr 12622 1 51 at like 3 9.14E-04 02 5.24 5.66 5.48 6.29 5.69 5.88
Dr_12668_1_Al 1.71E-
Dr 12668 1 Al at at 3.77E-04 02 6.93 6.95 6.32 6.99 6.76 6.83
3.29E-
Dr 1267 1 Slat zgc:55868 1.08E-03 02 7.58 7.17 7.43 6.93 7.18 6.94
phosphatidylino
sitol transfer 1.56E-
Dr_12713_1_Slat protein, alpha 4.03E-07 04 7.12 7.86 6.62 7.75 7.01 7.91
Dr 12794_1_S1 1.60E-
Dr 12794 1 S1 at at 3.24E-04 02 4.31 4.56 4.09 4.56 4.46 4.79
Dr 12811_1 Al 2.10E-
Dr 12811 1 Al at at 1.71E-05 03 5.36 5.85 4.88 5.39 5.31 5.58
2.48E-
Dr 12832 1_S1 at zgc:112289 6.84E-04 02 9.04 8.86 9.56 9.26 9.67 9.31
inhibitor of DNA
binding 2,
dominant
negative helix-
loop-helix 4.78E-
Dr_12836_1_Slat protein, like 1.88E-03 02 6.15 6.24 6.16 6.93 5.94 6.36
Dr_12847_1_Al 1.24E-
Dr 12847 1 Al at at 7.50E-06 03 9.85 9.51 9.49 8.91 8.89 8.77
Dr 12850_1_Al 3.01E-
Dr 12850 1 Al at at 9.23E-04 02 6.47 6.39 6.88 6.25 6.48 6.14
8.88E-
Dr_12863_1 Alat zgc:92582 1.34E-04 03 5.12 4.82 5.59 4.65 5.46 5.01
Dr_12880_1_Al 3.OOE-
Dr 12880 1 Al at at 9.09E-04 02 5.9 5.69 5.57 5.53 5.65 5.95
Dr 12881 1 Al 1.42E-
Dr 12881 1 Al at at 2.68E-04 02 4.64 4.98 4.3 4.89 4.6 4.9
1.55E-
Dr_1288_1_Alat wu:fa94a03 3.09E-04 02 4.05 3.94 4.74 3.96 4.65 3.88
Dr_12899_1_Al 1.08E-
Dr 12899 1 Al at at 1.76E-04 02 5.13 4.99 5.63 5.09 5.72 5.3
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Dr_12926_1_Al 1.51E-
Dr_12926_1_Alat 
_at 2.91E-04 02 6 5.42 5.97 5.63 5.44 5.28
Dr 12976_1_Al 4.49E-
Dr_12976_1 Al at _at 1.71E-03 02 4.54 4.82 4.84 4.9 4.85 5.01
v-fos FBJ murine
osteosarcoma
viral oncogene 3.74E-
Dr_12986_1_Ala at homolog 5.83E-08 05 7.92 5.56 7.66 4.78 7.3 4.94
v-fos FBJ murine
osteosarcoma
viral oncogene 1.53E-
Dr 12986 1 Al at homolog 3.85E-07 04 6.41 4.46 6.02 4.17 5.58 4.05
v-fos FBJ murine
osteosarcoma
viral oncogene 4.27E-
Dr 12986 2 S1 at homolog 1.56E-06 04 7.5 6.23 7.03 5.84 6.83 5.86
v-fos FBJ murine
osteosarcoma
viral oncogene 3.74E-
Dr 12986 3 S1 a at homolog 5.90E-08 05 7.64 5.69 7.05 5.15 6.68 5.31
2.94E-
Dr_1298_1_Alat zgc:110611 2.69E-05 03 3.83 4.1 3.71 4.23 3.56 4.07
platelet derived
growth factor 2.61E-
Dr 12 1 S2 at receptor alpha 7.42E-04 02 5.7 5.77 5.8 6.08 5.72 6.22
1.71E-
Dr 1300 1 Alat zgc:100935 3.81E-04 02 7.36 8.05 9.4 10 9.98 10.1
Dr_13055_1_Al 2.32E-
Dr 13055 1 Al at at 6.24E-04 02 4.89 4.49 4.91 4.29 4.72 4.57
8.84E-
Dr_13058_1_Alat sb:cb734 4.68E-06 04 5.85 5.07 7.63 6.37 7.25 6.62
Dr_13098_1_S1 4.28E-
Dr 13098 1 S1 at at 1.56E-03 02 6.87 6.55 6.95 6.48 6.73 6.48
Dr_13145_1_Al 3.10E-
Dr 13145 1 Alat _at 9.69E-04 02 6.27 5.96 6.12 5.85 6.07 5.81
growth arrest
and DNA-
damage-
inducible, beta 2.63E-
Dr_13161_1_S1_at like 7.54E-04 02 7.02 6.53 6.48 6.05 6.1 5.82
nuclear cap
binding protein 3.09E-
Dr 13168 1 S1 at subunit 2 1.01E-06 04 8.92 10 8.48 9.72 8.67 9.35
mutL homolog
1, colon cancer,
nonpolyposis 4.71E-
Dr_13195_1_Alat type 2 (E. coli) 5.32E-05 03 6.33 6.69 5.88 6.47 6.02 6.43
3.15E-
Dr 13391 1 Slat zgc:55696 2.99E-05 03 5.43 5.69 5.64 6.11 6.08 5.96
3.43E-
Dr_133_1_Alat wu:fa02gO8 1.15E-03 02 7.75 7.92 6.7 7.76 7.41 7.49
proliferating cell 1.71E-
Dr 1348 1 S1_at nuclear antigen 3.79E-04 02 12.6 12.6 12.3 12.7 12.6 12.6
3.19E-
Dr 13633 1_Alat zgc:92287 1.09E-06 04 6.22 5.9 7.71 6.06 8.2 7.17
6.37E-
Dr 13656 1 Alat zgc:103544 2.88E-06 04 7.63 7.77 6.85 7.39 6.86 7.46
glutaryl-
Coenzyme A 4.17E-
Dr 1368 2 Al at dehydrogenase 1.51E-03 02 12.2 12 12.2 11.7 11.8 11.6
4.47E-
Dr 1368 3 S1 at wu:fb80cO8 4.99E-05 03 11.4 11.1 11.5 11 11.3 11
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collagen, type 1, 2.06E-
Dr 1377 1 Alat alpha 2 5.19E-04 02 4.69 4.87 6.47 7.51 8.49 9.06
growth arrest
and DNA-
damage- 2.61E-
Dr_1378_1_S1_at inducible, beta 7.44E-04 02 7.75 7.08 7.35 7.12 6.94 6.83
4.49E-
Dr 13810 1 Slat zgc:55718 1.70E-03 02 4.75 4.42 4.58 4.32 4.55 4.23
Dr 13863 1 S1 1.94E-
Dr 13863 1 51 at at 1.49E-05 03 6.29 5.78 7.32 5.82 7.1 6.13
Dr 13863_2_Al 7.79E-
Dr 13863 2 Al at at 1.10E-04 03 4.93 4.57 5.94 4.66 5.81 4.77
4.OOE-
Dr 138 1 Al at zgc:65774 1.42E-03 02 5.79 5.51 5.77 5.37 5.64 5.49
Dr_14160_1 Al 2.78E-
Dr 14160 1 Al at at 2.37E-08 05 5.35 4.97 6.37 5.06 6.08 4.91
1.75E-
Dr 1435 1 51 at caveolin 3 3.92E-04 02 5.9 6.04 6.63 7.83 8.52 9.12
growth arrest
and DNA-
damage- 4.15E-
Dr_14374_1 Al at inducible, alpha 1.50E-03 02 5.75 5.45 6.12 5.57 5.53 5.49
2.52E-
Dr 1438 1 Slat zgc:103772 2.17E-05 03 10.6 10.6 10 11 10.8 11
3.27E-
Dr 14414 1 Alat zgc:112165 1.06E-03 02 6.89 6.7 7.05 6.63 6.96 6.29
1.69E-
Dr_14414_2_S1_at zgc:112165 3.62E-04 02 6.27 5.78 6.64 5.66 6.14 5.36
Dr 14425_1_Al 2.56E-
Dr 14425 1 Al at at 7.19E-04 02 3.97 3.92 4.7 3.76 4.38 3.95
Dr_14467_1_Al 3.04E-
Dr 14467 1 Al at at 9.39E-04 02 7 6.52 8.02 6.98 7.42 6.92
Dr 14467_2_Al 2.58E-
Dr 14467 2 Al at at 7.32E-04 02 5.86 5.47 6.31 5.77 6.01 5.56
2.32E-
Dr_14482_1_A1_at zgc:91853 1.96E-05 03 6.9 7.46 6.99 7.57 7.07 7.51
distal-less
homeobox gene 1.88E-
Dr 145 1 51 at 6a 4.30E-04 02 4.87 4.79 6.37 5.6 5.91 5.98
Dr_14615_1_Al 4.84E-
Dr_14615_1 Al at at 1.92E-03 02 4.04 3.97 4.57 4.09 4.67 4.34
4.50E-
Dr_14652_1_Alat hip2 1.72E-03 02 8.36 8.5 8.6 8.55 8.65 8.32
9.87E-
Dr 14673 1 Al at wu:fj36glO 5.31E-06 04 7.09 6.29 6.87 6.03 6.63 5.89
4.27E-
Dr_14673_2_Slat zgc:92830 1.57E-06 04 7.05 6.2 7.32 6.13 6.89 5.81
paired box gene 4.41E-
Dr 1467 2 S1 a at 9 4.89E-05 03 5.07 5.38 5.27 5.99 5.79 6
carnitine
palmitoyltransfe 8.75E-
Dr 146 1 Al at rase il 4.52E-06 04 6.96 6.62 7.69 6.97 7.65 7.08
Dr 14702_1_Al 1.55E-
Dr 14702 1 Al at at 3.05E-04 02 5.42 5.52 5.95 5.52 5.83 5.25
1.23E-
Dr 14704 1 Slat zgc:56307 2.17E-04 02 9.24 9.22 8.85 9.45 9.19 9.3
Dr 147571_Al 1.55E-
Dr 14757 1 Al at at 3.07E-04 02 3.15 3.13 3.19 3.46 3.42 3.81
ATPase, H+
transporting,
lysosomal, Vl
subunit C, 2.65E-
Dr 14783 1 S1 at isoform 1 2.36E-05 03 8.45 8.27 9.49 8.28 9.05 8.24
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SRY-box
containing gene 1.12E-
Dr 14800 1 Al at 21 b 6.51E-06 03 7.02 7.36 6.59 7.57 6.62 7.55
1.23E-
Dr 14868 1 S1at zgc:103699 2.13E-04 02 6.85 7.59 7.17 7.72 7.84 8.13
2.37E-
Dr 14880 1 S1at zgc:56308 6.40E-04 02 6.27 6.03 6.32 6.11 6.05 5.64
2.06E-
Dr_149_1_Al at wu:fa03ell 5.25E-04 02 9.69 9.64 9.92 9.44 9.54 9.61
Dr 15033_1_S1 2.78E-
Dr_15033_1_Siat at 1.93E-08 05 10 8.77 10.9 8.61 9.99 8.43
Dr 15043_1_51 1.34E-
Dr 15043 1 S1 s at s at 2.47E-04 02 8.14 7.73 7.95 7.59 7.69 7.25
4.49E-
Dr 15046 1 Al at wu:fb55fO5 1.70E-03 02 5.95 5.9 5.5 6.15 5.48 6.23
poly (ADP-
ribose)
polymerase
family, member 3.31E-
Dr 15150 1 Al at 3 3.29E-05 03 6.26 5.24 6.76 4.91 6.41 4.77
Dr 15205_1_Al 4.15E-
Dr_15205_1_Alat _at 1.50E-03 02 5.82 6.15 5.9 6.49 5.99 6.36
Dr 15256_1_Al 1.67E-
Dr 15256 1 Al at at 3.55E-04 02 3.5 3.8 3.53 3.88 3.94 4.5
3.48E-
Dr 15269 1 S1at zgc:56033 3.50E-05 03 6.27 6.56 6.43 7.17 6.94 7.23
4.94E-
Dr_15281_1_Alat wu:fkl4gO8 1.99E-03 02 4.55 4.53 5.38 4.61 4.73 4.5
1.43E-
Dr 15428 1 S1at zgc:109973 2.71E-04 02 10.9 11 10.9 11.4 11 11.1
1.23E-
Dr_15450_1_Alat im:7151765 2.14E-04 02 6.71 6.29 6.95 6.26 6.57 6.08
Dr 15486_1_Sl 1.71E-
Dr 15486 1 S1 a at a at 3.79E-04 02 6.49 6.31 5.55 6.28 5.97 6.22
1.94E-
Dr 15539 1 Alat zgc:111879 4.66E-04 02 5.19 4.85 5.19 4.93 4.96 4.92
Dr_15554_1_Al 1.56E-
Dr 15554 1 Al at _at 3.12E-04 02 4.2 4.61 4.23 5.07 4.94 5.42
1.26E-
Dr 15561 1 _S1at zgc:101797 7.75E-06 03 4.33 4.46 5.01 4.48 4.57 4.32
kinesin family 3.97E-
Dr_1557_1_Siat member 11 1.40E-03 02 9.52 9.5 8.76 9.51 9.36 9.54
Dr 15585_1_Sl 3.17E-
Dr_15585_1_Siat at 1.OOE-03 02 7.53 7.46 8.1 7.58 7.92 7.49
4.50E-
Dr_15600_1 S1at zgc:101002 1.72E-03 02 5.01 5.1 5.03 5.71 5.47 6.08
SET
translocation
(myeloid
leukemia- 4.55E-
Dr 15604 1_Alat associated) A 1.76E-03 02 5.14 5.41 6.39 5.86 6.03 5.88
Dr_ 156051_51 1.34E-
Dr_15605_1S1_at _at 2.45E-04 02 6.79 6.72 7.05 6.53 6.81 6.48
RAB36, member
RAS oncogene 2.47E-
Dr 15626 1 S1 at family 6.78E-04 02 5.92 5.67 6.58 5.79 5.75 5.32
RAB36, member
RAS oncogene 4.91E-
Dr 15626 2 Al at family 1.97E-03 02 5.23 5.06 5.65 5.03 4.98 4.61
7.57E-
Dr 15653 1 S1 at im:7151414 3.66E-06 04 9 9.07 8.14 8.99 8.8 9.05
2.37E-
Dr 15700 1 Alat zgc:63836 6.40E-04 02 7.61 7.51 7.54 7.21 7.54 7.45
Dr 15750 1_Slat zgc:92648 1.91E-03 4.81E- 8.04 8.13 7.84 8.32 8.01 8.1
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02
vaccinia related 4.77E-
Dr 15781 1 S1 at kinase 2 8.00E-08 05 6.95 5.81 7.61 5.85 7.09 5.52
Dr 15869_1_Al 3.17E-
Dr 15869 1 Al at at 1.OOE-03 02 7.6 8.21 6.98 7.99 6.94 7.4
2.52E-
Dr 15892 1 S1 at surfeit 5 6.96E-04 02 4.08 3.84 4.07 3.71 3.7 3.55
3.71E-
Dr_16011_1_Slat zgc:56295 1.28E-03 02 8.15 8.17 8.5 8.03 8.13 7.6
4.10E-
Dr_16048_1_Slat zgc:55680 4.39E-05 03 8.21 7.35 8.51 8.18 8.31 8
1.40E-
Dr_16113_1 S1 at inhibin, beta A 2.64E-04 02 5.95 5.94 5.93 5.41 5.41 5.45
Dr_16127_1_51 1.21E-
Dr 16127 1 51 at at 2.06E-04 02 8.93 9.5 7.86 9.15 7.82 8.47
Dr 16177_1_Al 8.88E-
Dr 16177 1 Al at at 1.31E-04 03 6 6.08 5.9 6.64 6.3 6.71
Dr_16251 1 Al 1.88E-
Dr 16251 1 Al at at 4.30E-04 02 4.01 4.13 3.87 4.13 3.95 4.15
Dr_16273_1_S1 1.10E-
Dr 16273 1 S1 at at 1.81E-04 02 8.84 8.29 8.89 8.09 8.61 7.9
1.99E-
Dr 1632 1 Al at wu:fb93c06 1.55E-05 03 6.68 6.79 5.99 7.01 6.78 6.99
Dr 16480_1_Al 9.87E-
Dr 16480 1 Al at at 5.35E-06 04 4.98 4.87 5.59 4.75 5.05 4.69
1.21E-
Dr 16522 1 Alat zgc:91971 7.16E-06 03 7.78 6.96 7.71 6.81 7.43 6.47
Dr_16548_1_51 3.OOE-
Dr 16548 1 51 at at 9.14E-04 02 6.6 6.6 7.01 6.75 7.06 6.65
Dr 16555_1_51 4.80E-
Dr 16555 1 S1 at at 1.89E-03 02 5.71 5.85 5.43 6.11 5.66 5.98
1.67E-
Dr 16557 1 S1 at wu:ft63e05 3.56E-04 02 7.37 7.34 7.55 7 7.21 6.98
Dr_1658_1_Al_ 2.98E-
Dr 1658 1 Al at at 8.98E-04 02 6.79 5.83 8.24 7.13 8.44 7.98
Dr_16595_1_S1 3.09E-
Dr 16595 1 S1 at at 9.64E-04 02 7.76 7.22 7.57 7.15 7.07 6.91
nuclear
receptor
subfamily 2,
group F, 8.18E-
Dr 16669 1_S1_at member 1, like 1.17E-04 03 3.21 3.06 3.89 4.94 4.67 5.33
4.40E-
Dr_16690_1_Alat zgc:85976 1.62E-03 02 4.8 4.77 5.06 4.81 4.99 4.77
myeloid
ecotropic viral
integration site 3.66E-
Dr 1680 1 S1 at 3 1.25E-03 02 9.42 9.49 8.51 9.06 8.91 9.22
Dr 16831_1_51 4.92E-
Dr 16831 1 S1 at at 1.98E-03 02 5.74 5.23 5.07 4.83 4.9 4.77
Dr_1689 2_Al_ 6.60E-
Dr 1689 2 Al a at a at 8.21E-05 03 3.82 4.21 4.77 6.46 6.31 6.79
ribonucleotide
reductase M2 2.74E-
Dr 1691 1 Slat polypeptide 8.30E-07 04 10.8 11.1 10.3 11.3 10.6 11.3
karyopherin
alpha 2 (RAG
cohort 1,
importin alpha 1.07E-
Dr 1691 4 Alat 1) 1.72E-04 02 10.8 10.9 10.4 11 11.2 11.3
7.55E-
Dr_1691_6 Alat zgc:66459 1.05E-04 03 9.03 9.25 7.9 9.25 8.79 9.35
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heterogeneous
nuclear
ribonucleoprote 7.74E-
Dr_17008_1_Alat in AO 1.45E-07 05 6.85 6.76 8.28 7.13 7.51 6.92
5.96E-
Dr_17009_1_S1_at im:6905175 2.57E-06 04 8.06 7.56 8.23 7.55 7.73 6.94
Dr_17100_1_Al 2.90E-
Dr_17100 1 Alat at 3.33E-08 05 6.87 8.11 7.1 8.44 7.56 8.44
Dr_17110_1_Al 5.72E-
Dr 17110 1 Al at at 6.90E-05 03 3.7 3.74 4.71 4.13 4.11 3.89
3.84E-
Dr_17122_1_Alat zgc:63779 1.34E-03 02 7.52 7.21 7.54 6.9 7.15 6.74
Dr_17146_1_Al 7.81E-
Dr_17146_1_Alat 
_at 3.93E-06 04 6.96 6.31 6.71 5.73 6.15 5.55
Dr_17168_1_Al 2.05E-
Dr 17168 1 Al at at 5.11E-04 02 5.82 5.71 6.25 5.82 6.11 5.89
8.84E-
Dr 17186 1 S1at zgc:56126 1.29E-04 03 4.67 4.73 5.04 4.72 4.74 4.57
8.88E-
Dr_17198_1 Alat zgc:113447 1.32E-04 03 3.92 3.67 3.78 3.47 3.7 3.47
1.37E-
Dr 17297 1 Al at id:ibd2775 2.53E-04 02 7.16 7.37 6.79 7.33 7.21 7.35
malignant T cell
amplified 1.29E-
Dr_17302_1_S1_at sequence 1 2.30E-04 02 10.1 9.72 10.2 10 9.95 9.49
H2A histone
family, member 1.13E-
Dr 17357 1 Al at X 1.87E-04 02 6.75 7.65 6.98 8.05 7.57 8.1
2.88E-
Dr_17358_1_Alat wu:fi04cl2 8.58E-04 02 5.62 5.24 5.66 5.26 5.43 4.97
Dr_17381_1_Al 4.50E-
Dr_17381_1 Al at at 1.72E-03 02 4.07 3.77 4.34 3.74 3.82 3.64
Dr_17394_1_Al 1.14E-
Dr 17394 1 Al at _at 1.91E-04 02 5.74 6.38 5.94 6.83 6.88 7.48
Dr_17394_2_51 3.02E-
Dr_17394_2 S1 at at 9.31E-04 02 5.96 6.39 5.97 6.48 6.48 7.04
Dr_17403_1_Al 1.84E-
Dr 17403 1 Al s at s at 4.18E-04 02 7.92 8.03 7.08 7.71 7.51 7.82
Dr_17464_1_Al 3.79E-
Dr 17464 1 Al at at 1.31E-03 02 6.24 6.73 6.65 7.18 6.62 6.76
ubiquitin-
conjugating
enzyme E2L 3, 1.96E-
Dr 17481 1_S1_at like 4.75E-04 02 8.58 8.01 8.69 8.16 8.53 8.07
4.50E-
Dr_175111 _S1at zgc:55731 1.72E-03 02 5.93 5.59 5.07 5.05 4.84 4.75
Dr_17564_1_Al 1.12E-
Dr_17564_1 A1_at _at 1.84E-04 02 4.54 5.03 6.27 6.8 6.46 7.01
MAP kinase-
interacting
serine/threonin 7.79E-
Dr_17570_2_Alat e kinase 2 1.09E-04 03 9.12 8.64 8.99 8.51 8.73 8.6
3.25E-
Dr 17634 1_Alat zgc:110258 1.04E-03 02 6.27 5.85 6.4 5.86 6.03 5.79
|-isoaspartyl
protein carboxyl
methyltransfera 4.99E-
Dr_17655_1_Alat se, like 2.03E-03 02 6 5.71 6.44 5.81 6.12 5.77
membrane
protein, 6.57E-
Dr_17659_1_S1lat palmitoylated 1 1.19E-07 05 7.15 5.14 8.55 4.9 6.73 4.8
Dr_17738_1_S1 2.64E-
Dr 17738 1_S1_at _at 7.82E-07 04 6.36 6.22 7.28 5.99 6.73 6.12
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Dr 17740_2_Al 1.48E-
Dr 17740 2 Al at at 2.84E-04 02 6.28 7.37 6.14 6.59 6.34 6.65
Dr_17783_1_S1 3.28E-
Dr 17783 1 Si at at 1.07E-03 02 7.73 7.16 7.9 7.2 7.26 6.77
Dr 17787_1_Al 4.47E-
Dr 17787 1 Al at at 1.68E-03 02 6.64 6.98 6.83 7.36 6.96 7.23
ras homolog
gene family, 1.71E-
Dr 17818 1 51 at member E 3.70E-04 02 9.15 8.7 9.88 9.17 9.47 8.9
7.35E-
Dr_17841_1_S1_at zgc:114109 9.96E-05 03 4.79 5.22 4.38 5.16 4.8 5.29
5.62E-
Dr_17841_3_Alat wu:fb82gOl 6.64E-05 03 6.67 7.3 6.58 7.53 6.93 7.61
Dr 17855 1 S1 4.40E-
Dr 17855 1 S1 at at 1.62E-03 02 6.74 7.03 6.65 7.55 7.21 7.42
Dr 17874 1 Al 5.07E-
Dr 17874 1 Al at at 2.06E-06 04 9.24 8.97 9.6 8.94 9.18 8.92
2.29E-
Dr_17890 2_Alat zgc:85723 6.11E-04 02 4.07 4.33 4 4.56 3.85 4.36
Dr_17912_1_51 4.98E-
Dr 17912 1 S1 at at 8.67E-08 05 4.71 4.98 5.31 5.92 5.74 7.04
HMT1 hnRNP
methyltransfera
se-like 2 (S. 9.85E-
Dr 17935 1_51_at cerevisiae) 1.55E-04 03 6.82 7.15 6.24 7.3 6.74 7.09
4.49E-
Dr_17944_1_Slat zgc:77827 1.69E-03 02 6.65 6.86 6.74 7.36 7.48 7.64
3.56E-
Dr 17965 1 51 at wu:fcl7dO3 1.21E-03 02 9.06 8.88 9.1 8.8 8.81 8.54
3.81E-
Dr 18018 1 Al at wu:fdl8fO9 1.33E-03 02 8.39 8.42 7.85 8.49 8.39 8.29
Dr 18025 1 Al 6.27E-
Dr 18025 1 Al at at 2.75E-06 04 7.65 7.78 6.76 7.85 7.25 7.82
4.86E-
Dr_18038_1 Slat zgc:101648 1.93E-03 02 6.35 5.69 5.73 5.62 5.22 5.45
5.76E-
Dr_18073_1_S1_at zgc:91853 2.43E-06 04 5.52 5.88 5.29 6.06 5.54 5.92
1.71E-
Dr 18103 1 S1at zgc:110357 3.72E-04 02 8.12 8.15 8.51 7.96 8.38 7.57
Dr 18151_1_S1 1.72E-
Dr 18151 1 S1 at at 1.22E-05 03 3.77 3.9 3.97 4.49 4.62 5.35
2.21E-
Dr 18154 1 51 at wu:fb96d05 5.81E-04 02 5.55 5.82 5.02 5.93 5.33 5.42
ubiquitin-like,
containing PHD
and RING finger 2.52E-
Dr 18169 1 S1_at domains, 1 6.99E-04 02 7.3 7.37 6.85 7.59 7.31 7.72
Dr 18212_1_S1 5.26E-
Dr 18212 1 51 at at 6.18E-05 03 4.51 5.02 5.1 6.09 5.73 6.22
Dr 18230 1 Al 8.88E-
Dr 18230 1 Al at at 1.32E-04 03 3.74 4.06 4.71 6.54 5.49 5.83
Dr 18238_1 Al 1.69E-
Dr 18238 1 Al at at 1.19E-05 03 6 6.92 5.95 7.03 6.3 7.22
4.49E-
Dr 18263 1 S1 at wu:fcl3cO2 1.71E-03 02 6.28 6.42 5.99 6.83 6.51 7.13
developing
brain homeobox 2.53E-
Dr 18269 1 Al at 2 7.03E-04 02 5.44 5.81 7 7.68 7.4 8.02
RGM domain
family, member 1.71E-
Dr 18272 1 S1 at A 3.76E-04 02 8.67 8.92 8.52 9.14 8.61 8.9
4.75E-
Dr 18349 1 Al at Janus kinase 1 5.39E-05 03 4.82 4.16 4.91 4.37 4.93 4.27
Dr 18350 1 A1 at Dr 18350 1 Al 8.77E-04 2.92E- 4.4 4.1 5.13 4.24 4.96 4.42
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at 02
1.99E-
Dr 18445 1 Slat zgc:73369 4.90E-04 02 8.73 8.5 8.45 8.32 8.4 8.06
Dr_18461_1_Al 4.40E-
Dr 18461 1 Al at at 1.62E-03 02 6.68 6.69 7.89 6.86 7.56 6.91
5.05E-
Dr 18503 1 Alat zgc:66407 5.80E-05 03 7.23 6.76 7.77 7.07 7.4 6.8
Dr_18544_1_Al 1.89E-
Dr 18544 1 Al at at 4.42E-04 02 5 5.39 5 5 4.98 4.85
2.28E-
Dr 18586 1 S1 at T-box 15 6.04E-04 02 4.64 4.77 4.84 5.49 5.42 5.7
Dr_18623_1_51 4.37E-
Dr 18623 1 S1 at at 1.60E-03 02 5.38 5.27 5.91 5.27 5.64 5.34
Dr 18631_1_51 2.32E-
Dr 18631 1 S1 at at 6.22E-04 02 8.78 7.89 7.5 6.59 7.2 6.38
5.07E-
Dr 18644 1 Al at im:7137769 2.09E-06 04 8.03 7.71 8.5 7.3 7.94 7.27
Dr 18774 1 Al 4.35E-
Dr 18774 1 Al at at 1.59E-03 02 3.47 3.3 3.48 3.31 3.59 3.35
6.64E-
Dr 18865 1 S1 at wu:fi89e03 8.30E-05 03 6.83 7.46 6.65 7.28 6.53 6.92
3.85E-
Dr_1899_2_Alat zgc:85948 1.35E-03 02 9.89 10.1 8.97 9.87 10.2 10.2
1.28E-
Dr 189 1 Al at wu:fa04hl2 8.24E-06 03 3.72 4.14 4.14 4.44 4.23 4.58
procollagen-
proline, 2-
oxoglutarate 4-
dioxygenase
(proline 4-
hydroxylase),
alpha 1.60E-
Dr 19144 1 Alat polypeptide 2 3.27E-04 02 7.69 7.12 7.83 6.98 7.18 6.89
aldolase c,
fructose- 1.13E-
Dr 19223 1_S1_at bisphosphate 1.90E-04 02 6.07 5.75 7.02 6.01 7.21 6.82
aldolase c,
fructose- 7.14E-
Dr_19223_1_S2_at bisphosphate 9.27E-05 03 6.35 5.89 7.97 6.65 8.04 7.44
forkhead box 4.07E-
Dr 19254 1 Al at Clb 1.46E-03 02 7.05 7.28 6.59 6.98 6.61 7.07
3.10E-
Dr 19263 1 51 at wu:fc22h03 9.71E-04 02 7.75 7.77 6.96 7.86 7.48 7.87
1.60E-
Dr 19318 1 Alat zgc:101741 3.26E-04 02 8.53 8.24 8.66 8.35 8.79 8.49
Dr_19402_1_Al 3.78E-
Dr 19402 1 Al at at 3.97E-05 03 5 5.12 7.1 9.39 9.4 10.4
otolith matrix 2.07E-
Dr_19416_1_Slat protein 5.27E-04 02 4.94 4.86 5.1 5.63 5.91 6.55
7.53E-
Dr_19458_1_Alat zgc:100817 1.04E-04 03 6.82 7.11 6.6 7.15 7.25 7.39
Dr_19463_1_Sl 4.99E-
Dr 19463 1 51 at at 2.02E-03 02 9.18 9.27 8.62 9.31 8.98 9.39
family with
sequence
similarity 46, 3.29E-
Dr 19488 1 Al at member C 1.09E-03 02 5.61 5.53 5.64 5.2 5.61 5.38
7.15E-
Dr_19552_1_Slat zgc:76878 9.36E-05 03 7.49 9.36 7.68 9.82 8.55 9.92
Dr 19575_2_Al 1.39E-
Dr 19575 2 Al at at 2.60E-04 02 3.51 3.67 3.47 3.91 3.7 3.97
Dr_19590_2_Al 1.27E-
Dr_19590_2 Ala at a at 2.25E-04 02 4.54 4.54 4.26 4.67 4.25 4.63
Dr 198 1 51 at follistatin 8.27E-04 2.80E- 8.19 7.97 8.37 7.64 8.17 7.04
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02
1.55E-
Dr 198 1 52 at follistatin 3.06E-04 02 7.94 8.03 8.79 7.72 8.89 7.38
3.25E-
Dr_20010_9_Slat zgc:103619 3.17E-05 03 7.42 7.59 7.77 8.46 8.29 8.97
interleukin
enhancer 6.11E-
Dr 20053 2_Alat binding factor 3 7.49E-05 03 10.6 10.8 10.9 10 10.4 10.1
1.65E-
Dr_20083_1_Alat cyclin G2 3.46E-04 02 5.09 5.67 4.9 5.81 5.57 6.3
polo-like kinase 1.09E-
Dr_20131_4_Slat 1 (Drosophila) 2.60E-07 04 10.3 10.4 9.52 10.4 9.99 10.3
1.53E-
Dr_20136_1 51 at wu:fdl4gO4 2.97E-04 02 8.06 6.93 6.66 5.67 5.34 4.92
5.18E-
Dr 20146 2 S1 at wu:fi25h02 6.02E-05 03 6.65 5.8 6.58 5.67 5.94 5.7
3.98E-
Dr 20190 1 S1at zgc:85772 1.41E-03 02 7.67 8.15 7.37 8.32 7.96 8.32
8.51E-
Dr 201 1 Al at wu:fb34c03 1.22E-04 03 5.26 6.12 5.19 6.24 5.73 6.44
3.25E-
Dr 2022 1 Alat arginase, type || 1.04E-03 02 4.65 4.2 4.69 4.07 4.53 4.24
3.26E-
Dr_20230_1_Slat zgc:56451 1.14E-06 04 9.4 10.3 10.1 10.9 10.4 10.8
1.28E-
Dr 20276 1 Al at wu:fb8lh03 8.18E-06 03 4.62 4.44 6.47 4.5 5.52 4.31
2.52E-
Dr 20362 1 Alat zgc:101602 7.OOE-04 02 7.49 7.72 6.79 7.27 7.01 7.28
2.53E-
Dr 20402 1 Al at wu:fb92e05 2.20E-05 03 7.66 7.76 6.78 7.64 7.49 7.57
2.35E-
Dr 20429 2 51 a at wu:fellc02 6.31E-04 02 8.89 8.41 7.42 8.29 7.87 8.28
AU RNA binding
protein/enoyl-
Coenzyme A 2.44E-
Dr_2043_1_Alat hydratase 6.64E-04 02 5.36 6.03 5.53 6.57 6.21 6.88
ciliary
neurotrophic 1.13E-
Dr 20443 1 Alat factor receptor 1.88E-04 02 6.73 6.83 7.69 7.12 7.46 7.07
selenoprotein 1.81E-
Dr_20495_1_S1_at W, 2a 1.31E-05 03 6.92 7.64 5.45 7.87 6.02 7.79
selenoprotein 5.76E-
Dr_20495_2_Alat W, 2a 2.45E-06 04 8.51 9.78 7.15 9.78 8.18 9.8
tumor protein 8.31E-
Dr,2052_1_Slat p5 3  1.74E-07 05 9.97 9.34 10.9 9.14 11 9.17
si:dkey- 1.15E-
Dr 2058 1 Al at 206f10.4 1.96E-04 02 7.19 7.21 6.75 7.24 7 7.21
8.96E-
Dr_2066_1_Alat wu:fb82g12 1.37E-04 03 9.22 9.49 8.5 9.62 8.96 9.05
1.65E-
Dr 2067 1 Al at wu:fb70aO9 3.48E-04 02 8.53 7.23 9.24 8.21 8.91 8.55
ubiquitin
specific 3.93E-
Dr_20720.1_Slat protease 1 1.38E-03 02 8.6 8.61 8.21 8.58 8.47 8.73
2.48E-
Dr 20740 1 Al at wu:fe26clO 6.81E-04 02 5.91 5.59 6.44 5.69 5.86 5.88
8.31E-
Dr_20778_1_Slat zgc:103456 1.78E-07 05 8.65 8.18 9.17 8.38 8.68 8.62
Dr 20814_1_Al 2.44E-
Dr 20814 1 Al at at 6.66E-04 02 6.49 6.67 5.93 6.41 6.14 6.22
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proteasome
(prosome,
macropain)
subunit, alpha 2.78E-
Dr 20872 1_Slat type, 6a 8.13E-04 02 11.1 10.8 11.3 11 10.9 10.6
1.67E-
Dr 20958 1 S1 at deltaD 3.54E-04 02 8.77 8.86 7.69 8.4 7.97 8.69
2.78E-
Dr 20969 1 51 at forkhead box 11 2.42E-08 05 7.35 6.43 7.29 6.05 6.56 5.86
1.13E-
Dr_21044_1_Slat zgc:56005 1.88E-04 02 7.2 6.09 7.88 7.41 8.03 7.56
POU domain 1.18E-
Dr 21068 1_S1_sat gene 1 2.01E-04 02 5 5.54 6.34 7.43 7.18 7.79
8.94E-
Dr_21080_1_Alat wu:fbl8gOl 1.36E-04 03 8.87 9 9.39 8.68 9.13 8.08
1.67E-
Dr 21089 1 Si at wu:fb59aOl 3.69E-09 05 4.68 5.58 4.03 5.33 4.16 5.25
2.78E-
Dr_21399_1_Alat wu:fj64h06 2.24E-08 05 6.1 4.81 6.09 4.14 5.61 4.32
Dr 214 1 Al a 4.60E-
Dr 214 1 Al at t 1.79E-03 02 7.44 7.48 8.04 7.47 7.62 7.48
1.75E-
Dr 2150 1 Al x at wu:fc38c03 3.93E-04 02 9.04 9.01 8.65 9.07 9.03 9.14
1.08E-
Dr 21551 1 Al at wu:fk9lbOl 1.76E-04 02 6.39 6.61 5.83 6.29 6.29 6.45
polo-like kinase 2.OOE-
Dr 2155 1 _S1at 3 (Drosophila) 4.92E-04 02 8.72 8.43 9.3 8.45 8.83 8.45
4.81E-
Dr 2155 2 S1at zgc:110186 1.90E-03 02 9.15 9.28 9.41 9.86 9.73 9.83
1.69E-
Dr 2168 1 Al at wu:fd20gO7 1.18E-05 03 4.9 4.65 5.03 7.5 7.04 8.05
1.55E-
Dr 21782 1 Al at wu:fc55f12 3.08E-04 02 5.36 6.05 6.24 6.93 6.72 6.86
3.72E-
Dr 21808 1 Alat wu:fc44g03 3.87E-05 03 5.8 6.21 6.95 8.32 8.83 9.82
4.43E-
Dr 21825 1 Al at wu:fc68b04 1.64E-03 02 4.95 4.66 4.78 4.31 4.85 4.45
1.67E-
Dr 21935 1 Al at wu:fc84a08 5.77E-09 05 5.01 3.82 6.86 3.53 7.26 3.77
8.03E-
Dr 21979 1 Al at wu:fc92elO 1.55E-07 05 6.97 5.48 7.38 5.22 6.98 5.22
thyroid
transcription 3.27E-
Dr 2198 1 S1 at factor lb 1.06E-03 02 3.92 4.37 3.64 4 3.93 4.13
1.60E-
Dr 22152 1 Al at wu:fd59bOl 3.24E-04 02 6.39 6.07 6.66 6.18 6.58 6.37
1.34E-
Dr_2219_1_Alat zgc:92785 2.46E-04 02 7.21 7.21 7.6 7.14 7.16 7
POU domain 2.17E-
Dr 221 1 51_at gene 47 5.61E-04 02 6.45 7.03 6.84 7.59 7.64 8
Dr 22258_1_Al 3.65E-
Dr 22258 1 Al at at 1.25E-03 02 7.31 7.76 6.68 7.26 6.95 7.17
3.69E-
Dr 22334 1_Slat wu:fj02fO5 1.27E-03 02 5.59 5.5 6.12 5.5 6.35 5.85
3.85E-
Dr 224 1 S1 at T-box gene 6 1.35E-03 02 8.06 8.56 6.55 7.36 6.22 6.49
Dr 22517_1_S1 3.05E-
Dr 22517 1 S1 at at 2.85E-05 03 4.52 3.92 5.62 3.99 5.49 4.5
1.62E-
Dr_22583_1 Slat zgc:91880 3.30E-04 02 6.19 6.37 6 6.11 5.98 6.16
pelota homolog 2.78E-
Dr 2260 1 Slat (Drosophila) 2.69E-08 05 7.98 9.11 7.88 9.23 8.12 8.83
Dr_22619_1_S1 2.93E-
Dr_22619_1_51_at at 8.82E-04 02 4.27 4.35 4.47 4.84 4.77 5.01
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4.02E-
Dr_22717_1_Alat wu:fj44d09 1.43E-03 02 7.71 7.28 7.84 7.32 7.51 7.38
4.45E-
Dr_22753_1_Alat wu:fj49a01 1.66E-03 02 5.8 6.13 6.48 6.74 6.42 6.74
1.55E-
Dr_22795_1_Alat wu:fj56fll 3.04E-04 02 5.03 5.27 4.77 5.42 5.14 5.47
2.75E-
Dr 22937 1 Al at wu:fc23c09 8.01E-04 02 4.25 3.93 5.35 6.75 5.83 6.23
4.54E-
Dr_22980_1_Alat wu:fj8laO7 1.75E-03 02 5.6 5.29 5.47 5.04 5.16 4.69
Dr 23066_1_S1 1.54E-
Dr 23066 1 Si at at 3.00E-04 02 9.14 8.73 9.32 8.85 8.79 8.32
Dr 233851_Al 1.05E-
Dr 23385 1 Al at at 1.69E-04 02 4.73 4.24 5.06 3.9 4.31 3.79
Dr_23386_1_Al 2.19E-
Dr 23386 1 Al at at 5.72E-04 02 3.35 3.21 3.38 3.83 4.18 5.77
2.90E-
Dr 23406 1 S1 at wu:fd50hl2 3.28E-08 05 5.52 5.02 8.08 5.45 7.57 6.12
POU domain 3.23E-
Dr 23454 2_S1_s-at gene 12 1.03E-03 02 4.75 5.05 5.88 6.48 5.78 6.65
9.11E-
Dr 23480 1 Al at bactin2 1.40E-04 03 3.82 3.73 4.08 4.73 4.31 4.96
3.01E-
Dr 23480 2 S1 at bactin2 2.80E-05 03 4.91 5.03 5.21 5.85 5.27 6.25
growth arrest
and DNA-
damage-
inducible, alpha 3.74E-
Dr 23587 1 Al at like 6.03E-08 05 6.59 4.08 7.43 4.1 6.07 4.11
3.28E-
Dr_2363_1_S1_at transgelin 2 1.07E-03 02 11.4 11 10.6 10 9.96 10.1
Dr_236_1_S1_a 7.57E-
Dr 236 1 S1 at t 3.65E-06 04 8.66 7.91 8.85 7.9 8.91 7.6
4.56E-
Dr_23996_1_Alat zgc:112498 1.77E-03 02 6.84 7.03 7.14 7.51 7.53 7.09
matrix
metalloproteina 1.89E-
Dr 2408 1 Al at se 2 1.42E-05 03 5.59 5.2 7.69 6.21 7.83 6.31
matrix
metalloproteina 1.89E-
Dr 2408 2 S1 at se 2 1.40E-05 03 7.47 7.12 9.77 8.1 9.68 8.19
Dr 24183_1_Al 2.78E-
Dr 24183 1 Al at at 8.18E-04 02 8.11 8.01 8.43 8.01 8.3 8.07
linker histone 1.33E-
Dr 24203 1 Si at H1M 2.42E-04 02 7.06 6.41 6.37 5.76 5.65 5.57
inositol
hexaphosphate 1.12E-
Dr 24232 1 Al at kinase 2 1.85E-04 02 7.56 7.87 7.92 8.13 7.99 8.3
2.09E-
Dr 24236 1 S1 at wu:fc55hOl 5.38E-04 02 5.83 6.22 7.59 8.42 8.43 9.15
KIAA0947-like 1.98E-
Dr_24277_1_Alat (H. sapiens) 4.86E-04 02 7.04 6.95 7.35 6.69 6.59 6.26
Dr 24285_1_Al 1.96E-
Dr 24285 1 Al at at 4.75E-04 02 3.95 4.11 4.2 5.09 4.55 4.87
3.OOE-
Dr 24313 1_51 at zgc:56122 9.07E-04 02 6.05 5.75 5.75 5.25 5.43 5.08
Dr 2439_1_Al_ 3.01E-
Dr 2439 1 Al at at 9.21E-04 02 4.22 4.18 3.99 4.5 4.4 4.61
8.17E-
Dr_24628_1_S1_at zgc:55466 4.16E-06 04 6.27 7.11 5.87 6.8 5.9 6.59
1.57E-
Dr_24685_2_Slat zgc:111961 3.16E-04 02 11.4 11.6 11.8 11.8 12.1 12
1.81E-
Dr 24730 1 Al at wu:fi29h06 4.11E-04 02 7.85 7.44 7.65 6.87 6.68 6.4
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3.56E-
Dr 24743 1 Al at wu:fj62c03 1.21E-03 02 4.99 5.22 4.98 5.39 5.25 5.42
thioredoxin
domain
containing 4
(endoplasmic 4.90E-
Dr 2478 1 S1 at reticulum) 1.96E-03 02 8.15 8.84 8.31 8.93 8.38 8.87
1.05E-
Dr_24858_1_Slat zgc:110540 5.92E-06 03 8.32 8.85 7.43 8.59 8.04 8.66
ureidopropiona 3.28E-
Dr 2487 1 Siat se, beta 3.22E-05 03 6.32 5.97 7.84 6.12 7.47 6.16
Dr 24890_1_51 1.98E-
Dr 24890 1 51 at at 4.80E-04 02 4.37 4.64 4.55 6.04 5.73 6.51
origin
recognition
complex,
subunit 6
homolog-like 5.12E-
Dr 24945 1 S1_at (yeast) 5.91E-05 03 6.68 7.38 6.22 7.56 6.85 7.44
4.90E-
Dr 24989 1_Slat zgc:110679 1.96E-03 02 8.9 9.96 11.1 11.9 12.1 12.4
Dr 25140_5_S1 3.79E-
Dr 25140 5 S1 x at x at 1.31E-03 02 8.21 8.56 9.65 10.5 10.8 10.9
WD repeat 1.64E-
Dr 25142 1 S1 at domain 8 4.33E-07 04 5.96 6.52 6.02 6.59 6.04 6.55
valosin
containing 3.01E-
Dr 25189 1 Slat protein 9.25E-04 02 11.3 11.1 11.7 11.3 11.2 10.9
WD repeat 4.54E-
Dr 2528 1 S1 x at domain 3 1.75E-03 02 9.21 8.97 9 8.94 8.77 8.58
4.40E-
Dr 2531 1 Al at wu:fc2lclO 1.65E-06 04 6.48 7.03 6.25 7.12 6.61 7.08
1.32E-
Dr_25337_1_S1_at wu:fclOfOl 2.39E-04 02 8.4 7.84 8.04 7.33 7.53 6.87
1.1OE-
Dr 25337 2 51 a at wu:fclOfOl 6.27E-06 03 8.63 7.92 8.42 7.49 7.81 6.99
2.29E-
Dr 25354 1 Al at wu:fc56dlO 6.09E-04 02 6.28 6.34 6.68 6.22 6.4 6.24
6.88E-
Dr_25378_1_Alat zgc:110540 8.75E-05 03 7.27 7.53 6.34 7.48 7.1 7.52
secreted
frizzled-related 7.14E-
Dr 25534 1 Slat protein 1 9.30E-05 03 7.93 7.51 6.06 7.17 5.72 7.02
4.05E-
Dr 25580 1 51 at wu:fd23c12 1.45E-03 02 7.79 8.04 7.65 8.29 8.04 8.45
Dr_25633_1_S1 2.04E-
Dr_25633_1_51_at -at 5.07E-04 02 5.82 6.42 6.72 7.24 7.28 7.59
9.76E-
Dr 25662 1_Alat zgc:103619 1.53E-04 03 7.2 7.37 7.37 8.12 7.89 8.81
1.67E-
Dr 25683 10 S1 at cathepsin L, b 3.53E-04 02 6.85 7.03 6.58 7.22 7.13 7.65
endothelial
differentiation,
sphingolipid G-
protein-coupled 2.19E-
Dr_25683_5_Alat receptor, 1 5.72E-04 02 6.31 6.53 6.85 7.67 7.59 8.41
7.57E-
Dr_25693_2_Ala at wu:fc26g07 3.62E-06 04 6.06 6.63 5.28 6.55 6.02 6.35
DEAD (Asp-Glu-
Ala-Asp) box 1.68E-
Dr 25720 1 Alat polypeptide 56 3.59E-04 02 9.17 8.71 8.98 8.35 8.59 7.95
2.22E-
Dr_25730_1_Slat zgc:92091 5.85E-04 02 8.39 8.1 9.2 8.53 8.74 8.63
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lamin B 1.59E-
Dr_25745_1_S1_at receptor 1.09E-05 03 8.67 8.82 7.96 8.94 8.72 9.06
Dr_25767_1_51 3.06E-
Dr 25767 1 51 at at 9.49E-04 02 10.7 9.19 9.64 8.61 9.25 8.4
Dr 25767_1_51 1.04E-
Dr 25767 1 S1 x at x at 1.65E-04 02 9.57 8.07 8.59 7.43 8.4 7.19
Dr 26003_1_Al 2.90E-
Dr 26003 1 Al at at 3.93E-08 05 6.55 5.14 6.81 4.89 6.53 4.97
NMDA
receptor-
regulated gene 2.78E-
Dr 2601 1 S1 at la 2.51E-08 05 7.68 9.18 7.51 9.02 7.96 9.11
Dr 26119_1_51 2.03E-
Dr 26119 1 51 at at 1.60E-05 03 4.16 3.93 4.73 4.19 4.88 4.48
phosphoenolpyr
uvate
carboxykinase 1 7.49E-
Dr_26132_1_S1_at (soluble) 1.03E-04 03 3.99 4.07 3.89 4.18 4.17 4.69
Dr 2634 1 Al 3.83E-
Dr 2634 1 Al at at 4.06E-05 03 5.88 6.72 5.98 7.05 6.79 7.34
8.88E-
Dr_26372_1_Alat zgc:112425 1.34E-04 03 5.71 4.77 6.62 4.59 5.67 4.83
1.98E-
Dr 263 2 S1_x_at plasticin 4.84E-04 02 4.02 4.18 4.08 4.46 4.88 4.79
lamin B 1.89E-
Dr_26402_1_Siat receptor 4.41E-04 02 8.83 9.24 8.27 9.32 9.1 9.53
3.29E-
Dr_26474_1_Slat zgc:64227 1.09E-03 02 8.03 7.78 7.92 7.26 7.6 7.29
chromosome 21
open reading 3.18E-
Dr 26477 1 S1 at frame 59-like 3.06E-05 03 7.94 7.58 8.17 6.99 7.12 6.71
2.43E-
Dr 264 1 S1_at gefiltin 6.60E-04 02 4.47 4.97 5.23 5.73 6.02 6.41
ribosomal 1.93E-
Dr 26511 1_S1_at protein L30 1.46E-05 03 10.7 11.3 11 11.6 10.8 11.6
Dr 26546_1_Al 1.02E-
Dr 26546 1 Al at at 1.62E-04 02 7.78 8.21 7.17 7.91 7.47 7.87
retinoblastoma
binding protein 4.19E-
Dr 2741 1 51 at 4 1.52E-03 02 10.4 10.8 10 10.7 10.5 10.7
2.55E-
Dr 2793 1 Al at wu:fc47a08 2.24E-05 03 9.76 9.47 9.95 9.23 9.83 9.27
1.33E-
Dr 2795 1 Alat zgc:110001 1.72E-09 05 6.79 8.69 6.12 8.65 6.64 8.65
5.62E-
Dr_2918_1_S1_at zgc:55387 6.73E-05 03 10.5 10.2 10.5 9.92 10.1 9.67
1.94E-
Dr 2929 2 51 at wu:fb50fO7 1.50E-05 03 6.44 6.75 6.46 7.29 6.93 7.48
2.37E-
Dr_2953_1_Siat zgc:55750 1.29E-08 05 8.28 7.09 8.06 5.81 7.24 5.6
2.09E-
Dr 2993 1 Al at sb:cb547 5.35E-04 02 6.34 5.94 5.86 6.26 6.11 6.68
distal-less
homeobox gene 3.92E-
Dr 2 1 S1 at 2a 1.38E-03 02 6.95 6.34 7.62 7.68 7.82 8.09
3.89E-
Dr 3025 1 Al at wu:fb8OaO7 4.14E-05 03 6.94 7.29 6.01 7.47 7.07 7.9
7.21E-
Dr 3063 1 51 at wu:fb76c12 9.67E-05 03 4.7 5.18 5.61 6.28 6.08 6.42
1.64E-
Dr_3081_1_Alat zgc:63749 3.42E-04 02 4.26 3.89 4.11 3.87 4.14 3.84
4.13E-
Dr 3089 1 Alat zgc:63990 1.48E-03 02 6.71 7.45 7.21 8.13 7.88 8.69
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proteasome
(prosome,
macropain) 26S
subunit, 2.04E-
Dr 3143 1 S1 at ATPase, 3 5.05E-04 02 10.7 10.5 11.2 10.7 10.8 10.4
transforming,
acidic coiled-coil
containing 2.24E-
Dr_3179_1_Alat protein 3 5.93E-04 02 9.09 8.93 8.36 9.03 8.82 8.94
achaete-scute
complex-like lb 2.75E-
Dr 318 1 Alat (Drosophila) 8.02E-04 02 6.69 6.94 6.73 7.45 7.82 8.58
4.49E-
Dr 3224 1 S1 at wu:fc33f12 1.71E-03 02 3.5 3.99 4.6 4.49 4.47 4.58
1.08E-
Dr 3337 1 S1at zgc:111795 1.75E-04 02 9.13 9.22 8.46 9.28 8.91 9.25
ubiquitin fusion
degradation 1- 1.28E-
Dr 3349 1 S1 at like 8.04E-06 03 8.09 7.91 8.79 8.36 8.39 8.06
4.99E-
Dr 3437 1 Al at wu:fbllb09 2.02E-03 02 3.75 3.63 4.27 3.73 4.05 3.7
9.38E-
Dr 3469 1 Al at wu:fblOhO6 1.45E-04 03 7.49 6.95 7.46 6.34 6.57 6.23
2.61E-
Dr 3490 1 Alat zgc:111823 7.42E-04 02 7.67 8 7.52 7.96 7.74 7.78
zinc finger 3.37E-
Dr_3517_1_Slat protein 207, b 1.12E-03 02 9.22 9.75 8.95 9.63 9.04 9.6
denticleless
homolog 2.06E-
Dr_3526_1_Slat (Drosophila) 5.18E-04 02 6.8 7.37 6.6 7.06 6.85 7.17
serine protease
inhibitor, Kunitz 2.44E-
Dr_3549_1_S1_at type 1-like 6.63E-04 02 7.29 7.01 7.6 6.88 7.4 7.08
cystathionase
(cystathionine 1.90E-
Dr 3560 1 Al at gamma-lyase) 4.45E-04 02 8 8.75 7.2 8.2 7.29 7.66
1.89E-
Dr_361_1_Siat selenoprotein H 4.36E-04 02 11.2 11.4 10.7 11.3 11.1 11.4
1.04E-
Dr_3645_1_Slat plasminogen 1.67E-04 02 6.26 6.71 6.57 7.8 8.16 8.63
3.78E-
Dr 3663 1 Al at wu:fb55bll 3.97E-05 03 8.04 9.64 8.98 10.7 10 10.8
2.57E-
Dr 36 1 S2_at sonic hedgehog 7.24E-04 02 7.36 7.76 7.33 7.63 7.65 7.8
2.65E-
Dr 371 1 S1 at sb:cb339 7.65E-04 02 6.44 6.47 8 9.35 9.6 10.1
primase 2.91E-
Dr_377_1_S1_at polypeptide 1 8.70E-04 02 8.31 8.58 8.05 8.89 8.38 8.68
1.98E-
Dr 3785 1 51 at wu:fc39c04 4.85E-04 02 9.37 9.83 10.1 10.5 10.4 10.4
POU domain 2.20E-
Dr_37_2_S1 at gene 12 5.74E-04 02 4.41 4.84 5.38 5.9 5.53 6.1
4.17E-
Dr 3831 1 Al at wu:fc3lbOl 1.51E-03 02 4.7 4.95 4.72 5.16 4.9 5.21
polymerase
(RNA) I 3.56E-
Dr 3838 1 Alat polypeptide C 1.21E-03 02 8.36 8.1 8.19 7.95 7.91 7.55
bcl2-associated 1.81E-
Dr_3880_1_S2_at X protein 1.30E-05 03 9.01 8.16 9.36 7.93 8.94 7.67
3.17E-
Dr_3887_1 S1at zgc:109893 1.OOE-03 02 10.6 10.4 10.7 10.3 10.6 10.4
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wingless-type
MMTV
integration site
family, member 8.94E-
Dr 389 1 Si at 5a 1.36E-04 03 7.25 7.91 6.49 7.09 6.41 6.9
3.27E-
Dr 3918 1 Al at wu:fc64dll 1.05E-03 02 6.8 6.48 7.2 6.39 6.6 6.23
Dr 39391Al 6.48E-
Dr 3939 1 Al at at 8.02E-05 03 6.27 6.62 5.96 7.02 6.59 7.19
erythrocyte
membrane
protein band 2.83E-
Dr 3945 1 Al at 4.1 like 5 8.39E-04 02 7.64 7.92 7.39 7.91 7.47 7.95
4.64E-
Dr_3950_1_Alat wu:fi25cOl 1.81E-03 02 7.68 8 7.68 7.98 7.85 7.99
Dr 3958_1 Al 3.27E-
Dr 3958 1 Al at at 1.06E-03 02 6.94 6.97 6.21 7.07 6.88 6.99
1.92E-
Dr_3966_1_Alat zgc:66052 4.59E-04 02 5.22 6.35 6.58 6.72 7.29 7.09
3.18E-
Dr 3996 1 Alat zgc:101724 3.06E-05 03 9.61 9.47 10.3 9.31 9.58 9.08
1.64E-
Dr 404 1 Al a at wu:fa11a12 3.43E-04 02 6.15 7.06 5.96 6.5 5.84 6.15
3.59E-
Dr 404 1 Al x at wu:fa11a12 3.66E-05 03 4.28 5.36 4.07 4.83 3.89 4.32
1.23E-
Dr 4087 1 Al at nicalin 2.16E-04 02 9.1 8.9 9.75 8.78 9.4 8.78
3.66E-
Dr_4127_1_Ala at zgc:92146 1.26E-03 02 9.2 9.11 8.31 8.92 8.77 8.85
Dr 4160_1_Al 1.63E-
Dr 4160 1 Al at at 3.35E-04 02 5.55 5.78 6.4 7.51 7.75 8.44
protocadherin 2 4.70E-
Dr_418_1_Alat gamma 20 1.84E-03 02 8.22 8.81 9.78 10.1 9.88 10.2
1.80E-
Dr_425,1_Alat zgc:92585 4.08E-04 02 7.88 8.12 7.49 8.06 7.88 8.13
branched chain
aminotransferas
e 2, 3.39E-
Dr 4325 1 Al at mitochondrial 1.13E-03 02 9.06 9.26 8.93 9.4 9.15 9.4
1.63E-
Dr 4338 1 Al at wu:fb99b07 3.38E-04 02 3.46 3.49 3.65 4.06 4.41 4.3
1.89E-
Dr_4350_1 Al at wu:fc02eO4 4.34E-04 02 4.15 4.37 3.76 4.42 4.18 4.44
1.59E-
Dr 4358 1 Al at wu:fclOfOl 1.08E-05 03 8.97 8.38 9.02 8.19 8.47 7.63
replication
factor C 2.53E-
Dr_4387_3_Slat (activator 1) 5 7.04E-04 02 8.34 8.35 7.86 8.56 8.37 8.58
topoisomerase 3.28E-
Dr 4412 19 Sls at (DNA) I alpha 1.07E-03 02 6.53 6.68 5.7 6.88 6.52 7.28
2.71E-
Dr_4416_1_Alat tubulin, beta 5 7.88E-04 02 8.42 8.82 8.94 9.63 9.6 9.89
4.19E-
Dr 4460 1 Al at wu:fc30cO7 4.59E-05 03 7.19 7.79 6.89 7.5 6.92 7.31
4.43E-
Dr 4460 2 S1 at wu:fc30cO7 1.64E-03 02 6.42 7 5.99 6.67 6.16 6.55
2.26E-
Dr 4460 3 S1 at wu:fc30cO7 1.90E-05 03 6 6.67 5.91 6.58 5.87 6.31
glutamyl-prolyl-
tRNA 3.37E-
Dr 4462 1 Alat synthetase 1.12E-03 02 9.64 9.2 10.3 9.78 10.1 9.79
1.28E-
Dr_4468_1_Slat zgc:56602 7.92E-06 03 10.1 9.63 10.7 9.82 10.1 9.36
Dr_4535_1_S1_at zgc:77109 2.12E-04 1.23E- 8.81 8.08 9.54 8.53 9.41 8.7
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02
3.79E-
Dr 4544 1 Si at sb:cb65 1.31E-03 02 8.58 9.03 7.85 8.71 7.98 8.66
5.62E-
Dr_455_1_Alat cyclin F 6.68E-05 03 8.38 8.39 7.64 8.45 8.29 8.5
3.43E-
Dr 45 1 Al at wu:fa0lblO 1.15E-03 02 5.74 5.5 5.8 5.36 5.54 5.07
ATPase, H+
transporting,
lysosomal
accessory 3.44E-
Dr 4628 1 Slat protein 1 3.44E-05 03 5.08 5.98 4.81 6.14 5.55 6.29
4.17E-
Dr_4660_1_Slat zgc:56344 4.51E-05 03 10.6 11 10.3 10.9 10.5 10.5
4.13E-
Dr 466 1 51 at zgc:113194 1.48E-03 02 7.23 7.57 6.69 7.15 6.67 7.04
7.35E-
Dr_4685_1_S1_at zgc:92177 1.OOE-04 03 8.03 8.75 7.94 8.66 7.7 8.21
2.78E-
Dr 4704 1 Alat zgc:101845 8.18E-04 02 8.79 9.01 8.3 8.77 8.36 8.4
3.54E-
Dr 4756 1 Al at wu:fb08fO9 1.20E-03 02 7.03 6.7 6.25 5.81 6.26 5.91
SRY-box
containing gene 1.51E-
Dr 4763 1 S2 at 11a 2.90E-04 02 8.92 9.16 8.67 9.17 8.95 9.45
4.86E-
Dr_4794_2_Slat zgc:66117 1.94E-03 02 5.18 6.2 8.27 9.12 9.27 9.29
ADP-
ribosylation 4.19E-
Dr 4828 1 S1 at factor 1 4.57E-05 03 6.59 7.1 6.12 7.06 6.46 6.84
3.09E-
Dr 4828 2 Al at wu:fc22c07 1.02E-06 04 8.33 9.07 8.32 9.07 8.51 9.02
kelch repeat-
containing 1.24E-
Dr_4833_3_Ala-at protein 7.53E-06 03 8.2 8.5 7.6 8.59 8.47 8.63
1.80E-
Dr 4833 6 51 at annexin Aic 4.06E-04 02 8.23 8.33 7.15 8.46 7.84 8.45
7.35E-
Dr_4833_8_Slat zgc:110727 9.94E-05 03 6.73 7.11 6.04 7.08 6.42 6.85
1.81E-
Dr_4838_1_Alat wu:fb5lgO6 4.90E-07 04 4.31 4.24 4.61 5.56 4.94 5.42
Dr 4859_1_Al_ 4.41E-
Dr 4859 1 Al at at 1.63E-03 02 4.53 5.26 6.52 7.75 8.1 8.04
3.17E-
Dr 4881 1 Al at wu:fb48h07 9.98E-04 02 4.39 4.67 3.74 4.24 3.56 3.7
uncoupling 4.45E-
Dr 4905 1 Slat protein 4 1.67E-03 02 5.45 5.75 5.73 6.7 6.66 7.02
2.05E-
Dr 4913 1 Al at wu:fb76b04 5.12E-04 02 5.01 5.24 4.95 5.62 5.55 5.71
2.80E-
Dr 496 1 S1_at engrailed 2a 8.26E-04 02 6.12 6.34 5.5 6.02 5.74 6.12
2.10E-
Dr 5079 1 S1 at wu:fc02dO2 5.43E-04 02 5.14 5.26 5.03 5.08 5.05 5.4
MCM4
minichromosom
e maintenance
deficient 4,
mitotin (S. 1.26E-
Dr_5091_1_S1_at cerevisiae) 2.22E-04 02 9.74 9.98 9.29 9.97 9.75 10.1
SRY-box
containing gene 2.92E-
Dr 5112 1 S2 at 11b 8.78E-04 02 8.5 8.58 8.4 8.73 8.63 9.17
7.55E-
Dr 5122 1 Slat zgc:77366 1.05E-04 03 9.75 10.6 9.97 10.7 10.7 10.9
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9.55E-
Dr_5122_1_S2_at zgc:77366 1.49E-04 03 9.92 10.5 9.44 10.6 10.2 10.6
6.30E-
Dr_5129.1_Slat zgc:56722 2.80E-06 04 11.1 9.96 11.4 8.96 10.3 9.31
GTP binding 1.29E-
Dr_515.1_Alat protein 1 2.32E-04 02 6.77 7.35 6.77 7.19 6.86 7.37
3.27E-
Dr 5192 1 Al at wu:fc30e03 1.07E-03 02 4.91 5.34 5.15 5.72 5.44 6.11
2.15E-
Dr 519 1_Alat wu:fb50eOl 1.77E-05 03 7.01 8.31 6.75 8.35 6.77 8.53
3.25E-
Dr_522_1_Alat zgc:92593 1.04E-03 02 8.44 8.59 7.8 8.29 7.95 8.19
2.91E-
Dr 5259 1 Si at archain 1 8.71E-04 02 8.26 8.99 8.53 8.79 8.31 8.76
4.03E-
Dr 5260 1 Al at im:6907149 1.44E-03 02 8.58 8.52 9.13 8.6 8.85 8.63
protein tyrosine
phosphatase, 1.44E-
Dr_5278_1_Alat receptor type, N 2.75E-04 02 4.76 5.38 6.57 7.63 7.27 8.04
eph-like kinase 2.65E-
Dr 536 1 51 at 1 7.65E-04 02 7.09 7.15 6.92 7.03 6.82 7.13
8.84E-
Dr_5372_5_Slat zgc:110292 1.30E-04 03 10.7 10.9 10.8 11.2 10.6 11.1
8.23E-
Dr 5372 7 Al x at hairy-related 4 1.18E-04 03 5.12 5.09 4.85 5.23 5.44 5.81
retinal
homeobox gene 4.45E-
Dr 539 1 51 s at 2 1.66E-03 02 5.78 6.26 5.21 5.77 5.25 5.74
7.57E-
Dr 5403 1 Al at sb:cb88 3.65E-06 04 9.94 9.4 9.67 8.89 9.3 8.57
2.52E-
Dr_5406_1_Alat zgc:65952 2.15E-05 03 7.02 7.37 6.78 7.3 7.27 7.34
4.45E-
Dr_5411_1_Slat zgc:55364 1.65E-03 02 3.84 4.15 5.02 6.62 7.39 7.57
topoisomerase 1.70E-
Dr_5418_2_51_at (DNA) II alpha 3.67E-04 02 7.8 8.06 6.69 8.32 7.69 8.47
HLA-B
associated 4.17E-
Dr_5423_1_Alat transcript 1 1.51E-03 02 8.2 7.68 9.53 8.14 8.64 7.83
murine double
minute 2 8.63E-
Dr_542_1_S1_at homolog 2.OOE-07 05 9.9 8.29 10.8 8.17 10.3 8.41
1.02E-
Dr_5431_1_Alat wu:fdl3fO3 1.61E-04 02 7.91 8.4 7.47 8.48 8.14 8.4
proteolipid 5.07E-
Dr_5434_1_S2_at protein la 2.04E-06 04 4.89 5 5.14 6.51 5.76 7.51
proteolipid 6.83E-
Dr_5434_1_S3_at protein la 8.64E-05 03 4.33 5.31 6.07 8.05 7.1 8.59
proteolipid 7.76E-
Dr_5434_1_S4_at protein la 3.85E-06 04 5 5.35 5.53 6.87 5.87 7
glycoprotein 2.19E-
Dr 5434 3 S1 at M6Aa 1.82E-05 03 5.04 5.14 5.27 6.49 6.73 7.53
proteolipid 1.91E-
Dr_5434_9_Alat protein la 4.55E-04 02 3.15 3.13 3.11 3.51 2.99 3.31
3.23E-
Dr 5442 1 Al at df:a0274750 1.03E-03 02 4.79 4.56 4.83 4.51 4.54 4.31
1.31E-
Dr 5464 1 S1at zgc:100972 8.55E-06 03 8.4 7.73 9.08 8.13 8.69 8.25
2.57E-
Dr 5471 1 Al at wu:fb23h04 7.24E-04 02 8.01 7.77 8.04 7.63 7.63 7.29
si:ch2ll- 1.64E-
Dr 5476 1 Al at 51e12.5 3.40E-04 02 7.34 6.8 7.76 7.27 7.78 7.45
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proliferation-
associated 2G4 7.19E-
Dr 5506 1 Alat ,b 9.60E-05 03 10.6 10.8 10.7 11.1 11 11
collagen, type 1, 1.89E-
Dr 5521 1 Slat alpha 2 4.40E-04 02 5.07 5.41 7.08 7.97 8.69 9.61
Dr 55221Si 2.85E-
Dr 5522 1 51 at at 8.46E-04 02 10.2 9.6 9.92 9.26 9.7 9
3.12E-
Dr_5594_1_Slat zgc:56374 9.80E-04 02 11.4 11.3 11.5 11.3 11.2 10.9
2.56E-
Dr 5605 3 51 x at wu:fb40f09 7.16E-04 02 12.5 12.6 12.4 12.9 12.8 12.8
Dr 56291Al 1.87E-
Dr 5629 1 Al at at 1.38E-05 03 7.84 7.62 6.81 7.46 7.03 7.5
cysteine-rich 3.OOE-
Dr_5660_1_S1_at protein 2 9.13E-04 02 6.66 7.13 8.05 9.37 9.75 9.99
bone
morphogenetic 7.10E-
Dr_568_1_S1_at protein 2b 9.16E-05 03 8.26 7.53 7.7 6.76 7.08 6.7
2.65E-
Dr 582 1 Sl a at connexin 43 7.67E-04 02 4.42 4.57 6.87 7.75 7.95 8.31
1.71E-
Dr_5845_1_Alat wu:fjOlaO6 3.76E-04 02 4.22 4.33 4.31 4.81 5.12 5.57
8.31E-
Dr 58 1 Alat zgc:73230 1.88E-07 05 8.11 6.96 8.51 6.46 8.27 6.86
1.12E-
Dr 5925 1 Al at wu:fi04fO9 7.26E-11 06 7.2 5.71 7.6 5.31 7.34 5.48
1.69E-
Dr 5929 1 S1 at wu:fjl7dO5 1.17E-05 03 5.26 5.17 5.82 5.26 5.34 5.1
1.45E-
Dr 6154 1 Al at wu:fjl9dO5 9.57E-06 03 7.26 6.25 8.04 7.64 8.2 7.56
1.12E-
Dr_6174_1_Alat wu:fj39bOl 6.53E-06 03 4.17 4.04 3.91 4.69 4.22 5.27
7.19E-
Dr 6288 1 Slat zgc:56517 9.60E-05 03 8.57 8.45 9.27 8.79 9.54 8.99
2.07E-
Dr_6328_1_Alat wu:fcl5gO4 1.67E-05 03 4.75 5.3 4.82 5.29 5.25 5.57
8.88E-
Dr_6377_1_Alat zgc:63486 1.33E-04 03 5.79 7.02 5.34 7.02 5.47 6.31
3.16E-
Dr_6419_1_Alat wu:fcl9gO3 4.49E-08 05 7.43 6.36 9.23 7.12 8.65 7.26
6.83E-
Dr 6469 1 Al at wu:fj46ell 8.62E-05 03 4.69 5.26 5.12 5.6 4.95 5.6
ferritin, heavy 8.31E-
Dr_6496_2_Alat polypeptide 1 1.84E-07 05 6.92 6.56 7.34 6.29 6.59 5.96
2.06E-
Dr_6498_1_Slat zgc:56179 1.65E-05 03 6.57 6.77 6.05 6.58 6.41 6.58
Dr 65501Al 2.43E-
Dr 6550 1 Al at at 6.59E-04 02 6.38 6.59 6.21 6.81 6.97 7.54
1.21E-
Dr_6653_1_Alat zgc:101690 2.08E-04 02 7.37 6.93 7.29 6.65 6.77 6.73
Ca2+-
dependent
activator
protein for 3.29E-
Dr 6658 1 Al at secretion 2 1.08E-03 02 5.44 5.65 5.42 5.78 5.74 5.9
si:dkeyp- 5.81E-
Dr 6686 2 Al a at 117h8.4 7.08E-05 03 6.66 6.51 5.69 6.35 6.07 6.19
2.17E-
Dr_6709_1_S1_at wu:fjlOeO8 9.81E-09 05 10.2 9.49 10.9 8.48 9.58 7.63
3.27E-
Dr 670 1 Al at wu:fa3lcO6 1.06E-03 02 8.36 8.53 7.69 8.07 7.44 7.9
1.93E-
Dr 6767 1 Alat zgc:55843 1.47E-05 03 6.47 6.3 6.73 5.95 6.25 6.01
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2.04E-
Dr 6782 1 Alat wu:fj55b03 5.07E-04 02 5.89 6.22 6.63 7.17 6.76 7.25
Dr 6786 1Al 2.78E-
Dr 6786 1 Al at at 8.19E-04 02 9.06 9.29 8.56 9.2 8.83 9.01
4.90E-
Dr 6804 1 Al at wu:fd21d08 1.97E-03 02 8.83 8.95 8.9 9.27 9.1 9.41
7.19E-
Dr 681 1 Alat zgc:65909 9.49E-05 03 8.81 8.44 9.09 8.12 8.56 8.24
GTP binding 1.67E-
Dr_6820_1_A1_.at protein 1, like 6.47E-09 05 7.68 6.5 8.82 6.22 8.14 6.34
solute carrier
family 31
(copper
transporters), 9.38E-
Dr 6847 2 S1 at member 1 1.45E-04 03 10.5 10 10.2 9.66 9.59 8.98
1.63E-
Dr 691 1 S1 at wu:fal8b09 3.36E-04 02 8.25 7.73 8.25 7.31 7.39 7.04
M-phase
phosphoprotein
10 (U3 small
nucleolar
ribonucleoprote 1.88E-
Dr_7116_1_S1_at in) 4.31E-04 02 8.55 8.02 8.15 7.53 7.56 6.8
3.06E-
Dr_7164_1_Alat zgc:92668 9.46E-04 02 7.57 7.2 7.68 6.94 7.13 6.75
mitochondrial
carrier homolog 7.93E-
Dr 7215 1 S1 at 2 1.12E-04 03 9.34 9.26 9.78 9.33 9.67 9.37
glutamate-
cysteine ligase, 3.52E-
Dr 7271 1 51 at catalytic subunit 1.19E-03 02 8.33 8.22 8.71 8.37 8.53 8.21
serine
carboxypeptidas 3.52E-
Dr 7306 1 51 at e 1 1.19E-03 02 9.44 9.18 9.18 8.5 8.16 7.46
3.12E-
Dr 7339 1 _S1at cyclin T2 9.81E-04 02 7.71 7.02 7.67 7.06 7.36 6.81
8.59E-
Dr 733 1 Al at wu:fa20fO4 1.24E-04 03 7.06 7.01 6.1 6.58 6.31 6.64
1.44E-
Dr 7344 1_Alat zgc:92063 2.73E-04 02 6.34 7.03 6.76 7.69 6.94 7.36
5.07E-
Dr_7344_2_Ala at zgc:92063 2.06E-06 04 6.7 7.29 6.92 7.69 7.16 7.44
6.97E-
Dr_7344_2_Al at zgc:92063 3.19E-06 04 6.46 6.97 6.43 7.13 6.65 6.89
2.06E-
Dr_7419_1_Alat zgc:113006 5.20E-04 02 6.46 5.96 6.45 5.23 6.04 5.27
3.96E-
Dr_745_1_Alat zgc:56116 1.39E-03 02 7.29 7.12 8.03 7.42 7.64 7.33
5.81E-
Dr 7516 1 Alat zgc:103694 7.05E-05 03 7.78 7.85 6.98 7.54 7.1 7.55
4.64E-
Dr 7525 1 Al at zgc:110154 1.81E-03 02 9.59 9.85 9.59 9.43 9.8 9.25
4.40E-
Dr 7612 1 Alat spil 1.62E-03 02 4.13 4.43 4.89 4.37 4.54 4.35
ADP-
ribosylation 3.60E-
Dr 7615 1 Al at factor-like 10C 3.69E-05 03 6.57 7.06 6.63 7.06 6.71 7.24
calmodulin 2, 1.OOE-
Dr 7638 1 Slat gamma 5.50E-06 03 4.88 5.59 5.03 5.94 5.65 6.97
calmodulin 2, 4.41E-
Dr_7638_1_S2_at gamma 4.86E-05 03 4.97 5.62 5.15 6.28 5.87 7.27
3.09E-
Dr 7668 1 Al at wu:fi04dlO 1.OOE-06 04 6.4 7.6 6.32 7.94 6.56 8.08
Dr_7758_1_Alat zgc:76986 1.66E-03 4.45E- 5.94 5.65 6.17 5.57 5.72 5.48
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02
1.29E-
Dr 7768 1 Alat zgc:85901 2.30E-04 02 6.33 7.22 6.34 7.02 6.13 6.67
2.52E-
Dr_7771_1_Slat zgc:111858 2.18E-05 03 6.07 4.9 5.97 4.67 5.28 4.67
Dr 7787_1_51 2.90E-
Dr 7787 1 Si at at 3.63E-08 05 10.8 9.35 11.5 8.88 11.2 8.86
1.55E-
Dr_7805_1_Slat zgc:55665 1.03E-05 03 8.2 7.11 8.06 7.25 7.57 6.84
Dr 7856_1_Si_ 5.62E-
Dr 7856 1 S1 at at 6.74E-05 03 7.98 8.42 7.62 8.72 7.7 8.39
4.17E-
Dr 7881 1 Al at si:xx-35d8.1 1.51E-03 02 4.29 4.57 3.74 4.33 4.18 4.69
1.29E-
Dr 7882 1 Ala at zgc:91941 2.32E-04 02 6.95 7.75 6.85 7.77 6.75 7.33
1.59E-
Dr 7882 1 Alat zgc:91941 1.07E-05 03 7.07 7.73 7 7.63 6.9 7.32
membrane-
associated ring
finger (C3HC4) 7.19E-
Dr_7894_1_S1_at 5, like 9.58E-05 03 7.07 6.93 7.69 7.2 7.55 7.15
7.06E-
Dr 7926 1 Alat zgc:77199 9.07E-05 03 9.5 9.17 9.47 8.87 9.15 8.62
bridging
integrator 2, 1.14E-
Dr 7929 1 S1 at like 1.93E-04 02 6.48 6.29 6.94 6.37 6.42 6.15
1.05E-
Dr 7989 1 Al at wu:fe06elO 5.87E-06 03 8.18 7.78 8 7.46 7.51 7.26
2.79E-
Dr 79 1 Al at sb:cb382 2.54E-05 03 6.09 5.95 8.91 8.01 9.05 8.57
ribosomal 3.59E-
Dr_8001_6_Sla-at protein S26 1.22E-03 02 12.2 12.4 12.2 12.7 12.4 12.6
frizzled 3.79E-
Dr_8067_1_S1_at homolog 10 1.31E-03 02 9.03 9.34 8.72 9.02 8.51 8.97
developing
brain homeobox 4.45E-
Dr 8072 1 51 at lb 1.67E-03 02 4.63 4.89 4.9 5.5 5.63 5.76
frizzled-related 3.48E-
Dr 8085 1 Slat protein 3.52E-05 03 5.41 3.91 3.67 3.44 3.4 3.44
2.08E-
Dr 8124 1 S1 at crestin 5.32E-04 02 6.68 7.27 7.87 8.85 8.6 8.97
insulin-like
growth factor 2 2.07E-
Dr_8145_1_Slat precursor 5.88E-07 04 8.1 6.77 8.52 6.87 8.24 6.59
faciogenital 1.56E-
Dr_8178_1_S1_at dysplasia 3.1OE-04 02 6.76 7.24 6.87 7.4 7.08 7.35
3.OOE-
Dr 819 1 Al at wu:fa28h03 9.16E-04 02 8.83 8.56 9.03 8.56 8.49 8.65
forkhead box 3.09E-
Dr 8209 1 S2 at 05 9.67E-07 04 8.95 6.6 9.91 7.35 9.34 7.43
chemokine (C-X-
C motif) ligand
12a (stromal
cell-derived 2.06E-
Dr 822 1 S2_at factor 1) 1.63E-05 03 6.21 6.71 5.13 6.08 5.31 5.75
3.15E-
Dr 822 1 S3 at wu:fcl6hl2 2.97E-05 03 7.25 7.94 6.41 7.33 6.67 7.11
muscle-specific
beta 1 integrin 2.71E-
Dr 8283 1 S1 at binding protein 2.44E-05 03 9.92 10.2 8.98 10.2 9.59 9.97
fibrinogen alpha 1.21E-
Dr 845 1 Al at chain 7.17E-06 03 4.32 4.83 5.05 7.28 7.32 8.1
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ubiquitin
carboxyl-
terminal
esterase Li
(ubiquitin 2.06E-
Dr 8724 1 Siat thiolesterase) 5.22E-04 02 6.05 5.5 6.15 5.46 6.32 5.83
2.20E-
Dr 873 1 Al at wu:fb02f03 5.77E-04 02 9.27 9.98 9.33 10.1 9.7 10.1
Dr 9046_1_Al_ 2.58E-
Dr 9046 1 Al at at 7.30E-04 02 4.16 4.33 4.55 4.24 4.5 4.21
zinc finger 2.90E-
Dr_9180_1_Alat protein-like 1 3.43E-08 05 5.05 6.43 5.41 6.35 5.38 6.01
1.23E-
Dr_9196_1_S1_at zgc:55549 2.15E-04 02 7.83 8.14 8.66 8.21 8.82 8.12
timeless
homolog 1.39E-
Dr_921_1_Alat (Drosophila) 2.61E-04 02 7.25 7.86 6.88 7.61 7.23 7.61
splicing factor,
arginine/serine- 3.23E-
Dr_9221_1_S1_at rich, 10 1.03E-03 02 9.18 9.7 9.07 9.41 9.04 9.38
4.81E-
Dr 9236 2 Al at wu:fcl8hll 1.90E-03 02 4.49 4.76 5.5 6.16 6.29 6.29
1.55E-
Dr 923 1 Alat sequestosome 1 3.05E-04 02 7.34 6.9 8.02 7.25 7.78 7.15
2.22E-
Dr 9288 1 S1 at wu:fc2lhO8 5.87E-04 02 5.7 5.92 7.39 6.3 7.26 6.58
Dr 9310_1_Al 1.91E-
Dr 9310 1 Al at at 4.50E-04 02 8.3 8.29 8.27 7.63 7.89 7.43
1.94E-
Dr_9353_1_S1_at zgc:55733 4.65E-04 02 6.19 7.04 7.04 8.37 8.23 8.64
1.89E-
Dr_9366_1_Alat zgc:92505 4.42E-04 02 9.48 8.44 9.15 8.73 9.21 8.57
9.38E-
Dr 9388 1 Al at wu:fc22h03 1.46E-04 03 6.51 6.55 5.96 6.51 6.5 6.69
1.31E-
Dr 938 1 S1 at zgc:56626 2.37E-04 02 7.56 7.29 7.65 7.19 7.45 7.21
4.98E-
Dr_938_2_S1_a-at zgc:56626 2.01E-03 02 5.23 5.1 5.3 4.91 5.14 5.02
zinc finger 4.45E-
Dr_93_1_Ala-at protein 207, a 1.67E-03 02 10.4 10.2 10.2 9.59 9.4 9.35
si:dkey- 3.72E-
Dr 9514 1 Al at 204f11.65 3.84E-05 03 7.81 8.41 8.25 8.78 8.37 8.63
multiple
substrate lipid 4.OOE-
Dr 9556 1 51 at kinase 1.42E-03 02 3.65 4.13 3.71 4.36 3.88 4.16
Dr_9683 1 51 2.17E-
Dr 9683 1 S1 at at 5.64E-04 02 6.72 7.06 6.68 7.56 6.83 7.5
2.10E-
Dr 9704 1 Al at wu:fk26h02 1.72E-05 03 8.41 8.81 8.38 9.03 8.66 8.97
2.68E-
Dr_9743_2_S1_a-at zgc:101854 7.77E-04 02 11.1 11 10.3 10.8 10.3 10.6
8.84E-
Dr 9746 7 Al at wu:fc5lfO4 4.62E-06 04 10.5 10.7 9.86 10.8 10.2 10.8
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To add a further level of robustness to our model, gene transcripts were investigated
using a modified t-test, the R version of CyberT. Using this conservative t-test, transcripts were
defined as significantly regulated between mutant and control if they had a P-value below 0.01
and had a |mean fold change| of greater than or equal to two between NDST1 morphant vs.
control, shown in Tables 3A and 3B. Differential transcripts analyzed by this method were
considered only if they were identified using both RMA and Mas5 normalization methods.
Similar to the ANOVA results, the 20S stage had the most genes "regulated" by the NDST1
knockdown. 28 gene transcripts are regulated for all three time points with p-values below 0.0
and fold changes greater than two, shown in Table 3A. Table 3B displays regulated transcripts
for individual developmental stages designated with Affymetrix IDs.
Table 3A CyberT transcripts P<0.01
Affymetrix ID transcript Average Fold Change- Average Fold Change-
Mas5 RMA
Dr.11242.1.A1_at pleckstrin A3 8.31107438 7.142879315
Dr.12986.1.A1 a at FOS 12.98552339 5.882362088
Dr.12986.1.A1 at FOS 5.658322904 3.580107475
Dr.15033.1.S1_at NA 3.284860454 3.317206271
Dr.15150.1.A1_at PARP3 3.38258317 2.924472353
Dr.15781.1.S1_at vaccinia-related kinase 2 4.144766147 2.845678705
Dr.17659.1.S1_at membrane protein, 15.69223907 6.819752667
palmitoylated 1
Dr.19552.1.S1_at importin 7 0.285622907 0.311503918
Dr.20495.2.A1_at selenoprotein W, 2a 0.283048294 0.309335343
Dr.21979.1.A1 at wu:fc92el0 3.52747678 3.570554333
Dr.23587.1.A1_at GADD45 9.916073969 6.85496079
Dr.25767.1.S1_at NA 2.428031067 2.275016401
Dr.26003.1.A1 at NA 6.486144101 3.117610127
Dr.2601.1.S1_at NMDA receptor- 0.376035692 0.386424879
regulated gene 1a
Dr.2795.1.A1_at SWI/SNF chromatin 0.210819411 0.232190116
regulator
Dr.2953.1. S1at Ras-like family 11 3.07112232 3.009433352
Dr.519.1.A1_at NA 0.330687831 0.356304669
Dr.542.1.S1 at MDM2 4.600951684 4.198799974
Dr.58.1.A1_at Pl3Kinase related 3.293170103 2.899185161
Dr.5925.1.A1_at NA 4.880790611 3.687013956
Dr.6820.1.Alat GTP Binding protein 1 5.466729147 3.81620217
Dr.7668.1.A1 at NA 0.234720272 0.361524694
Dr.7787.1.S1_at ribosomal protein S27 4.742320073 4.327828857
Dr.8145.1.S1 at IGF2 2.870026972 2.954819643
Dr.8209.1.S2 at Foxo5 5.913491568 4.914263842
Dr.10334.1.S1_at Caspase8 13.90100671 5.46548094
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Table 3B CyberT transcripts P<0.01
MasS 6somite Mas5 20ssomite Mas5 24hrs RMA 6somite RMA 20somite RMA 24hrs
Dr.11242.1.Al-at Dr.21935.1.Al-at Dr.21935.1.Al-at Dr.21935.1.Al-at Dr.21935.1.Al-at Dr.21935.1.Al-at
Dr.17659.1.Sl-at Dr.11242.1.Al-at Dr.11242.1.Al-at Dr.11242.1.Al-at Dr.11242.1.Al-at Dr.11242.1.Al-at
Dr.23587.1.Al-at Dr.17659.1.Sl-at Dr.17659.1.Sl-at Dr.17659.1.Sl-at Dr.17659.1.Sl-at Dr.17659.1.Sl-at
Dr.10334.1.Sl-at Dr.23587.1.Al-at Dr.23587.1.Al-at Dr.23587.1.Al-at Dr.23587.1.Al-at Dr.23587.1.Al-at
Dr.12986.1.Al-a-at Dr.10334.1.Sl-at Dr.10334.1.Sl-at Dr.10334.1.Sl-at Dr.10334.1.Sl-at Dr.10334.1.Sl-at
Dr.8209.1.S2 - at Dr.12986.1.Al - a - at Dr.12986.1.Al-a-at Dr.12986.1.Al-a-at Dr.12986.1.Al-a-at Dr.12986.1.Al-a-at
Dr.7787.1.Sl-at Dr.8209.1.S2-at Dr.8209.1.S2-at Dr.8209.1.S2-at Dr.8209.1.S2-at Dr.8209.1.S2-at
Dr.2795.1.Al-at Dr.7787.1.Sl-at Dr.7787.1.Sl-at Dr.7787.1.Sl-at Dr.7787.1.Sl-at Dr.7787.1.Sl-at
Dr.542.1.Sl-at Dr.2795.1.Al-at Dr.2795.1.Al-at Dr.2795.1.Al-at Dr.2795.1.Al-at Dr.2795.1.Al-at
Dr.20495.2.Al-at Dr.542.1.Sl-at Dr.542.1.Sl-at Dr.542.1.Sl-at Dr.542.1.51-at Dr.542.1.51-at
Dr.6820.1.Al-at Dr.11479.1.Al-at Dr.11479.1.Al-at Dr.20495.2.Al-at Dr.11479.1.Al-at Dr.11479.1.Al-at
Dr.5925.1.Al-at Dr.20495.2.Al-at Dr.20495.2.Al-at Dr.6820.1.Al-at Dr.20495.2.Al-at Dr.20495.2.Al-at
Dr.21979.1.Al-at Dr.6820.1.Al-at Dr.6820.1.Al - at Dr.5925.1.Al-at Dr.6820.1.Al-at Dr.6820.1.Al-at
Dr.15033.1.51 - at Dr.23406.1.Sl-at Dr.23406.1.51-at Dr.21979.1.Al-at Dr.23406.1.51-at Dr.23406.1.Sl-at
Dr.19552.1.51-at Dr.5925.1.Al-at Dr.5925.1.Al-at Dr.15033.1.Sl-at Dr.5925.1.Al-at Dr.5925.1.Al-at
Dr.12986.1.Al-at Dr.10914.1.Al-at Dr.10914.1.Al-at Dr.6419.1.Al-at Dr.10914.1.Al-at Dr.10914.1.Al-at
Dr.26003.1.Al-at Dr.21979.1.Al-at Dr.21979.1.Al-at Dr.19552.1.Sl-at Dr.21979.1.Al-at Dr.21979.1.Al-at
Dr.2953.1.Sl-at Dr.20495.1.Sl-at Dr.20495.1.Sl-at Dr.12986.1.Al-at Dr.20495.1.Sl-at Dr.20495.1.Sl-at
Dr.12986.3.Sl-a-at Dr.11481.1.Al-at Dr.11481.1.Al-at Dr.26003.1.Al-at Dr.11481.1.Al-at Dr.11481.1.Al-at
Dr.5129.1.Sl - at Dr.15033.1.Sl-at Dr.15033.1.Sl-at Dr.2953.1.51-at Dr.15033.1.Sl-at Dr.15033.1.Sl-at
Dr.15150.1.Al-at Dr.6419.1.Al-at Dr.6419.1.Al-at Dr.12986.3.Sl-a-at Dr.6419.1.Al-at Dr.6419.1.Al-at
Dr.58.1.Al-at Dr.6709.1.Sl-at Dr.6709.1.51-at Dr.5129.1.Sl-at Dr.6709.1.Sl-at Dr.6709.1.51-at
Dr.8145.1.Sl at Dr.19552.1.Sl-at Dr.19552.1.Sl-at Dr.15150.1.Al-at Dr.19552.1.Sl-at Dr.19552.1.Sl-at
Dr.15781.1.Sl-at Dr.12986.1.Al-at Dr.12986.1.Al-at Dr.58.1.Al-at Dr.12986.1.Al-at Dr.12986.1.Al-at
Dr.519.1.Al-at Dr.26003.1.Al-at Dr.26003.1.Al-at Dr.8145.1.Sl-at Dr.26003.1.Al-at Dr.26003.1.Al-at
Dr.25536.1.Al-at Dr.2953.1.Sl-at Dr.2953.1.Sl-at Dr.15781.1.Sl-at Dr.2953.1.Sl-at Dr.2953.1.Sl-at
Dr.21399.1.Al-at Dr.19794.1.Al-at Dr.19794.1.Al-at Dr.519.1.Al-at Dr.19794.1.Al-at Dr.19794.1.Al-at
Dr.610.2.Sl-at Dr.12986.3.Sl-a-at Dr.12986.3.51-a-at Dr.25536.1.Al-at Dr.12986.3.Sl-a-at Dr.12986.3.Sl-a-at
Dr.6337.1.51 at Dr.5129.1.Sl-at Dr.15150.1.Al-at Dr.21399.1.Al-at Dr.5129.1.51-at Dr.15150.1.Al-at
Dr.7668.1.Al - at Dr.15150.1.Al-at Dr.58.1.Al-at Dr.610.2.Sl-at Dr.15150.1.Al-at Dr.58.1.Al-at
Dr.26372.1.Al-at Dr.58.1.Al-at Dr.8145.1.Sl-at Dr.6337.1.Sl-at Dr.58.1.Al-at Dr.8145.1.Sl-at
Dr.2601.1.Sl-at Dr.8145.1.Sl-at Dr.15781.1.Sl-at Dr.7668.1.Al-at Dr.8145.1.Sl-at Dr.15781.1.Sl-at
Dr.10257.1.Al - at Dr.15781.1.Sl-at Dr.519.1.Al-at Dr.2601.1.Sl-at Dr.15781.1.Sl-at Dr.519.1.A-l-at
Dr.12458.1.Al-at Dr.519.1.Al-at Dr.2052.1.Sl-at Dr.12458.1.Al-at Dr.519.1.Al-at Dr.2052.1.Sl-at
Dr.6377.1.Al-at Dr.2052.1.Sl-at Dr.21399.1.Al-at Dr.20198.1.Sl-a-at Dr.2052.1.Sl-at Dr.21399.1.Al-at
Dr.1142.1.Al-at Dr.25536.1.Al-at Dr.2408.2.Sl-at Dr.6377.1.Al-at Dr.25536.1.Al-at Dr.2408.2.51-at
Dr.3663.1.Al-at Dr.21399.1.Al-at Dr.7668.1.Al-at Dr.1142.1.Al-at Dr.21399.1.Al-at Dr.7668.1.Al-at
Dr.20198.2.Sl-x-at Dr.12386.2.Sl-a-at Dr.26372.1.Al-at Dr.3663.1.Al-at Dr.12386.2.Sl-a-at Dr.20276.1.Al-at
Dr.17100.1.Al-at Dr.2408.2.Sl-at Dr.20276.1.Al-at Dr.20198.2.Sl-x-at Dr.2408.2.Sl-at Dr.2408.1.Al-at
Dr.2260.1.Sl-at Dr.610.2.Sl-at Dr.2408.1.Al-at Dr.10141.1.Al-at Dr.610.2.Sl-at Dr.2601.1.Sl-at
Dr.25767.1.Sl-x-at Dr.6337.1.Sl-at Dr.2601.1.Sl-at Dr.17100.1.Al-at Dr.6337.1.Sl-at Dr.10257.1.Al-at
Dr.1658.1.Al - at Dr.7668.1.Al-at Dr.10257.1.Al - at Dr.2260.1.Sl-at Dr.7668.1.Al-at Dr.12458.1.Al-at
Dr.12986.2.Sl-at Dr.26372.1.Al-at Dr.12458.1.Al-at Dr.25767.1.Sl-x-at Dr.26372.1.Al-at Dr.2487.1.Sl-at
Dr.11520.1.Sl-at Dr.20276.1.Al-at Dr.6377.1.Al-at Dr.1658.1.Al-at Dr.20276.1.Al-at Dr.1212.1.Sl-at
Dr.19223.1.S2-at Dr.2408.1.Al-at Dr.2487.1.Sl-at Dr.1316-8.1.Sl-at Dr.2408.1.Al-at Dr.22517.1.Sl-at
Dr.14673.2.Sl-at Dr.2601.1.Sl-at Dr.1212.1.51-at Dr.12986.2.Sl-at Dr.2601.1.Sl-at Dr.13633.1.Al-at
Dr.7771.1.51-at Dr.10257.1.Al-at Dr.22517.1.Sl-at Dr.7771.1.Sl-at Dr.10257.1.Al-at Dr.3880.1.S2-at
Dr.2067.1.Al-at Dr.12458.1.Al-at Dr.3663.1.Al-at Dr.2067.1.Al-at Dr.12458.1.Al - at Dr.5434.1.53 ::: at
Dr.11520.3.Sl-a-at Dr.20198.1.Sl-a-at Dr.13633.1.Al-at Dr.24146.1.Sl-at Dr.20198.1.Sl-a-at Dr.21089.1.Sl-at
Dr.11520.2.Sl-a-at Dr.6377.1.Al-at Dr.3880.1.S2 at Dr.25767.1.Sl-at Dr.6377.1.Al-at Dr.4103.1.Al-at
Dr.7638.1.S2-at Dr.2487.1.Sl-at Dr.5434.1.S3-at Dr.9180.1.Al-at Dr.2487.1.Sl-at Dr.10141.1.Al-at
Dr.13826.1.Al-at Dr.1212.1.Sl at Dr.16350.1.Al-at 1 Pr.7805.1.Sl at Dr.1212.1.Sl-at Dr.14160.1.Al-at--]
Dr.24146.1.Sl-at Dr.22517.1.51-at Dr.13863.1.Sl-at Dr.404.1.Al-x-at Dr.22517.1.Sl-at Dr.25767.1.Sl-x-at
Dr.11310.2.Sl-at Dr.1142.1.Al-at Dr.21089.1.Sl-at Dr.6154.1.Al-at Dr.1142.1.Al-at Dr.13863.2.Al-at
Dr.18238.1.Al-at Dr.3663.1.Al-at Dr.4103.1.Al-at Dr.21044.1.Sl-at Dr.3663.1.Al-at Dr.14673.2.Sl-at
Dr.20969.1.Sl-at Dr.13633.1.Al-at Dr.10141.1.Al-at Dr.4572.1.Sl-at Dr.13633.1.Al-at Dr.5434.1.S2-at
Dr.25767.1.Sl-at Dr.3880.1.S2-at Dr.25767.1.Sl-x-at Dr.13604.1.Sl-at Dr.3880.1.S2-at Dr.236.1.Sl-at
Dr.9180.1.Al-at Dr.5434.1.S3 at Dr.13863.2.Al-at Dr.9366.1.Al-at Dr.5434.1.S3-at Dr.7638.1.S2-at
Dr.201.1.Al-at Dr.20198.2.51-x-at Dr.12986.2.Sl-at Dr.17740.2.Al-at Dr.20198.2.Sl-x-at Dr.25534.1.51-at
Dr.7805.1.Sl-at Dr.13863.1.Sl-at Dr.14673.2.Sl-at Dr.20136.1.Sl-at Dr.16350.1.Al-at Dr.198.1.S2-at
Dr.17357.1.Al-at Dr.21089.1.Sl-at Dr.7771.1.Sl-at Dr.17891.1.Sl-at Dr.13863.1.Sl-at Dr.7638.1.Sl-at
Dr.404.1.Al-x-at Dr.13058.1.Al-at Dr.2970.1.Sl - at Dr.24989.1.Sl-at Dr.21089.1.Sl-at Dr.5434.1.S4-at
Dr.21044.1.Sl-at Dr.4103.1.Al-at Dr.13750.1.Sl - at Dr.8085.1.Sl-at Dr.13058.1.Al-at Dr.19402.1.Al-at
Dr.11310.2.Sl - x - at Dr.10141.1.Al-at Dr.5434.1.S2-at Dr.5462.1.Sl-at Dr.10141.1.Al-at Dr.17437.1.51-at
Dr.14673.1.Al-at Dr.17100.1.Al-at Dr.236.1.Sl-at Dr.11590.1.Al-s-at Dr.17100.1.Al-at Dr.20850.1.Sl-at
Dr.19223.1.Sl-at Dr.5423.1.Al-at Dr.12713.1.Sl - at Dr.159.1.Al-at Dr.5423.1.Al-at Dr.198.1.Sl-at
Dr.8209.1.Sl-at Dr.2260.1.Sl-at Dr.10389.1.Al-at Dr.3966.1.Al-at Dr.2260.1.Sl-at Dr.17912.1.Sl-at
Dr.10244.1.Sl-at Dr.14160.1.Al-at Dr.7638.1.S2-at Dr.8472.1.Sl-at Dr.14160.1.Al - at Dr.21080.1.Al-at
Dr.11310.1.Sl-at Dr.25767.1.Sl-x-at Dr.24146.1.Sl-at Dr.26487.1.Sl-at Dr.25767.1.Sl-x-at Dr.6174.1.Al-at
Dr.20850.1.Sl-at Dr.2168.1.Al-at Dr.18238.1.Al-at Dr.4837.1.Al-at Dr.2168.1.Al-at Dr.23386.1.Al - at
Dr.7768.1.Al-at Dr.1658.1.Al-at Dr.25534.1.Sl-at Dr.5549.1.Sl-at Dr.1658.1.Al-at Dr.10314.1.51-a-at
Dr.13604.1.51-at Dr.13168.1.Sl-at Dr.198.1.S2-at Dr.4200.1.Al-at Dr.13168.1.51-at Dr.20010.14.Sl-at
Dr.20146.2.Sl-at Dr.13050.1.Sl-at Dr.7638.1.Sl-at Dr.13050.1.51-at DrAffx.1.80.Sl-at
Dr.9366.1.Al-at Dr.5418.2.Sl - at Dr.16749.1.Al-at Dr.5418.2.Sl-at
Dr.18349.1.Al-at Dr.13863.2.Al-at Dr.201.1.Al-at Dr.13863.2.Al-at
Dr.381.1.Al-at Dr.845.1.Al-at Dr.10648.1.Sl - at Dr.845.1.Al-at
Dr.404.1.Al-a-at Dr.12986.2.51-at Dr.5434.1.S4-at Dr.12986.2.Sl - at
Dr.18865.1.Sl - at Dr.11520.1.51 - at Dr.16522.1.Al-at Dr.11520.1.Sl-at
Dr.7882.1.Al-at Dr.19223.1.52-at Dr.4412.19.Sl-s-at Dr.19223.1.S2-at
Dr.5278.1.Al-at Dr.14673.2.Sl-at Dr.14414.2.Sl-at Dr.14673.2.Sl-at
Dr.57.1.Sl-at Dr.7771.1.Sl-at Dr.10085.2.Sl-a-at Dr.7771.1.Sl-at
Dr.8614.1.Al-at Dr.2067.1.Al-at Dr.17459.1.51 - a - at Dr.2067.1.Al-at
Dr.14482.1.Al - at Dr.3025.1.Al-at Dr.17437.1.Sl-at Dr.3025.1.Al-at
Dr.17394.2.Sl-at Dr.16127.1.Sl-at Dr.14673.1.Al - at Dr.16127.1.51-at
Dr.8124.1.Sl-at Dr.13750.1.Sl-at Dr.20850.1.Sl-at Dr.13750.1.Sl-at
Dr.16164.1.Al-at Dr.5434.1.S2-at Dr.389.1.Sl-at Dr.5434.1.S2-at
Dr.3063.1.Sl-at Dr.11520.3.Sl-a-at Dr.198.1.Sl-at Dr.11520.3.Sl-a-at
Dr.24989.1.Sl-at Dr.236.1.Sl-at Dr.5434.3.Sl-at Dr.4628.1.Sl-at
Dr.20815.1.Sl-at Dr.4628.1.Sl-at Dr.1288.1.Al-at Dr.12713.1.Sl-at
Dr.16595.1.Sl-at Dr.12713.1.Sl-at Dr.17896.2.Al-at Dr.10389.1.Al-at
Dr.24313.1.Sl - at Dr.10389.1.Al-at Dr.18631.2.Al-at Dr.11520.2.Sl-a-at
Dr.8085.1.Sl-at Dr.11520.2.Sl-a-at Dr.17912.1.Sl-at Dr.10624.1.Sl-at
Dr.15964.1.Al-at Dr.10624.1.Sl-at Dr.21080.1.Al-at Dr.7638.1.S2-at
Dr.17137.1.Sl-at Dr.7638.1.S2-at Dr.539.1.Sl-s-at Dr.13826.1.Al-at
Dr.11590.1.Al - s - at Dr.13-826.1.Al-at Dr.6174.1.Al-at Dr.11310.2.Sl-at
Dr.159.1.Al-at Dr.24146.1.Sl-at Dr.23386.1.Al - at Dr.24945.1.Sl-at
Dr.815.1.Sl-x-at Dr.11310.2.Sl-at Dr.25337.1.Sl-at Dr.18238.1.Al-at
Dr.5555.1.Sl-at Dr.24945.1.Sl-at Dr.17717.1.Al-at DrAffx.1.46.Sl-at
Dr.3966.1.Al-at Dr.18238.1.Al-at Dr.10314.1.Sl-a-at Dr.25534.1.Sl-at
Dr.4794.2.Sl-at DrAffx.1.46.Sl-at Dr.14456.1.Al-at Dr.20969.1.Sl-at
Dr.815.1.Sl-at Dr.25534.1.Sl-at Dr.26439.1.Sl-at Dr.25767.1.Sl-at
Dr.25468.1.Al-at Dr.20969.1.Sl-at Dr.23480.2.51-at Dr.4535.1.Sl-at
Dr.8192.1.Sl - at Dr.25767.1.Sl-at Dr.24764.1.Sl-at Dr.198.1.S2-at
Dr.34.1.Sl-at Dr.4535.1.Sl-at Dr.20010.14.51at Dr.10504.1.Al-at
Dr.4794.1.Al-at Dr.198.1.S2-at Dr.546.1.Sl-at Dr.24858.1.Sl-at
Dr.20971.1.S2-at Dr.7638.1.Sl-at Dr.17890.2.Al-at Dr.16749.1.Al-at
Dr.1450.1.Sl-at Dr.10504.1.Al-at Dr.23454.2.Sl-s-at Dr.1691.6.Al-at
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Dr.24554.1.Al-at Dr.24858.1.Sl-at Dr.12036.1.Al-at Dr.10602.1.Al-at
Dr.4887.1.Al-at Dr.16749.1.Al-at Dr.14702.1.Al-at Dr.14783.1.Sl-at
Dr.24923.2.Al-at Dr.1691.6.Al-at Dr.23480.1.Al-at Dr.1194.1.Sl-at
Dr.1543.1.51-at Dr.10602.1.Al-at Dr.12.1.Sl-at Dr.201.1.Al-at
Dr.4837.1.Al-at Dr.14783.1.Sl-at Dr.24222.1.Al-at Dr.8208.1.Sl-at
Dr.5342.1.Al-at Dr.1194.1.Sl-at Dr.26132.1.Sl-at Dr.25693.2.Al-a-at
Dr.2499.1.Sl-at Dr.201.1.Al-at DrAffx.1.80.Sl-at Dr.4833.6.Sl-at
Dr.11071.1.Al - at Dr.8208.1.Sl-at Dr.12.1.S2 - at Dr.2204.1.Al-at
Dr.11214.1.Al-at Dr.25693.2.Al-a-at Dr.10610.1.Al-at Dr.5434.1.S4-at
Dr.6531.1.Al-at Dr.4833.6.Sl at Dr.25770.4.Al-at Dr.19402.1.Al-at
Dr.5549.1.Sl-at Dr.2204.1.Al-at Dr.6502.1.Al-at Dr.3560.1.Al-at
Dr.7206.1.Al-at Dr.5434.1.S4-at Dr.5461.1.Al-at Dr.17008.1.Al-at
Dr.3224.1.51-at Dr.19402.1.Al-at Dr.15295.1.Al-at Dr.17738.1.Sl-at
Dr.4681.1.Al - at Dr.3560.1.Al-at Dr.3554.1.Al-at Dr.7419.1.Al-at
Dr.19575.1.Sl - at Dr.17008.1.Al-at Dr.16262.1.Al-at Dr.4412.19.Sl-s-at
Dr.560.1.Sl-at Dr.17738.1.Sl-at DrAffx.2.73.Sl-at Dr.14467.1.Al-at
Dr.12704.1.Al - at Dr.7419.1.Al-at Dr.26202.1.Al-at Dr.5122.1.S2-at
Dr.14283.1.Sl-at Dr.4412.19.51-s-at Dr.25714.1.Al-at Dr.2634.1.Al-at
Dr.17587.1.Al - at Dr.14467.1.Al-at Dr.13073.1.Sl-at Dr.24890.1.51-at
Dr.4200.1.Al-at Dr.5122.1.S2-at Dr.26505.2.Sl-at Dr.7856.1.Sl-at
Dr.9933.1.Sl-at Dr.2634.1.Al-at Dr.25504.1.Al-at Dr.11244.1.Sl-at
Dr.15967.1.Al-at Dr.24890.1.Sl-at Dr.18295.1.Sl-a-at Dr.18644.1.Al-at
Dr.7856.1.Sl-at Dr.142SO.l.Sl-at Dr.9288.1.Sl-at
Dr.15869.1.Al-at Dr.1565.1.Sl-at Dr.17357.1.Al-at
Dr.11244.1.51-at Dr.25932.1.Al-at Dr.23385.1.Al-at
Dr.822.1.S2-at Dr.14033.1.Al-at Dr.8283.1.Sl-at
Dr.18644.1.Al-at Dr.14286.3.Al-at Dr.12365.1.Al-at
Dr.9288.1.Sl-at Dr.22142.1.Al-at Dr.179.1.Sl-at
Dr.224.1.Sl-at Dr.20553.2.Al-x-at Dr.17841.3.Al-at
Dr.17357.1.Al-at Dr.6933.1.Al-at
Dr.23385.1.Al-at Dr.25378.1.Al-at
Dr.404.1.Al-x-at Dr.11310.2.Sl-x-at
Dr.8283.1.Sl-at Dr.4833.8.Sl-at
Dr.6208.1.Al-at Dr.2043.1.Al-at
Dr.26388.1.51-at Dr.18461.1.Al-at
Dr.12365.1.Al-at Dr.372.1.Sl-at
Dr.179.1.Sl-at Dr.18025.1.Al-at
Dr.17841.3.Al-at Dr.6496.2.Al-at
Dr.25337.2.Sl-a-at Dr.1689.2.Al-a-at
Dr.26414.1.Sl-x-at Dr.3939.1.Al-at
Dr.25378.1.Al-at Dr.19223.1.Sl-at
Dr.17437.1.Sl-at Dr.21808.1.Al-at
Dr.11310.2.Sl-x-at Dr.26402.1.Sl-at
Dr.4833.8.Sl-at Dr.9353.1.Sl-at
Dr.2043.1.Al-at Dr.9240.1.Al-at
Dr.18461.1.Al-at Dr.6923.1.Sl-at
Dr.20083.1.Al-at Dr.18230.1.Al-at
Dr.372.1.Sl-at DrAffx.2.16.Sl-at
Dr.18025.1.Al-at Dr.10742.2.51-a-at
Dr.1689.2.Al-a-at Dr.9654.1.Al-at
Dr.14673.1.Al-at Dr.11310.1.Sl-at
Dr.12555.1.Sl-at Dr.20850.1.Sl - at
Dr.3939.1.Al-at Dr.4572.1.Sl-at
Dr.19223.1.Sl-at Dr.17935.1.Sl-at
Dr.21808.1.Al-at Dr.26477.1.Sl-at
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Dr.8209.1.Sl-at Dr.2S548.1.Sl-at
Dr.9353.1.Sl-at Dr.20131.2.Al-at
Dr.9240.1.Al-at Dr.5431.1.Al-at
Dr.1691.1.Sl-at Dr.25542.1.Al-at
Dr.9746.1.Sl-a-at Dr.3469.1.Al-at
Dr.18230.1.Al-at Dr.3645.1.Sl-at
Dr.3089.1.Al at Dr.3996.1.Al-at
DrAffx.2.16.Sl-at Dr.5434.3.Sl-at
Dr.11447.1.Al-at Dr.24320.1.Sl-at
Dr.10742.2.Sl-a-at Dr.2066.1.Al-at
Dr.18350.1.Al-at Dr.133.1.Al-at
Dr.10244.1.Sl-at DrAffx.1.52.51-at
Dr.9654.1.Al-at Dr.20136.1.Sl-at
Dr.16273.1.Sl at Dr.17462.1.Sl-at
Dr.2960.1.Al-at Dr.1632.1.Al-at
Dr.11310.1.Sl-at Dr.26116.1.Sl-at
Dr.4087.1.Al-at Dr.7722.1.Al-at
Dr.20850.1.Sl at Dr.4160.1.Al-at
Dr.6819.1.Al-at Dr.4925.1.Sl-x-at
Dr.7768.1.Al-at Dr.5278.1.Al-at
Dr.17394.1.Al at Dr.1435.1.Sl-at
Dr.17935.1.Sl-at Dr.2452.1.Al - at
Dr.17146.1.Al-at Dr.21068.1.Sl s at
DrAffx.2.64.51-at Dr.4827.1.Al-x-at
Dr.26477.1.Sl-at Dr.5411.1.Sl-at
Dr.25548.1.Sl-at Dr.2452.2.Al x at
Dr.20131.2.Al-at Dr.20821.1.Al-at
Dr.179.1.S2-at Dr.5660.1.Sl-at
Dr.10051.1.Al-at Dr.1015.1.Al-at
Dr.5431.1.Al-at Dr.11590.1.Al-at
Dr.25542.1.Al-at Dr.25624.1.51-at
Dr.18631.1.Sl-at Dr.1250.1.Al-at
Dr.3469.1.Al at Dr.1837.1.Al-at
Dr.3645.1.Sl-at Dr.16669.1.Sl-at
Dr.5434.3.Sl at Dr.4907.1.Sl-at
Dr.1288.1.Al-at Dr.2132.1.Al-at
Dr.17424.1.Al-at Dr.371.1.Sl-at
Dr.24320.1.Sl-at Dr.1015.2.Sl-x-at
Dr.5477.1.Sl-at Dr.4797.1.Sl-at
Dr.20146.2.Sl-at Dr.309.1.Sl-at
Dr.17896.2.Al-at Dr.8379.1.Sl-at
Dr.23656.1.Al-at Dr.23067.1.Sl-at
Dr.6285.1.Sl at Dr.22937.1.Al - at
Dr.12863.1.Al-at Dr.4859.1.Al-at
Dr.2066.1.Al-at Dr.20815.1.Sl-at
Dr.381.1.Al-at Dr.1377.1.Al-at
Dr.8055.1.51-at Dr.15286.1.Al-at
Dr.14425.1.Al-at Dr.6814.1.Sl-at
Dr.25745.1.Sl-at Dr.4812.1.Sl s at
DrAffx.1.52.Sl-at Dr.20214.1.Al-at
Dr.4766.1.Al-at DrAffx.2.15.Sl-at
Dr.20136.1.51-at Dr.18186.1.Sl-at
Dr.681.1.Al-at Dr.2914.1.Sl-at
Dr.404.1.Al-a-at Dr.1580.1.Al-at
Dr.24292.3.Al-a-at Dr.5479.1.Sl-at
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Dr.539.1.Sl-s-at Dr.24950.1.Sl-at
Dr.20067.1.Sl-at Dr.1448.1.Sl-at
Dr.6174.1.Al-at Dr.20010.7.Sl-at
Dr.18212.1.Sl-at
Dr.26116.1.Sl-at
Dr.7722.1.Al-at
Dr.8724.1.Sl-at
Dr.15554.1.Al-at
Dr.4160.1.Al-at
Dr.17717.1.Al-at
Dr.7111.2.Sl-at
Dr.4925.1.Sl-x-at
Dr.18263.1.Sl-at
Dr.37.1.Sl-a-at
Dr.16709.1.Al-at
Dr.19263,1.Sl-at
Dr.9893.1.Al-at
Dr.5278.1.Al at
Dr.16298.1.Al-at
Dr.1435.1.Sl-at
Dr.2452.1.Al-at
Dr.21068.1.Sl-s-at
Dr.25677.1.Al-at
Dr.4827.1.Al-x-at
Dr.20163.1.Sl-at
Dr.5005.1.Al-at
Dr.12386.1.51-x-at
Dr.5411.1.Sl-at
Dr.16480.1.Al-at
Dr.2452.2.Al-x-at
Dr.25683.5.Al-at
Dr.15046.1.Al-at
Dr.19643.1.Al-at
Dr.6237.1.Sl-at
Dr.4905.1.Sl-at
Dr.20821.1.Al-at
Dr.17814.1.Sl-at
Dr.7155.2.Sl-at
Dr.11981.1.Al-at
Dr.23480.2.Sl-at
Dr.7891.1.Al-at
Dr.15281.1.Al-at
Dr.5660.1.Sl-at
Dr.8086.1.Sl-s-at
Dr.4827.1.Al-at
Dr.7508.1.Al-at
Dr.25710.1.Al-at
Dr.18103.1.Sl-at
Dr.17394.2.Sl-at
Dr.7344.2.Al-at
Dr.25659.1.Sl-at
Dr.7155.1.Sl.at
Dr.8124.1.Sl-at
DrAffx.2.79.Sl-at
Dr.10342.1.Sl-at
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Dr.4925.1.S1 at
Dr.11590.1.A1 at
Dr.15600.1.S1 at
Dr.17855.1.S1 at
Dr.21771.1.A1_at
Dr.7912.1.A1_at
Dr.15486.1.S1 x at
Dr.9953.1.S1 at
Dr.26119.1.S1 at
Dr.25617.1.A1 at
Dr.18169.1.S1 at
Dr.25323.1.S1 at
Dr.190.1.S1_at
Dr.2794.1.A1_at
Dr.6183.1.A1_at
Dr.11483.1.S1_at
Dr.1250.1.A1_at
Dr.9556.1.S1_at
Dr.1298.1.A1 at
Dr.16183.1.S1_at
Dr.6136.2.S1_at
Dr.12622.1.S1_at
Dr.15486.1.S1_a at
Dr.3332.1.A1_at
Dr.17890.2.A1_at
Dr.24285.1.A1_at
Dr.1725.1.A1_at
Dr.4838.1.A1_at
Dr.1462.1.S1_at
Dr.16669.1.S1 at
Dr.18319.1.S1 at
Dr.16555.1.S1 at
Dr.12850.1.A1_at
Dr.5162.1.A1_at
Dr.4907.1.S1 at
Dr.2132.1.A1_at
DrAffx.2.104.S1 at
Dr.17923.1.S1_at
Dr.371.1.S1_at
Dr.15238.1.S1 at
Dr.21187.1.A1 at
Dr.11464.1.A1_at
Dr.8121.1.S1 at
Dr.5521.1.S1 at
Dr.16380.1.A1 at
Dr.4797.1.S1 at
Dr.1467.2.S1 a at
Dr.12036.1.A1 at
Dr.13699.1.S1 at
Dr.17853.1.A1_at
Dr.18019.1.S1_at
Dr.24752.1.S1_at
Dr.6453.1.A1 at
Dr.309.1.S1_at
Dr.15304.1.S1 at
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Dr.8379.1.Sl-at
Dr.2433.2.Al at
Dr.4867.1.Al at
Dr.8162.1.Sl-at
Dr.23067.1.Sl-at
Dr.4913.1.Al-at
Dr.12484.1.Sl-at
Dr.7815.1.Sl-at
Dr.13270.1.Al-at
Dr.22937.1.Al-at
Dr.20163.2.Al-at
Dr.914.1.Al-a-at
Dr.17891.1.Sl-at
Dr.17921.1.Al-at
Dr.4859.1.Al-at
Dr.18146.2.51-at
Dr.18164.1.Al at
Dr.5404.1.51-at
Dr.20815.1.51-at
Dr.16276.1.Al-at
Dr.24203.1.Sl-at
Dr.24000.1.Al at
Dr.17623.1.Sl-at
Dr.5845.1.Al-at
Dr.569.1.Sl-at
Dr.1377.1.Al-at
Dr.2S838.1.Al-at
Dr.16770.1.Al-at
Dr.15286.1.Al-at
Dr.22145.1.Al-at
Dr.13104.1.Al-at
Dr.17923.2.Al-at
Dr.5531.1.Sl-a-at
Dr.19416.1.Sl-at
Dr.13161.1.Sl-at
Dr.6814.1.Sl-at
Dr.424.1.Sl-at
Dr.25770ASI-at
Dr.11240.1.Al-at
Dr.6952.1.Al-at
Dr.26444.1.Sl-at
Dr.20214.1.Al-at
Dr.5462.1.Sl-at
Dr.15964.1.Al-at
Dr.4920.1.Al-at
Dr.436.1.Al-at
Dr.22841.1.Al-at
Dr.5531.3.Sl-at
Dr.15599.1.Sl-at
Dr.6658.1.Al-at
DrAffx.2.15.Sl-at
Dr.17508.1.Al-at
Dr.25770.4.Al-at
Dr.13487.1.Sl-at
Dr.15715.1.Slat
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Dr.5434.9.Al-at
Dr.11540.1.Al-at
Dr.10941.1.Al-at
Dr.1221.1.Al-at
Dr.16543.1.Sl-at
Dr.18186.1.Sl-at
Dr.12467.1.Al-at
Dr.14757.1.Al at
Dr.17226.1.Al at
Dr.2959.1.Al at
Dr.19674.1.Alat
Dr.5673.1.Sl-at
DrAffx.2.63.Sl-at
Dr.423.1.Al-at
Dr.21907.1.Al-at
Dr.16998.1.Al-at
Dr.7605.1.Al-at
Dr.12115.1.Al-at
Dr.2914.1.Sl-at
Dr.815.1.Sl-x-at
Dr.1580.1.Al-at
Dr.13466.1.Al-at
Dr.9236.2.Al at
Dr.10834.3.Alaat
Dr.16428.1.Al-at
Dr.20114.1.Al-at
Dr.14390.1.Sl-at
Dr.2914.1.S2-at
Dr.25118.1.Sl-at
DrAffx.1.85.Al-at
Dr.22764.1.Al-at
Dr.20160.1.Sl-at
Dr.25500.1.Sl-at
Dr.582.1.Sl-a-at
DrAffx.2.70.Al-at
Dr.5479.1.Sl-at
Dr.24655.1.Al-at
Dr.24950.1.Sl-at
Dr.14648.1.Al-at
Dr.21625.1.Al-at
Dr.1448.1.Sl at
Dr.13609.1.Al-at
Dr.6064.1.Al-at
Dr.18267.1.Sl-at
Dr.19575.1.Sl-at
Dr.6928.2.Sl-at
Dr.23305.1.Sl-at
Dr.25422.1.Sl-s-at
Dr.20010.7.Sl-at
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Independent Component Analysis is a higher order statistical method independent of
traditional statistical assumptions to find pattern sets in the data and confirm conclusions from
other statistical tests. The purpose is to find additional regulated transcripts that are not found
through traditional statistical methods. Non-orthogonal components displayed on rows of a
Hinton Plot represent gene signatures that may be characteristic for experimental conditions.
ICA track 2 revealed a signature that separated wild-type and mutant chips. Transcripts were
assigned relative "contributions" to each component using the ICA model. Only 2 regulated
transcripts by joint normalization according to the cyberT test do not overlap with the top 0.5%
of transcripts contributing to the ICA track 2, Dr.10141.1Ala and Dr.25767.1Ala. An
additional 34 genes were found in the top 0.5% of ICA track 2, shown in Table 4.
Table 4 Additional ICA Track 2
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Affymetrix ID transcript Track Contribution
Dr.10257.1.A1 at Peptidase D 5.58E+00
Dr.10914.1.A1 at NA -7.52E+00
Dr.1142.1.A1_at Dolichyl-diphosphooligosaccharide 5.02E+00
glycosyltransferase
Dr.11479.1.A1 at NA -8.40E+00
Dr.11481.1.A1 at NA -7.35E+00
Dr.1212.1.S1_at cyclin G1 -5.24E+00
Dr.12386.2.S1_a at Mesogenin1 5.99E+00
Dr.13058.1.A1_at solute carrier 12a7 -4.63E+00
Dr.13633.1.A1_at NA -5.01E+00
Dr.13863.1.S1 at NA -4.72E+00
Dr.16350.1.A1 at NA 4.80E+00
Dr.19794.1.A1 at NA -6.58E+00
Dr.20198.1.S1 a at heat-shock 70kD protein 8 -5.41E+00
Dr.20198.2.S1_x_at heat-shock 70kD protein 8 -4.85E+00
Dr.20276.1.Alat angiotensin converting enzyme -5.77E+00
Dr.2052.1.S1 at tumor protein 73 -6.22E+00
Dr.21089.1.S1_at NA 4.66E+00
Dr.22517.1.S1 at NA -5.04E+00
Dr.23406.1.S1 at NA -7.79E+00
Dr.2408.1.A1_at matrix metalloproteinase 2 -5.74E+00
Dr.2408.2.S1_at matrix metalloproteinase 2 -5.98E+00
Dr.2487.1.S1 at ureidopropionase, beta -5.29E+00
Dr.24938.1.S1_a at aldehyde dehydrogenase 3D1 -6.52E+00
Dr.24938.1.S1 x at CREB-binding protein -4.97E+00
Dr.25536.1.A1_at heat shock 90kDa protein 1, beta -6.22E+00
Dr.26372.1.A1 at NA -5.80E+00
Dr.3663.1.A1 at NA 5.02E+00
Dr.4103.1.A1 at NA 4.59E+00
Dr.5434.1.S3 at sestrin 1 4.86E+00
Dr.610.2.S1_at proteolipid protein 1a -5.98E+00
Dr.6337.1.S1 at heat shock 90kDa protein 1, beta 5.96E+00
Dr.6377.1.A1_at cytochrome-P450 ClAl 5.32E+00
Dr.6709.1.S1 at NA -7.14E+00
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IDr.3880.1. S2_at -4.95E+00
